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Advances  in  tumour biology have  led  to  studies  of new  biological  markers,  which 
may  predict  treatment  response  and  clinical  outcome  independently  of  standard 
clinicopathological  variables.  An  immunohistochemical  analysis  of  a  panel  of 
molecular  markers  was  studied,  in  a  series  of  anorectal  tumours,  treated  with 
5’fluorouaracil (5FU) chemoradiation.
240 tumour samples  from the ACT  I anal  cancer trial  were analysed.  Patients were 
randomised  to  radiation  alone  (RT)  or  concurrent  mitomycin/5FU/RT  (CMT).  On 
multivariate  analyses  tumour  stage,  treatment  response,  CD34  (vascularity), 
thymidine  phosphorylase  (TP)  and  p53  expression  were  independent  predictors  of 
clinical  outcome.  Tumour  stage  and  p53  expression  were  associated  with  a  poorer 
response to treatment in both randomisation arms. Increasing cyclin A and decreasing 
bcl-2  predicted  for  an  improved  response  to  radiation  alone  whilst  CD34,  tumour 
stage and TP expression predicted for an improved survival in the CMT arm.
Archived  tumour  samples  from  60  patients  with  locally  advanced  rectal  carcinoma 
were also studied.  On multivariate analyses resection margin, nodal stage, treatment 
response, EGFR and p53 expression were independent predictors of clinical outcome. 
Increasing TP and cyclin A expression were associated with an improved response to 
chemoradiation.
The response of TP  and  thymidylate synthase (TS)  to  radiation  was  investigated  in 
two  colon  carcinoma  cell  lines.  TP  activity  significantly  increased  in  response to  a 
single and fractionated RT dose and TS significantly decreased. This may explain the 
lack  of  prognostic  significance  of  TS  and  confirms  that  capecitabine,  which  is 
activated by TP in tumour cells, is a rational agent to combine with radiation.
In  conclusion  survival  and  treatment  response  in  anorectal  carcinomas  can  be 
predicted independently of standard clinicopathological characteristics. They can also 
predict  survival  between  different  therapeutic  modalities,  which  may  lead  to 
improved  chemoradiation  strategies.  Tailoring  the  treatment  to  the  individual  may 
become a future possibility.
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Chapter 1
Section 1  Anal Carcinoma
1.1  Introduction
Epidermoid cancer of the anus is relatively rare and accounts for less than 3% of all 
large bowel malignancies. It includes tumours of the anal canal and perianal skin i.e. 
tumours within a radius of approximately 5cm from the anal orifice.
In the United Kingdom approximately 700 new cases are registered annually.  There 
are two peak incidences; one at 40-50 years and another at 70-80 years.  There is a 
slight female preponderance overall.  Cancers of the anal canal are three times more 
common in females, whereas cancers of the anal margin are commoner in males.
1.2  Aetiology
Human papilloma virus (HPV) infection is closely correlated with squamous cell anal 
carcinoma [1].  Using PCR, the presence of the HPV genome has been identified in 
80-85%  of cases;  HPV  type  16  was  the  most  frequent  type  detected  [2,  3].  This 
parallels the prevalence seen in cervical and vulval carcinoma in women [4].
Even before the current HIV epidemic, an excess risk of 40-50 times was observed in 
the homosexual population [5].  Immunosuppression is a further important risk factor, 
and anal cancer is not uncommon in renal and cardiac transplant recipients.  There is 
also an increased risk associated with cigarette smoking.  In a case-control  study by 
Daling and colleagues  [6], current cigarette smoking was a major risk factor in both 
sexes,  relative  risk  7.7  in  women  and  9.4  in  men.  This  is  similar to  the  report by 
Daniell [7] who noted that 54% of 13 women with anal cancer were current smokers 
compared to only 26% of 202 age-matched patients with colon cancer.
1.3  Pathology
Macroscopically the tumour arises close to the anal margin either in the skin or anal 
canal. Early appearances are often of a warty nodule or infiltrating area of ulceration. 
Microscopic appearances demonstrate that more than 90% are squamous, basaloid or 
cloacagenic  carcinomas  arising predominantly from  the  squamous  epithelium.  Less
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than 5% appear to represent adenocarcinoma arising from the glandular mucosa of the 
upper anal  canal,  the  anal  glands  and  ducts  and  these  are  usually mucus  secreting. 
Other less common tumours include anal melanomas, sarcomas and lymphomas.
Tumours arising at the anal margin tend to be well differentiated and keratinising akin 
to  squamous  skin  cancers,  whereas those  arising  in the  anal  canal  are often poorly 
differentiated  squamous  cell  carcinomas.  Basaloid tumours  arise in the transitional 
zone around the dentate line and constitute 30-50% of all anal canal tumours.
1.4  Clinical presentation
The initial and most common symptom is bleeding and occurs in approximately 50% 
of  patients  [8-10]  and  25%  [10]  present  with  an  obvious  mass  and  discomfort. 
Pruritus  and discharge occur in  25%  [10]  and  less  commonly patients may present 
with  faecal  incontinence or a rectovaginal  fistula.  Diagnosis  can be made on rectal 
examination.
Approximately  one  third  of patients  have  enlarged  inguinal  lymph  nodes  but  on 
biopsy  only  50%  will  confirm  metastatic  spread.  The  remainder  are  caused  by 
secondary infection.  Biopsy or fine-needle aspiration  is  therefore recommended to 
confirm the involvement of inguinal nodes.
1.5  Staging and grading
The TNM (Tumour-Node-Metastasis) staging system is most commonly used (UICC 
1997);  see  Table  1.1  [11].  The  TNM  classification  of  anal  cancers  is  primarily 
clinical, taking into account the fact that primary treatment is now a combination of 
chemotherapy and radiotherapy.  Nodal  status is based on distance from the primary 
site  rather  than  the  number  of  nodes  involved,  as  this  has  more  prognostic 
significance.
Tumours are graded according to a three-grade system, which takes into account the 
degree  of  anaplasia  according  to  the  nuclear  to  cytoplasmic  ratio  and  nuclear 
frequency. They are graded as well, moderate or poorly differentiated.
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TNM Staging (UICC 5th Edition 1997)
T- Primary tumour (T)
TX Primary tumour cannot be assessed
TO No evidence of primary tumour
Tis Carcinoma in situ
T1 Tumour 2 cm or less in greatest dimension
T2 Tumour more than 2cm but not more than 5cm in greatest dimension
T3 Tumour more than 5cm in greatest dimension
T4 Tumour of any size invading adjacent organ(s), e.g., vagina, urethra,
Bladder
N- Regional lymph nodes (N)
NX Regional lymph nodes cannot be assessed
NO No regional lymph node metastasis
N1 Metastasis in perirectal lymph node(s)
N2 Metastasis in unilateral internal iliac and/or inguinal lymph node(s)
N3 Metastasis in perirectal and inguinal lymph nodes and/or bilateral
internal iliac and/or inguinal lymph nodes
M- Distant metastasis (M)
MX Presence of distant metastasis cannot be assessed
MO No distant metastasis
Ml Distant metastasis
Table 1.1 The TNM staging system for anal carcinoma
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1.6  Pattern of spread
The primary tumour usually grows in an annular fashion extending through the wall 
of the anal canal to involve the perianal tissue or rectum.  It may also spread outwards 
into the sphincters, the rectovaginal septum and the vagina.  Lymph node metastases 
are  found  initially  in  the  perirectal  group  of  nodes  and  thereafter  in  inguinal, 
haemorrhoidal and lateral pelvic lymph nodes.
Anal  margin  tumours  are  more  likely  to  involve  inguinal  nodes  than  anal  canal 
tumours.  30% of patients will have involvement of their inguinal nodes, however in 
early  T1/T2  tumours  the  rate  of involvement  is  approximately  12%  [8-10].  It  is 
usually unilateral and occasionally bilateral but never contralateral to the tumour.
The  pelvic  nodes  will  almost  always  also  be  involved  particularly  with  increasing 
tumour  stage  and  in  poorly  differentiated  tumours.  When  the  rectum  is  directly 
involved, the cancer may spread via the inferior mesenteric lymph nodes.  The overall 
incidence of pelvic lymph node metastases is in the region of 25-30% [10].
The  prognosis  is  much  worse  with  synchronously  involved  nodes  than  with 
metachronous  spread.  Haematogenous  spread  tends  to  occur  late  and  is  usually 
associated with advanced local disease.  The principal sites of metastases are the liver 
and  lung,  however  at  presentation  <5%  have  spread  to  these  sites  [10,  12,  13]. 
Metastases have also been described in the kidneys, brain and adrenal glands.
1.7  Treatment
Up until the mid  1980’s surgery was the first line treatment for anal carcinomas. An 
abdominoperineal  excision  was  commonly  performed  necessitating  a  permanent 
colostomy.  However,  non-surgical  radical  treatment  with  combined  chemotherapy 
and radiotherapy has become the treatment of choice in most cases.  Following early 
work  by  Nigro  et  al  [14]  chemoradiation  has  become  the  standard  treatment. 
Chemoradiation allows preservation of anorectal function with survival rates similar 
to those of surgery.  In a series of non-randomised prospectively designed protocols, 
Cummings  et  al  [15]  established  that  the  combination  of 5-fluorouracil  (5FU)  and
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mitomycin C (MMC) given concurrently with radiotherapy was more effective than 
5FU and radiotherapy alone.
Three phase III trials addressed the issue of combining radiotherapy (RT) with 5FU 
and  MMC  [16-18].  The two  European  trials,  UKCCR  and  EORTC,  looked  at the 
addition of the two chemotherapy agents to radiotherapy whilst the US  RTOG trial 
investigated  the role  of adding  MMC  to  5-FU  and  radiotherapy.  All  trials  used  a 
continuous  four  or  five  day  infusion  of  5-FU  in  the  first  and  last  weeks  of 
radiotherapy.
1.7.1  ACT I trial
The  UK  Anal  Cancer  Trial  (ACT  I)  [16],  undertaken  by  the  UK  Co-ordinating 
Committee for Cancer Research (UKCCR) was the largest trial with 585 patients.  It 
randomised  patients  to  split-course  radiotherapy  alone  or  chemoradiotherapy  with 
5FU  and  MMC,  see  Figure  1.1.  The  5FU  was  given  as  1000mg/m2  over 24  hours 
days 1-4 and 29-32 of radiotherapy
ACT  I had a median follow-up of 42 months and it demonstrated  a 46% reduction 
(95%CI  0.42-0.69,  x2=24.6,  p<0.0001)  in  the  risk  of local  treatment  failure  using 
CMT (5FU + MMC + RT) over that achieved by radiotherapy alone in patients with 
anal  cancer.  There  was  also  a  reduced  risk  of death  from  anal  cancer  (RR=0.71, 
95%CI  0.53-0.95;  %  =5.4,  p=0.02)  and  a non-significant  overall  survival  advantage 
(RR=0.86, 95%CI 0.67-1.11, x^l.3, p=0.25).
Analysis  of the  parallel  quality  of life  (QOL)  study  showed  that  the  addition  of 
chemotherapy did not impair QOL [19].
1.7.2  RTOG and EORTC trials
The  European  Organisation  for  Research  and  Treatment  of Cancer  (EORTC)  [17] 
trial of 110 patients also demonstrated similar results to ACT I. The trial run by the 
Radiation Therapy Oncology Group (RTOG) [18] demonstrated an advantage for the 
addition  of MMC  to  5-FU  and  radiotherapy,  improving  the  disease-free  survival 
(DFS)  at  5  years  from  50  to  67%  (p<0.003).  In  a  series  of  non-randomised
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prospectively  designed  protocols,  Cummings  et  al  [15]  also  established  that  the 
combination  of  5FU  and  MMC  given  concurrently  with  radiotherapy  was  more 
effective than 5FU and radiotherapy alone.
As a result of these trials, the current standard treatment for patients with epidermoid 
anal  carcinoma is a combination of RT +  5-FU  + MMC,  with  surgery reserved  for 
those who fail on this regimen, thus saving the majority of patients from the necessity 
of living with a colostomy.
1.8  Current research
The results of ACT I showed that patients with anal carcinoma have a relatively poor 
prognosis; 46% (265/577) had a local treatment failure and 50% were dead at 5 years. 
Thus  further effort  is  necessary to  optimise treatment to  improve local  control  and 
survival  rates.  Current  research  is  concentrating  on  several  different  approaches; 
including  modification  of the  radiotherapy  schedule;  changing  the  chemotherapy 
regimen given concurrently with radiotherapy and administering additional courses of 
chemotherapy.  Another  promising  area  of  research  is  whether  it  is  possible  to 
determine  which  pre-treatment  factors  are  predictive  of  patients’  responses  to 
chemoradiation.
1.8.1  ACT II trial
This  trial  employs  a  continuous  course  of radiotherapy,  unlike  the  trials  described 
previously, which all involved gaps at different time points during the schedule.  ACT 
II  also  investigates the role of cisplatin in combination with  5FU  and radiotherapy. 
Cisplatin  has  been  found  to  be  more  effective  than  MMC  in  other  squamous  cell 
tumours  [20-22],  and phase  II  trials  in  anal  carcinoma have demonstrated  a higher 
response  rate  with  lower  colostomy  rates  [23].  ACT  II  also  incorporates  a  further 
randomisation  to  additional  chemotherapy  with  cisplatin  and  5FU  at  the  end  of 
chemoradiation, to assess whether maintenance chemotherapy will benefit patients in 
terms of DFS, see Figure 1.2.
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1.9  Conclusion
Anal  cancer  is  one  of  the  few  disease  sites  where  chemoradiation  has  made  a 
significant impact on treatment.  A large proportion of patients can now be spared a 
permanent  colostomy  and  retain  sphincter  function.  Further  research  is  needed  to 
maximise the benefit which  can be gained  from  this  combined modality treatment. 
Some authors dispute the benefit of chemoradiation over surgery alone for small T1 
tumours. In contrast, the results of chemoradiation in larger T3 and T4 cancers remain 
poor. Many surgeons advocate either surgery alone or a combination of preoperative 
chemoradiation followed by surgery.
The present study aims to look at the potential role of molecular markers in predicting 
response and outcome to treatment. It also aims to look at the role of capecitabine, a 
new  and  exciting  oral  5FU  agent,  in  which  chemoradiation  phase  II  trials  in  anal 
cancer  are  currently  underway.  This  chemotherapy  has  the  potential  to  improve 
therapeutic benefit by selective conversion to  5FU  within the tumour cells  and  not 
normal tissues.
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Patients with confirmed primary epidermoid anal cancer
(Staged and biopsied by EUA & CT scan)
1
Randomise
4  1
Radiotherapy alone  Combined chemoradiation
45Gy daily 5 weeks  45Gy + 5FU + MMC
I
All patients assessed 6 weeks after first RT treatment
|  i
Radical surgery if <50% response  If >50% response RT boost further
15Gy as photons/electrons or 25Gy 
iridium implant
Figure 1.1 ACT I algorithm
Patients with confirmed primary epidermoid anal cancer
(Staged and biopsied by EUA & CT scan)
1
GFR > 50 ml/min
4
Randomise
1 4  4 4
RT + 5FU + MMC RT + 5FU + MMC  RT + 5FU + CDDP RT + 5FU + CDDP
+ +  + +
No maintenance Maintenance  No maintenance Maintenance
(2 # 5FU/CDDP) (2 # 5FU/CDDP)
Figure 1.2 ACT II algorithm
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Section 2  Rectal Carcinoma
1.10  Introduction
Colorectal carcinoma is one of the commonest cancers in Western countries and the 
fourth commonest cancer worldwide. Despite recent advances in early diagnosis and 
adjuvant therapy; this disease is still associated with a high mortality [24].  There are 
28,000 new cases a year in the United Kingdom and 20,000 deaths (CRC fact sheet). 
Men and women are affected equally and incidence increases with age. Cancers of the 
rectum  and recto-sigmoid junction  account  for approximately 50%  of all  colorectal 
carcinomas.
1.11  Aetiology
1.11.1  Environmental factors
Colorectal cancer is more common in westernised countries and for this reason it is 
often termed  an  ‘environmental’  disease.  A high intake of dietary fat and meat has 
been  linked  to  an  increased  incidence  [25]  and  dietary  fibre  has  been  proposed  as 
accounting  for the differences  in the rates  of colorectal  cancer between  Africa  and 
westernised  countries.  This  is  on  the  basis  that  the  increased  intake  of fibre  may 
increase faecal bulk and reduce transit time through the bowel [25].
There  is  evidence to  support an  association  between higher physical activity  and a
reduced risk of colorectal cancer; however the data currently available  does not  show
a consistent association between obesity and an increased risk in this disease. There is 
evidence  however,  which  suggests  there  is  an  association  between  obesity  and  an 
increased  risk  of  developing  adenomas  [26],  a  common  precursor  of  sporadic 
colorectal  carcinomas.  The  use  of  hormone  replacement  therapy  in  women  also 
appears to have some protection against the development of colorectal cancer and the 
risk seems lowest among long-term users. The risk appears to halve with 5-10 years 
use  [27],  However  it  is  not  clear  if this  is  a true  causal  association  or  a  selection 
factor.
1.11.2  Sporadic colorectal adenomas
More than 70% of colorectal cancers develop from sporadic adenomatous polyps, and 
post-mortem studies have shown the incidence of adenomas to be 30-40% in Western
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populations. Polyps are asymptomatic in the majority of cases and are often multiple. 
A number of genetic alterations, occurring as part of a sequence [28, 29], have been 
proposed  to  explain  the  development  of a  colorectal  carcinoma  from  an  adenoma 
[30].
1.11.3  Family history
Recognised  hereditary  conditions  account  for  approximately  5%  of all  colorectal 
cancers.  The  commonest  are  familial  adenomatous  polyposis  (FAP)  and hereditary 
non-polyposis colon cancer (HNPCC). Patients with these conditions usually have a 
family history of colorectal  cancer presenting at  a much  earlier age  than  expected. 
Both FAP and HNPCC show dominant Mendelian inheritance.
In the case of FAP there is  a germline mutation in the tumour suppressor gene for 
adenomatous polyposis coli (APC) on chromosome 5.  If DNA is available from an 
affected  individual,  mutation  detection  is  possible  in  about  70%  of  families.  In 
HNPCC  germline  mutations  in  DNA  mismatch  repair  enzymes  occur.  Five  genes 
have  now  been  identified;  hMSH2,  hMLHl,  hPMSl,  hPMS2  and  GTBP.  If both 
copies of the genes are mutated the cell and all its daughter cells are missing a vital 
mechanism for DNA repair.
1.11.4  Ulcerative colitis
Patients  with  ulcerative  colitis  have  a  2-8.2  relative  risk  of developing  colorectal 
cancer  compared  to  the  general  population,  accounting  for  about  2%  of colorectal 
cancers  [31].  The  risk  increases  with  the  duration  of the  colitis  and  the  extent  of 
disease is also important.  Involvement of the right and transverse colon has a higher 
risk of developing colon cancer [31].
1.12  Pathology
Colorectal cancers can be exophytic or fungating, or tumours may be ulcerated. More 
than 90%  are adenocarcinomas.  Tumours  are generally classified according to their 
grade and histological  subtype.  See Table  1.2.  The grading system is a combination 
of the degree of glandular formation, as well as cytological and nuclear features.
32Chapter 1
Histological suh-tvne Grade
Mucinous adenocarcinoma Well
Signet-ring adenocarcinoma Moderate
Adenosquamous carcinoma Poor
Squamous carcinoma
Small cell carcinoma
Choriocarcinoma
Medullary carcinoma
Table 1.2 World Health Organisation Classification of malignant primary 
tumours of the large intestine
Most  colorectal  cancers  are  moderately  differentiated,  gland-forming 
adenocarcinomas.  The  less  common  sub-types  are  classified  on  the  basis  of the 
predominance of an unusual pattern as compared with the usual  adenocarcinoma of 
the colon.  Mucinous or colloid carcinomas exhibit the majority of tumour in mucin 
pools, which are often of low cellularity. Signet ring tumours display a large amount 
of intra-cellular mucus  pushing the nucleus to  the  side  of the  cell.  These are often 
associated  with  diffuse  intramural  spread beyond  the obvious mucosal  lesion.  Less 
common colorectal tumours include carcinoid, small cell carcinomas and sarcomas.
1.13  Clinical presentation
The  symptoms  at  presentation  depend  significantly  on  the  site  of disease.  Colon 
carcinomas may present simply as a change in bowel habit, unexplained weight loss 
or an iron deficiency anaemia. If the tumour is annular or exophytic, obstruction may 
occur  resulting  in  pain,  abdominal  distension  and  vomiting.  In  the  case  of rectal 
carcinomas  the  commonest  presentation  is  rectal  bleeding,  which  may  be
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accompanied by pain and tenesmus. Partial or complete obstruction may also occur in 
5-15% of rectal tumours, and if it occurs, it is associated with a poorer survival [32].
1.14  Staging and diagnosis
The first widely used staging system for colorectal cancer was introduced by Duke in 
the  1930’s.  This  is  still  commonly used but the preferred  system is often the TNM 
classification.  This is  a unified  staging system  from the UICC  (International Union 
Against Cancer) and AJCC (American Joint Committee on Cancer) [11].  It includes 
accounting for the number of positive lymph nodes, which is an important prognostic 
factor,  Tables  1.3  and  1.4.  The new TNM  classification calls  for at least  12  lymph 
nodes to be examined.
Any  patient  with  a  clinical  history  suggesting  colorectal  cancer  should  undergo 
examination  of the  entire  colon.  The  aim  is  to  diagnose  the  primary  tumour  and 
exclude any synchronous polyps or cancers. This is commonly done by colonoscopy 
or barium  enema.  Metastases  should be  excluded  either by CT  or chest  X-ray  and 
liver ultrasound.  In the case of rectal carcinoma, a pre-operative CT, see Figure  1.3, 
or  preferably  an  endorectal  ultrasound  or  MRI  may  also  be  performed  to  try  and 
accurately stage the primary tumour.  This is necessary as pre-operative treatment is 
now common in locally advanced rectal tumours.
1.15  Pattern of spread
Histological  stage of spread  at diagnosis  is the most important prognostic variable. 
The depth of mural invasion is one of the most important prognostic factors. In colon 
carcinoma,  the mesentery and  serosal  surfaces  are at  greatest risk  for local  tumour 
penetration.  However  in  rectal  cancer  perirectal  fat  and  adjacent  organs  are  most 
commonly  involved  by  direct  invasion  through  the  bowel  wall.  This  difference  in 
local  spread between the two sites is extremely important in terms of treatment and 
prognosis. If perineural invasion has occurred local recurrences are more common.
The  degree  of lymph  node  involvement  correlates  with  the  depth  of tumour  and 
involvement occurs in almost 50% of those with deep tumours. Approximately 10-
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TNM Staging (UICC 5,h Edition 1997)
T- Primary tumour (T)
TX Primary tumour cannot be assessed
TO No evidence of primary tumour
Tis Carcinoma in situ
T1 Tumour invades submucosa
T2 Tumour invades muscularis propria
T3 Tumour invades through muscularis propria into subserosa, or into
non- peritonealised pericolic or perirectal tissues
T4 Tumour directly invades other organs or structures, and/or perforates
visceral peritoneum
N- Regional lymph nodes (N)
NX Regional lymph nodes cannot be assessed
NO No regional lymph node metastasis
N1 Metastasis in 1  to 3 regional lymph nodes
N2 Metastasis in 4 or more regional lymph nodes
M- Distant metastasis (M)
MX Presence of distant metastasis cannot be assessed
MO No distant metastasis
Ml Distant metastasis
Table 1.3 The TNM staging system for colorectal carcinoma
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Stage Grouping
TNM Dukes
Stage 0 Tis NO MO
Stage I T1 NO MO A
T2 NO MO
Stage II T3 NO MO B
T4 NO MO
Stage III Any T N1 MO C
Any T N2 MO
Stage IV Any T Any N Ml D
Table 1.4 TNM stage grouping
Figure 1.3 CT demonstrating a carcinoma of the rectum
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15%  of all  colorectal  cancer  patients  will  present  with  metastatic  disease  and  the 
commonest sites are liver and lung followed by adrenals, ovaries and bone. The colon 
drains  into  the portal  venous  system directly to  the liver,  whereas the rectum has a 
dual  system.  The  superior haemorrhoidal veins  enter the portal  system to the liver, 
whereas the middle and inferior haemorrhoidal veins drain to the inferior vena cava 
and  then  spread  to  the  lungs  via  the  systemic  circulation.  Lung  metastases  are 
therefore found more commonly in patients with cancers of the lower rectum.
1.16  Treatment of rectal cancer
Local recurrence (LR) is a frequent problem in rectal  cancer and this is reflected in 
the current treatment strategies for this disease. LR is an important cause of mortality 
and morbidity, and occurs in 10-60% of rectal cancers even after a curative resection 
[33, 34], with a median time to recurrence of twelve months.  When local failure does 
occur,  it  is  severely  debilitating  and  salvage  therapy  has  been  of limited  success. 
Most  local  recurrences  are  isolated  and  unaccompanied  by  disseminated  disease. 
This is in contrast to colonic carcinoma where LR is rare and usually accompanied by 
disseminated disease [35].
Surgical resection is the treatment of choice in patients with localised rectal cancer.  It 
potentially offers the chance of cure.  However,  more than half of all patients with 
rectal  cancer will  die of metastatic disease and this  includes up to  20%  of patients 
with apparent early stage tumours [32].
Two major factors influence local recurrence in rectal cancer.  Surgery-related factors 
include the type of surgery performed, for example total mesorectal excision (TME) 
or  a  low  anterior  resection.  The  extent  of lymphadenectomy,  presence  of post­
operative  anastomotic  leakage  and  inadvertent tumour perforation during operation 
are also  important  factors  for local recurrence  [36].  Tumour-related  factors  include 
anatomical  location,  histological  subtype,  tumour  grade,  status  of circumferential 
margin and presence of neural, venous or lymphatic invasion [37].
Approximately 20% of patients with rectal cancer will present with locally advanced 
tumours, which are partially or totally fixed (T3/T4).  Standard surgical resection in
37Chapter  1
these  patients  is  associated  with  high  rates  of incomplete  excision  and  later  local 
recurrence.  Tumour fixation is recognised as one of the most important pre-treatment 
factors  for  predicting  the  likelihood  of achieving  a  curative  resection  as  well  as 
achieving good overall and disease-free survival  [38].  After surgery, tumour located 
1mm  or  less  from  the  radial  margin  of  the  excision  is  usually  considered  an 
incomplete resection (Rl). This is associated with a high risk of local recurrence.
It  is therefore important to  achieve  a curative  surgical  excision in the treatment of 
rectal  cancer.  For early tumours,  surgery may be  all  that  is required  and  in  recent 
years major advances have been made in the surgical treatment of rectal cancer. In the 
UK  the  majority  of patients  will  now  undergo  a total  mesorectal  excision  (TME). 
However, in the case of more locally advanced tumours, surgery may be preceded by 
chemoradiation.
1.16.1  Total Mesorectal Excision
A  significant  number  of  patients  with  rectal  carcinoma  will  have  full-thickness 
penetration  of the  bowel  wall  or  involvement  of mesorectal  lymph  nodes.  The 
mesorectum  is  the  lymphovascular,  fatty  and  neural  tissue that  is  circumferentially 
adherent  to  the  rectum.  The  rectum  and  potentially  affected  mesorectum  should 
therefore  be  considered  as  a  single  entity.  TME  results  in  the  removal  of the 
carcinoma and mesorectum en bloc.  The aim is to reduce the incidence of positive 
post-operative margins and therefore, local recurrence.
Several  series  have  shown  a  decrease  in  local  recurrence  rates  following  TME 
surgery, with  LR rates reduced to  5-8%  [39, 40].  A recent study by Kapiteijn  [41], 
demonstrated that pre-operative radiotherapy in addition to TME reduced the risks of 
local recurrence further.  The rate of local recurrence at two years was 2.4% in the 
radiotherapy-plus-surgery group and 5.3% in the surgery-only group.
1.16.2  Neoadjuvant treatment
1.16.2.1  Short course radiotherapy
Currently,  in  resectable  rectal  cancer  there  are  two  choices  for  the  delivery  of 
adjuvant  radiotherapy,  either  pre-operative  or  post-operative.  Pre-operative
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radiotherapy has advantages of producing less morbidity with better compliance rates. 
Since the publication of the Swedish Rectal Cancer Trial, which revealed a significant 
improvement  in  local  control  and  survival  with  intensive  short-course preoperative 
radiation,  some  physicians  have  advocated  this  radiation  schedule  [42].  A  recent 
meta-analysis  of 14  trials  also  revealed  a  significant  improvement  in  survival  with 
intensive  short-course  preoperative  radiation  [43].  Typically,  the  intensive  short- 
course  includes  25Gy  in  five  daily  fractions  followed  by  surgery  one  week  later. 
Although a survival benefit was demonstrated this schedule has been associated with 
some morbidity and it does not enhance sphincter preservation.  It also does not lead 
to  significant downstaging and therefore is not ideal  for the more  locally advanced 
rectal tumours. In a study by Marijnen [44] a decrease in tumour size and the number 
of recovered lymph nodes was observed but there was no change in tumour or lymph 
node classification.
1.16.2.2  Pre-operative chemoradiation
Between 20-30% of cases of rectal cancer present as locally advanced tumours, which 
are  either  fixed  or  tethered  because  of direct  invasion  to  other  pelvic  organs,  the 
pelvic  sidewall  or  sacrum.  This  is  a  particular  problem  in  males  with  anterior 
tumours where there is little, if any surgical plane between the rectal cancer and the 
prostate.  Fixity has been shown to predict the likelihood of a non-curative resection 
[45, 46].
Surgical  resection  in  these  patients  is  associated  with  high  rates  of  incomplete 
excision and later local recurrence.  In this group of patients the aim is to downstage 
the tumour rendering it resectable.  The results with radiotherapy alone,  at doses of 
40-50Gy, do show increased resectability rates [47, 48] with reduced rates of LR [47]. 
However, when chemotherapy and radiotherapy are synchronously combined further 
downstaging  may  be  achieved  [49].  The  rationale  for  chemoradiation  is  that  it 
combines  systemic  treatment  simultaneously  with  a  loco-regional  treatment.  In 
addition there are synergistic or additive effects between the two modalities.  When 
compared to surgery alone and surgery plus post-operative radiotherapy, the addition 
of concomitant  and  adjuvant  chemotherapy  to  radiotherapy  in  the  post-operative 
setting has shown improved results in local control and survival [50, 51].  However, 
the value of adding radiotherapy to chemotherapy in the post-operative setting is not
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so clear.  In the NSABP R-02 (National Surgical Adjuvant Breast and Bowel Project) 
trial,  patients  were  randomised  to  post-operative  chemotherapy  with  or  without 
radiotherapy.  The radiotherapy led to a significant reduction in local relapse rates but 
the  incidence  of  distant  relapse  and  hence  survival  was  unchanged  [52].  This 
suggests that only those patients deemed  at high risk of local  recurrence  should be 
offered post-operative chemoradiation.
Pre-operative  chemoradiation  produces  less  morbidity  and  better  compliance  rates 
than in the post-operative setting.  It is clear pre-operative chemoradiation can lead to 
significant downstaging of the tumour  [49,  53].  In the  study by Rich  et al  [53],  a 
complete  pathological  response  was  achieved  in  29%  with  infusional  5FU  and 
radiotherapy.  Others  have  also  confirmed  favourable  resectability  rates  for  fixed 
cancers  and  demonstrated  improved  local  control,  when  5FU  is  combined  with 
radiation  [54,  55].  One  study  demonstrated  a  100%  10  year  survival  for  patients 
achieving  a  complete  pathological  response  (CPR)  following  pre-operative 
radiotherapy alone [56].
For patients with clinically resectable disease, the preoperative approach is commonly 
used  in  situations  where,  at  initial  presentation,  sphincter-preserving  surgery is  not 
technically possible.  In tumours that are likely to have an Rl resection, pre-operative 
chemoradiation is given to downstage the primary tumour so that an R0 resection rate 
is more  likely to  be  achieved.  However,  even with this  pre-operative  approach the 
overall five year survival rate for this group of patients is still low at 20-30%, despite 
a curative resection [57] and there is still a high risk of local recurrence [54].
1.17  Current research
Despite  recent  improvements  in  surgery  and  pre-operative  radiotherapy  and 
chemotherapy,  the  survival  remains  poor  for  those  patients  with  locally  advanced 
carcinoma  of  the  rectum.  Future  research  into  the  newer  chemotherapy  drugs, 
oxaliplatin and irinotecan, alone or in combination with radiotherapy is needed. The 
main  strategies  for improving outcome in rectal  cancer must  address  the following 
issues; ensuring a curative surgical resection, reducing the risk of metastatic disease 
and what is the most effective adjuvant chemotherapy.
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Section 3  5FU-based chemoradiation
1.18  Introduction
For many years the combination of chemotherapy and radiotherapy has  constituted 
one  of the  main  avenues  for research  in  oncology.  The  biological  mechanisms  of 
combination  therapy  are  complex  and  not  fully  elucidated.  Used  alone  or  in 
combination with surgery, chemoradiation is rapidly becoming the gold standard for 
the  treatment  of  certain  tumours,  for  example  anal  and  locally  advanced  rectal 
carcinomas.  This is due to observed improvements in local  control in particular but 
also survival.
To maximise the benefit from the combination of these two treatment modalities it is 
important to understand the nature of how the drugs and radiation interact.
1.19  Rationale for combined chemotherapy and radiotherapy
The  purpose  of combining  radiation  and  chemotherapy  is  to  achieve  a therapeutic 
gain by increasing the effect on the tumour without concomitantly enhancing critical 
normal  tissue reactions.  The mechanisms  of interaction between  chemotherapy and 
radiotherapy have been divided into four generic types by Steele [58].
1.  Spatial  Co-operation:  each  modality treats  a  different  anatomical  site  e.g. 
systemic adjuvant chemotherapy and local radiotherapy in breast cancer.
2.  Independent cell kill:  agents act independently of each other and produce a 
greater effect than either agent alone.
3.  Protection of normal tissue: the tolerance of the dose-limiting normal tissue 
can be modified allowing a higher dose of the treatment modality to be used 
e.g. the use of amifostine as a radio-protector.
4.  Enhancement of tumour response:  agents may sensitise tumour cells to the 
effects  of  another  treatment  modality.  The  interaction  may  therefore  be 
additive, supra-additive or sub-additive.
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Another purpose for using combined modality treatment is that it may overcome sub­
clones of cells in tumours with increased resistance to drugs and radiotherapy. These 
sub-clones may have a selective advantage and their survival and growth may lead to 
treatment  failure.  This  resistance  to  treatment  might  be  reduced  through  the 
combined  use  of radiation  and  drugs,  provided  the  mechanisms  of resistance  are 
independent. For example radiation failure is often related to radio-resistant hypoxic 
cells in areas of poor vascularity. Mitomycin C is an established chemotherapy agent 
which, under hypoxic conditions functions as an alkylating agent.  Co-administration 
of this  agent  with  radiation  may  overcome  the  problem  of radio-resistant  hypoxic 
cells.
Achieving a therapeutic gain can be difficult because one of the major limitations is 
that of selectivity of the treatment to the tumour cells  and not normal tissues.  The 
combination  of treatments  must  take  this  into  account,  as  the  toxicity  of normal 
tissues is invariably the dose-limiting factor for both of these modalities when used 
alone;  in  combination  this  toxicity  may  be  much  more  severe.  A  small  survival 
benefit  may  not justify  a  significant  increase  in  toxicity  by  using  a  combination 
schedule.
When  analysing the results of studies using chemoradiation and  for future research 
into the mechanisms of interaction, Coleman and colleagues [59] have suggested the 
following considerations:
1.  What is the target of each agent? e.g. DNA, RNA, enzyme, cell receptor
2.  Is  the  target  stable?  e.g.  cell  cycle  variation,  tumour  heterogeneity,  drug 
resistance, hypoxia
3.  Can the target be reached?
4.  What is the optimum schedule?
5.  What are the combined toxicities?
It is important to determine the optimum timing and dose of each modality to achieve 
the most effective schedule, with acceptable normal tissue toxicity.  In  vitro and in 
vivo research can help define the mechanisms of interaction between each modality,
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facilitating the development of clinical schedules. In current clinical practice there are 
several variations of radiotherapy and chemotherapy combinations:
1.  Sequential: one modality following completion of the other.
2.  Concurrent: both modalities are given at the same time.
3.  Alternating: each modality is divided into blocks and alternated.
Most  patients’  die  from  metastatic  disease  and  therefore  combined  modality 
treatment, as well as improving local control, must also target tumour dissemination. 
As  a  consequence  of this,  the  concept  of adjuvant  and  neoadjuvant  treatment  has 
emerged.  This  strategy  targets  micrometastases  at  an  early  stage  in  the  patient’s 
treatment and an example would be neoadjuvant 5FU-based chemoradiation in locally 
advanced rectal cancer.
1.20  5-Fluorouracil
1.20.1  Mode of action and sensitivity
5-fluorouracil is a prodrug that is subject to both catabolism and anabolism.  80% of 
the  dose  is  catabolised  and  inactivated  in  the  liver  by  dihydropyrimidine 
dehydrogenase (DPD) [60].  An additional 15-20% is excreted in the urine [60].
5FU  is  an  analogue  of  uracil  and  during  anabolism  a  series  of phosphorylation 
reactions  lead  to  the  formation  of  5-fluoro-2’-deoxyuridine-5’-monophosphate 
(FdUMP),  5-fluoro-2’-deoxyuridine-5’-triphosphate  (FdUTP),  and  5-fluorouridine- 
5’-triphosphate (FUTP), the active metabolites of fluorouracil.  The cytotoxic effects 
of fluorouracil  are  thought  to  result  from  the  binding  of 5-FdUMP  to  thymidylate 
synthase  (TS),  which  is  the  enzyme  responsible  for  converting  deoxyuridine 
monophosphate (dUMP) to thymidylate (dTMP), a necessary step in the synthesis of 
DNA,  see Figure  1.4.  This results in the inhibition of DNA synthesis and apoptosis 
with  a  depletion  of thymidine  nucleotides  and  an  accumulation  of deoxyuridine 
nucleotides. This leads to changes in other nucleotide pools [61, 62], arrest of cells in 
S  phase  of  the  cell  cycle  (growth  arrest),  and  ultimately  to  DNA  damage  and 
fragmentation.  However,  it  must  be  remembered  that  a  salvage  pathway  exists  as 
demonstrated  in  vivo,  in  which  nucleosides  are  brought  into  the  cell  and  used  for
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DNA and RNA synthesis.  This allows the bypass on any endogenous block and may, 
in part, explain resistance to 5FU [63].
Mechanism of action of 5FU
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Figure 1.4 Mechanism of action of 5FU
As  well  as  inhibition  of TS,  FdUMP  can  also  be  converted  to  fluorodeoxyuridine 
triphosphate (FdUTP) and become incorporated into DNA [64].  However, this route 
of incorporation into DNA does not seem necessary for cell death to occur [65].  5FU 
can  also  kill  cells  by  RNA-dependent  mechanisms.  5FU  can  be  metabolised  to 
fluorouracil monophosphate (FUMP) and then ultimately to fluorouracil triphosphate 
(FUTP)  which  can  be  incorporated  readily  into  RNA  in  preference  to  UTP;  this 
affects the production of ribosomal RNA [66].  It also interferes with messenger RNA 
function including transcription [67], translation [68] and splicing [69].
Sensitivity  to  5FU  is  determined  by  a  number  of  factors.  Recent  studies  have 
suggested  that  patients  with  low  primary  tumour  levels  of TS  expression  or  TS 
messenger  RNA  (mRNA)  have  a  superior  overall  response  to  the  drug  and  better 
survival rates [70, 71].  Response rates to 5FU can be increased by combination with
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leucovorin  [72].  Leucovorin  acts  by  increasing  and  prolonging  the  competitive 
inhibition of TS by stabilising the ternary complex formed by the active metabolite of 
fluorouracil [73]. The size of the intracellular pool of reduced folate is also important 
in  determining 5FU  sensitivity.  Improved response rates to  5FU have been  seen in 
head and neck cancer patients with high intra-tumoural levels of reduced folates [74]. 
DPD is the primary rate-limiting enzyme in the catabolism of 5FU and a low level of 
DPD  is  correlated  with  a  higher  likelihood  of tumour  response  [75]  due  to  the 
resulting higher levels of 5FU. With the introduction of capecitabine (Xeloda), an oral 
5FU analogue, expression of thymidine phosphorylase has also become important as 
this enzyme catalyses the final conversion of the drug to 5FU [76].
Since  the  1960’s  5FU  has  remained  the  most  extensively  used  chemotherapeutic 
agent  in colorectal  cancer.  It  is used in the  adjuvant  setting at present  as  a single 
agent.  In the metastatic setting 5FU has been combined with other cytotoxic agents 
to  enhance  response  rates.  These  regimens  are  associated  with  increased  toxicity. 
Oxaliplatin  and  irinotecan  are  currently  the  two  chemotherapy  agents,  which  are 
attracting the most interest in colorectal cancer and in the case of anal cancer, MMC 
and cisplatin.  5FU is also commonly used in the treatment of upper gastrointestinal 
tumours particularly in the metastatic setting and in chemoradiation protocols.  It can 
be  administered  either as  an intravenous bolus  (IV)  or in  an  infusional  form.  The 
dose limiting toxicities vary with the mode of administration.  In the case of IV bolus, 
immune suppression is the major toxicity and with infusional it is diarrhoea and the 
‘plantar-palmar’ syndrome.
1.20.2  5-Fluorouracil as a radiosensitiser
In  addition  to  being  cytotoxic,  5FU  also  acts  as  a radiosensitiser  [77,  78]  and has 
become one of the agents most widely used to sensitise tumour cells to the effects of 
radiation in clinical practice. As a radiosensitiser it is likely to be most effective when 
given concurrently with radiation.
1.20.2.1  Possible mechanisms of radiosensitisation
FdUrd (5-fluoro-2’-deoxyuridine) is an analogue of deoxyuridine and is also used as a 
chemotherapeutic agent.  It differs from 5FU in that it primarily has DNA effects and
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it is metabolised directly to FdUMP by phosphorylation (via thymidine kinase). It has 
been shown that FdUrd is a potent radiosensitiser of HT29 cells [79] and it was more 
effective when drug treatment preceded radiation compared with following radiation. 
The  degree  of  sensitisation  correlated  with  the  level  of  TS  inhibition  [79]  and 
depletion of dTTP pools [61] and was blocked by co-incubation with thymidine [79]. 
There was also a decrease in double-strand break and sub-lethal damage repair [61, 
64].
Three  hypotheses  have  been  generated  to  account  for  fluoropyrimidine-induced 
radiosensitisation:
1.  Nucleotide  pool  perturbations:  The pool  of nucleotide  substrates  necessary for 
the  repair  of  radiation  induced  DNA  damage  is  depleted  [78].  This  depletion 
compromises the ability of polymerases to find the correct base for repair, leading to 
misrepair, single strand breaks (SSB) and double strand breaks (DSB).  However the 
dTTP pools are depleted within 1  -2 hours of drug exposure whereas radiosensitisation 
takes several hours to develop.  Therefore pool changes alone do not solely account 
for radiation sensitivity.
2. Cell cycle redistribution: Treatment with 5FU arrests cells in S phase and blocks 
cells that are not in S phase at the Gl/S phase interface.  It has been suggested that 
early  S  phase  is  a  sensitive  phase  to  radiation  [62],  and  this  accounts  for  the 
radiosensitisation  effect.  Work  by  Lawrence  et  al  [80]  showed  that  HT29  cells 
exposed to FdUrd generated significantly higher levels of cyclin E-dependent kinase 
activity.  Cyclin E is responsible for driving cells into early S phase.  However, some 
studies have shown that 5FU  can sensitise cells after radiation.  Byfield  [81]  found 
that  in  Hela  and  HT29  cells,  5FU  radio sensitisation  only  occurred  when  drug 
exposure followed radiation.  In colorectal  cancer cell  lines marked differences  are 
not apparent in radiation sensitivity between different phases of the cell cycle  [82]. 
Therefore cell cycle effects also do not account fully for the radiosensitisation effect.
3. Incorporation of FdUTP into DNA:  This does not appear to be a requirement for 
radiosensitisation.  This is based on results of experiments with TS inhibitor CB3717.
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This  inhibitor  cannot  be  incorporated  into  DNA  and  yet  it  is  an  excellent 
radiosensitiser in HT29 cells [82].
4.  Increased intra-cellular retention of 5FU and its metabolites:  This results from 
radiation exposure and has recently been demonstrated  in  vivo  by Blackstock  [83]. 
This  study  examined  HT29  colon  cancer  xenografts  in  athymic,  nude  mice.  One 
group received  5FU  alone  and  a second  group  received  5FU  after  a  lOGy dose of 
radiation.  Spectroscopic analysis was then performed.  The tumour retention of 5FU 
was more prolonged in the group receiving radiation before the drug infusion. This is 
consistent with the hypothesis  that radiation  is potentiating the cytotoxic  effects  of 
5FU.
These  are  all  possible  mechanisms  for  5FU  radiosensitisation  but  clearly  no  one 
mechanism is responsible. Lawrence et al [78] have proposed that, rather than taking 
the viewpoint that 5FU  sensitises cells to the effects of radiation, it is reasonable to 
consider that radiation may potentiate the cytotoxic effects of 5FU.  This may explain 
the differences seen between different schedules.  Radiosensitisation appears to take 
place under conditions that produce some cytotoxic effect  from  5FU  alone  [62,  79, 
81].  This  would  suggest  that  the  cytotoxic  effect  from  5FU  is  important  in  the 
mechanism  of  cell  radiosensitisation.  Byfield  [63]  determined  that  the  extent  of 
radiosensitisation was dependent on the duration and concentration of exposure to the 
drug as well  as  sensitisation occurring only when  5FU  is  administered at cytotoxic 
doses.
It is clear to see that the mechanisms of interaction between 5FU and radiation still 
remain  elusive.  As  a  result,  determining  the  appropriate  scheduling  of  the  two 
treatment  modalities  is  difficult.  Administering  5FU  as  a  continuous  infusion 
overcomes  some  of these  difficulties  of scheduling  and  is  thought  to  increase  the 
exposure of cells in S phase to the drug.  The limitations of drug exposure are that 
only 3-25% of colorectal cancer cells are actively synthesising DNA at any moment 
in  time  and,  because  TS  inhibition  after  administration  of bolus  doses  of 5FU  is 
relatively short-lived (half-life approx  10 minutes),  the fraction of colorectal  cancer 
cells susceptible to bolus 5FU is small [73]. However, even if the results are superior, 
the use of protracted infusional 5FU given with radiotherapy is not an approach that is
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currently  feasible  in  many  UK  centres  because  of the  cost  and  additional  staffing 
requirements.
1.20.3  Capecitabine (Xeloda)
5FU is one of the main chemotherapies used alone or in combination, in the systemic 
treatment  of  solid  cancers  and  it  forms  the  mainstay  of  treatment  in  colorectal 
tumours.  5FU is given in intra-venous form and is associated with morbidity, which 
limits  the  intensity  and  duration  of treatment;  these  include  diarrhoea,  stomatitis, 
neurological  and  myelosuppressive  toxicity  [84].  Although  protracted  intravenous 
infusion provides a continuous exposure to 5FU and limits the problems of cell cycle 
specificity and short half-life of bolus 5FU, it still has associated toxicity requires the 
insertion of a central venous catheter.
The development of an oral form of 5FU has several important advantages including 
patient  convenience  and  reduced  cost.  One of the  first  oral  forms  of 5FU  to  show 
promise  was  Doxifluridine  (5’-DFUR).  This  was  a  prodrug  with  preferential 
conversion to  5FU  at the tumour site, by exploiting the higher levels of pyrimidine 
nucleoside  phosphorylase  (PyNPase)  found  in  tumour  tissue  compared  to  normal 
tissue  [85].  It  showed  good  bioavailability  after  oral  administration.  The  major 
disadvantage however was its dose-limiting toxicity, principally diarrhoea, which was 
as a result of 5FU generation by PyNPase, in the gastrointestinal tract [86].
Capecitabine (Xeloda, N4-pentoxycarbonyl-5’-deoxy-5-fluorocytidine) is a new oral 
fluoropyrimidine carbamate which is converted to 5FU by three enzymatic steps [87], 
see Figure 1.5.
Capecitabine is initially metabolised in the liver to  5’-deoxy-5-fluorocytidine.  It is 
subsequently  metabolised  to  5’-deoxy-5-fluorouridine  by  cytidine  deaminase, 
expressed  in  higher  concentrations  in  the  liver  and  some  solid  tumours  [88].  The 
final step is conversion to 5FU by TP an enzyme in higher concentration in tumour 
cells  relative  to  normal  tissues  [89].  After  oral  administration  it  is  extensively 
absorbed  unchanged  from  the  gastrointestinal  tract,  thereby  avoiding  the  direct 
release  of 5FU  from  5’-DFUR  by  PyNPase  in  the  small  intestine.  In  the  clinical
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setting its efficacy has been shown to be equivalent to bolus  IV  5FU  in metastatic 
colonic  carcinoma  [90].  Capecitabine  achieves  long  term  inhibition  of  TS  and 
mimics protracted infusional 5FU. It has the additional important advantage of being 
converted to 5FU predominantly within the tumour cells [91].  There is also evidence 
that  capecitabine  (Xeloda)  might  offer  an  enhanced  therapeutic  ratio  in 
chemoradiation schedules.
HiC.
y-Oftoxy^fiuorocytkJine
(S'-DPCR)
5'*Deoxy-5-fluorouridine
(S'-OFUR)
Figure 1.5 Conversion of capecitabine to 5FU
1.  Xeloda is preferentially activated in tumour tissue by the enzyme thymidine 
phosphorylase.  This  selective activation has been  validated in humans by a 
small  study in  colorectal  cancer,  which demonstrated  3.2  times the level  of 
5FU in tumour compared to normal tissues after oral Xeloda [91]. This is in 
part due to the higher levels of TP found in tumour cells compared to normal 
tissues [89].
2.  In  studies  performed  in  several  human  tumour  xenografts,  radiation 
upregulates TP in tumour but not in normal tissue.  A single local irradiation 
of 5Gy increased TP 13 fold at 9 days after irradiation [92].
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3.  In the WiDr colon and MX-1 mammary human tumour xenograft models, the 
combination of a single local X-ray irradiation with either Xeloda or 5’-dFUrd 
was  much  more  effective  than  either  radiation  or  chemotherapy  alone.  In 
contrast, treatment with radiotherapy and 5FU in combination showed at most 
additive effects [92].
4.  Sawada [93] has also shown that TP expression can also be induced by other 
chemotherapy agents including MMC and the taxanes, the same induction of 
TP has also recently been demonstrated for cyclophosphamide [94].
For this reason Xeloda is now being investigated as an alternative to IV 5FU in many 
chemotherapy regimens for solid tumours. This includes several phase II trials in both 
anal and rectal carcinomas.
1.21  Chemoradiation in anorectal carcinomas
Chemoradiation is being increasingly used in the treatment of many cancer sites.  In 
the case of anal  cancer it has  changed  current practice  in the  last  decade.  In rectal 
cancer its role is still to be clearly defined and we await current trials. It appears to be 
most  promising  in  downstaging  locally  advanced  rectal  cancers  to  ensure,  where 
possible, a curative resection with negative margins. Most chemoradiation schedules 
deliver  a  dose  of 45-50.4Gy  in  25-28  fractions  over  5-6  weeks  with  synchronous 
chemotherapy delivered in days 1-5 and 29-33.  The origin of this schedule lies in the 
work  of Charles  Moertel  published  in  1969  [95]  and  Norman  Nigro  in  1974  [14]. 
This introductory chapter explains in detail the current role of chemoradiation in the 
treatment of anal and rectal carcinomas.
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Section 4  The role of molecular markers
1.22  Introduction
Prognostic markers  are relevant  factors in the management of patients  with  cancer. 
They  help  to  stratify  patients  for treatment  by  identifying  different  risk  groups  in 
order  to  improve  survival  and  reduce  morbidity  [96].  These  markers  include 
biological,  clinical,  pathological  and  genetic  features.  Currently  clinical  and 
pathological  features  are used  commonly in treatment decision-making  for patients 
with cancer. In anal and rectal cancers the extent of the primary tumour (T stage) and 
lymphatic  spread  (N  stage),  as  well  as  certain  histological  features  are  already 
established  prognostic  indicators.  However,  these  factors  are  not  easy  to  predict 
preoperatively.  Thus  there  have  been  considerable  efforts  to  define  accurate 
histological, pathological  and molecular information preoperatively, which could be 
used to predict outcome.
In the future it may become possible for clinicians to individualise the treatment of 
patients with cancer by tailoring the treatment based on the molecular biology of each 
individual’s tumour.  By understanding the tumour biology, molecular markers could 
be  identified,  which  may  be  predictive  of both  patient  response  and  outcome  to 
treatment,  and  are  independent  from  the  traditional  clinical  and  pathologic  factors. 
Although the combination of radiotherapy and chemotherapy holds great promise for 
the treatment of both anal and locally advanced rectal cancer, survival rates could be 
much improved.  In developing potential prognostic  and predictive markers in these 
two disease sites it could help the clinician identify those patients most at risk of local 
recurrence and metastatic disease and treat them with more intensive chemoradiation 
regimens or in the case of anal cancer, primary surgery.
Many  of  these  molecular  marker  proteins  can  be  assayed  using  standard 
immunohistochemical  techniques,  from  formalin-fixed,  paraffin-embedded tissue or 
by western blot or flow cytometric analysis.  Other laboratory techniques have been 
developed  to  identify  specific  genetic  alterations  using  the  reverse-transcriptase 
polymerase chain reaction and DNA sequencing.  However, achieving a reliable and 
informative predictive marker is not a trivial task due to the complexity, redundancy 
and  interdependence  of the biological  processes  that  determine how  a tumour will
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respond  to  the  radiotherapy,  chemotherapy  or  a  combination  of the  two  treatment 
modalities.
1.23  Choice of molecular markers
There  are  potentially  numerous  molecular  markers,  which  could  be  studied  in 
predicting the  response to  combined  chemotherapy and radiotherapy,  and  survival. 
The two treatment modalities may interact in many ways; they may be active against 
different  tumour  cell  subpopulations  and  chemotherapy  may  inhibit  the  repair  of 
sublethal damage of tumour cells after radiation exposure.
One  approach  is  to  consider  key  elements  in  each  of the  major  pathways  in  the 
context  of tumour  structure,  see  Figure  1.6  [97]  and  proteins  involved  in  5FU
metabolism.  This  can  provide  a  basic  profile  of  tumours,  which  can  then  be 
augmented  with  further  parameters.  This  approach  has  determined  the  choice  of 
markers  for  this  study.  All  of the proteins  analysed  have been  shown  in  previous 
studies to be potential candidates for predicting both prognosis and response to 5FU- 
based chemoradiation.
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Figure 1.6 The complex pathways of tumour growth [97]
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1.23.1  P53
The human p53 gene encompasses 20kb of DNA on the short arm of chromosome 17 
[98].  It is a tumour suppressor gene which plays a critical role in cell-cycle control 
and apoptosis  [99].  In response to  DNA damage p53  is  upregulated  leading to  G1 
cell  cycle  arrest,  allowing  DNA  repair  to  occur,  thus  limiting  propagation  of the 
genetic abnormalities.  Mutations in this gene are believed to be the most common 
genetic  abnormality  in  human  tumours  providing  cells  with  a  selective  growth 
advantage [100]. Many clinical studies have suggested that a mutated p53  gene is a 
marker for adverse prognosis [101] and poor response to treatment in various tumour 
types  [99,  102,  103].  A  very  close  correlation  between  over-expression  of p53 
protein, on immunohistochemistry, and mutations of the p53 gene has been described 
[104, 105].
In rectal  cancer non-functional p53  can be found in up to  84% of cases  [106].  In a 
study  by  Spitz  [107]  p53  overexpression  correlated  inversely  with  pathological 
response  to  pre-operative  chemoradiation  in  45  locally  advanced  rectal  tumour 
specimens.  Similar  associations  between  p53  expression  and  a  poor  response  to 
radiotherapy/chemotherapy were found in studies by Qiu [108] and Luna-Perez [109].
Other studies however have not found this association [110]. Rebischung [111] found 
that in patients with rectal cancer who received pre-operative RT, the presence of a 
p53 mutation was associated with a significantly shorter 5 year survival and this is in 
agreement with other studies [112-114].  Goh [115]  demonstrated a lower likelihood 
of benefiting  from  adjuvant  therapy when  a mutation  in  the p53  gene  was  present 
[116].  Schwandner  [117]  suggested  that  p53  had  an  independent  effect  on  both 
recurrence and disease-free survival.  Interestingly Diez  [118]  found the presence of 
p53  overexpression was an indicator of a high risk of recurrence only after the first 
year of follow-up. The results with p53  in rectal cancer however remain conflicting. 
In a study of 146 rectal tumours by Wiggenraad [119] which received post-operative 
RT  no  significant  association  was  found between p53  expression  and  survival  and 
several other studies have also reported negative results [119-122].
In  anal  carcinomas  overexpression  of p53  has  been  demonstrated  [123-125].  In  a 
study by  Bonin  of 64  anal  carcinomas  [126]  there  was  a trend  for patients  whose
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tumours  overexpressed  p53  to  have  inferior  loco-regional  control  and  absolute 
survival, however this was not statistically significant.  Tanum’s study  [124]  of 113 
patients  also  did  not  show  the  expression  of p53  to  be  of prognostic  significance. 
However,  Wong  demonstrated  in  [125]  patients  with  anal  carcinoma  that  p53 
expression was an independent prognostic marker for disease-free survival  and in a 
study  by  Mullerat  [127]  looking  at  pre-invasive  precursor  lesions,  p53  expression 
increased significantly as the lesions became more dysplastic and invasive. This has 
led  to  the  hypothesis  that  p53  is  involved  in  the  progression  of  anal  cancer. 
Alterations in p53 protein function in anal cancers may result from sequestration by 
the E6 viral oncoprotein of the human papilloma virus (HPV) [123,  128, 129].
1.23.2  Ki-67
Ki-67  is  one  of the most  commonly used markers  of proliferation.  It  equates  to  a 
measure of growth fraction and shows considerable heterogeneity between individual 
tumours. It is expressed within all phases of the cell cycle except GO. In rectal cancer 
fast proliferating tumours have been shown to demonstrate a high immediate response 
to  high  dose  radiation  therapy  [130]  and  an  improved  response  to  chemoradiation 
[131,  132].  In a study by Adell [133] using short-course preoperative radiotherapy a 
high Ki-67 predicted for an increased risk of treatment failure suggesting that those 
patients whose tumours demonstrated a higher proliferation rate should be offered the 
longer course chemoradiation schedules.
The apoptotic index is a marker of cell loss which is related to cell proliferation.  It 
may therefore be a surrogate marker for proliferation. In rectal cancer, a reduced local 
recurrence is observed following both surgery alone and preoperative chemoradiation, 
in  tumours  demonstrating  a higher  apoptotic  index  [134,  135].  In  cancers  with  a 
lower  apoptotic  index,  recurrence  rates  were  improved  with  the  addition  of pre­
operative radiotherapy [134].
Evidence to date has revealed that anal carcinomas have a high proliferation rate with 
a high incidence of aneuploidy [136]; however the prognostic significance of this is 
uncertain.  In  the  study  by  Mullerat  [127]  Ki-67  expression,  in  addition  to  p53, 
significantly  increased  with  progression  from  dysplastic  lesions  to  invasive  anal 
carcinoma.  It may therefore be a useful marker of early dysplasia. This finding was
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also found in a study by Calore [137] of low grade intra-epithelial neoplasia in HIV, 
where Ki-67 expression correlated with recurrence. Similar studies have not shown a 
prognostic correlation with Ki-67 in anal cancer [138, 139].
1.23.3  Bcl-2
Bcl-2  is  a membrane bound  protein  found  predominantly  in  the  nuclear  envelope, 
endoplasmic  reticulum  and  mitochondria  [140].  Bcl-2  was  discovered  in  a  B-cell 
lymphoma in which a 14:18 translocation placed bcl-2 under control of the promoter 
for  the  immunoglobulin  heavy  chain  gene,  a  rearrangement  leading  to  abnormal 
expression of the bcl-2 protein [141]. Bcl-2 expression is common in many tissues in 
the embryo but is uncommon in adult tissues with a few exceptions such as B cells 
and intestinal crypt cells.  However, a wide variety of malignancies do express bcl-2 
including 60% of follicular lymphomas and commonly breast cancer [142,  143]. Bcl- 
2  is  a negative  regulator  of apoptosis  and  when  active  it  inhibits  the  induction  of 
apoptosis from a wide variety of stimuli including radiation and chemotherapy [144]. 
Overexpression potentially promotes resistance to both treatment modalities.
In rectal carcinoma Kim [132] found a higher rate of complete pathological response 
to pre-operative chemoradiotherapy in bcl-2 negative tumours, however other studies 
have  failed  to  confirm  this  [108,  110,  132,  135].  In  studies by Buglioni  [116]  and 
Schwandner  [117]  bcl-2  expression  was  associated  with  an  improved  prognosis  in 
colorectal  carcinomas.  However,  Bhatavdekar  [145]  demonstrated  that  in  Dukes  C 
colorectal  carcinoma  patients  there  was  a  significant  poorer  overall  survival  if the 
tumours were bcl-2 positive.
In anal carcinoma there is currently little published data on the prognostic role of bcl-
2.  A recent study by Allal  et al  [146]  demonstrated that a lack of bcl-2  expression 
correlated  with  a  lower  local  control  and  5-year  survival,  and  this  remained 
significant on multivariate analysis.
1.23.4  Cyclins
The cyclins are a family of regulatory proteins, which interact with cyclin-dependent 
kinases (CDK’s). These are responsible for regulation of cell cycle transitions. Cyclin 
A is a marker of proliferation which is expressed predominantly by cells in the S and
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G2 phases  of the cell  cycle.  It is useful  in conjunction  with ki67.  Cyclin D1  binds 
cdk4,  and  this  complex  promotes  cell  cycle progression by phosphorylation  of the 
retinoblastoma protein, which is required for transition through the Gl/S checkpoint. 
Overexpression  of  cyclin  D1  could  facilitate  the  process  of  repopulation  by 
recruitment and it is found commonly overexpressed in head and neck cancers [147]. 
Several studies in the same tumour site have suggested that cyclin D1  expression may 
provide independent prognostic value for clinical outcome [148, 149].
Cyclins  D1  and  E  have  been  found  to  be  over-expressed  in  colorectal  carcinoma 
[150],  however  in  a  study  by  Schwandner  [151]  cyclin  D1  was  not  found  to  be 
associated with prognosis in rectal cancer. There is little further data on the potential 
prognostic role of cyclins in anorectal carcinomas.
1.23.5  Carbonic Anhydrase 9
Tumours  which  are  low  in  oxygen  are  often  associated  with  a  poor  response  to 
radiotherapy  [152]  and  as a result are less  curable.  Markers which can  identify the 
amount of hypoxia within a tumour are therefore potentially important.
CA9  is  a member of the  carbonic  anhydrase  family which  catalyses  the reversible 
hydration Of carbon dioxide to carbonic acid. Transcription of this gene is known to 
be regulated by the Von Hippel-Lindau tumour suppressor gene, the protein product 
of which is part of a ubiquitin ligase complex [153]. This complex is responsible for 
targeting  HIF-la  for  oxygen-dependent  proteolysis  [154,  155].  The  interaction  of 
Von Hippel-Lindau protein with HIF-la  appears  to be governed by iron-dependent 
hydroxylation of a specific proline in the oxygen-dependent degradation domain of 
HIF-la [156,  157]. Therefore at low levels of oxygen, HIF-la is stabilised causing an 
increase in expression of CA9. Areas of high expression of CA9 have been shown to 
co-localise with regions of tumour hypoxia in bladder, skin and more recently cervix 
cancer,  and  incubation  of tumour  cells  under  hypoxia  has  been  shown  to  induce 
expression of CA9 [158-161].
Expression of CA9 occurs in several tumour sites [158], It was recently found to be a 
significant predictor of disease-specific and metastasis-free survival in patients with 
squamous  cell  cancer  of the  cervix  [162].  The  role  of hypoxia  in  rectal  and  anal
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carcinomas  and  how  it  may  influence  response  to  chemoradiation  is  largely 
unexplored with little or no published data.  Hypoxia in other tumour sites especially 
squamous cell carcinomas has been shown to be important in predicting response to 
treatment  and  influencing  clinical  outcome.  Determining  the  effect  of hypoxia  in 
squamous anal carcinomas was therefore of particular interest.
1.23.6  CD34
There  is  considerable  interest  in  angiogenesis  and  its  role  in  the  growth  of solid 
tumours.  Measuring micro-vessel density (MVD) within tumours has been suggested 
as an indirect way of studying angiogenesis, which may act as a powerful prognostic 
tool. CD34 stains small and large vessels with equal intensity in normal and tumour 
tissues.
Some investigators have  shown a relationship between high MVD  and lymph node 
and distant metastases in colorectal cancer [163-165]. Galindo-Gallego [166] showed 
that  the  presence  of  microvessels  was  prognostic  for  overall  survival  but  not 
progression free survival,  at all Dukes staging.  This was supported by Takebayashi 
[165].  In a study by Vermeulen [163]  145 colorectal tumours were examined. A high 
MVD  was  associated  with  a  shorter  survival  in those patients  undergoing  surgery. 
This  group  also  showed  that  a  high  MVD  correlated  with  a  higher  incidence  of 
haematogenous  but  not  lymphogenic  metastases,  suggesting  that  in  those  patients 
with  a  Dukes  B  tumour  with  a  high  MVD,  adjuvant  chemotherapy  should  be 
considered.  Interestingly  a  study  by  Saclarides  [167]  demonstrated  an  inverse 
association between a high concentration MVD and decreased survival, this was also 
found  in  the  study  by  Qui  [108]  following  pre-operative  RT  and  surgery.  These 
conflicting results may arise because they involve  selection  of areas near or at the 
edge  of  a  tumour  to  identify  the  highest  areas  of  activity,  thereby  introducing 
selection bias.
In anal carcinoma there is little data on the potential role of angiogenic markers. In a 
study of CD31  [168],  a platelet  endothelial  cell  adhesion molecule,  like  CD34,  no 
correlation with neoplastic relapse was noted but there was a significant correlation 
with  the  depth  of tumour  invasion.  This  finding  supports  the  concept  that  tumour 
growth is angiogenesis-dependent.
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1.23.7  Thymidylate synthase (TS)
Thymidylate synthase (TS) is the enzyme required for the production of thymidine in 
DNA  synthesis,  and  its  inhibition  is  one  of the  primary  mechanisms  by  which  5- 
fluorouracil  (5FU)  inhibits  growth  of colorectal  carcinoma.  TS  is  therefore  a  rate- 
limiting  enzyme  in  the  DNA  synthetic  pathway.  TS  levels  within  a  tumour  are 
associated  with  5FU  sensitivity  and  overexpression  of  TS  is  associated  with  an 
impaired response to anti-metabolite treatment and thus a poorer survival [169].
High  levels  of TS  have been  shown to  correlate with high rates  of recurrence  and 
decreased survival in colorectal cancer patients particularly in those treated with 5FU 
[ 170, 171 ].  In a study [ 171 ] of patients entered into the NSABP-RO1, 49% of patients 
with low TS  levels were free of disease at 5  years  compared to 27% in those with 
high  TS  levels.  In  Edler’s  study  [172]  high  TS  protein  expression  predicted  for  a 
poorer disease-free  survival  and  overall  survival  independently of Dukes  stage  and 
5FU  treatment.  Okonkwo  [110]  demonstrated  that  the  TS  level  in  rectal  tumours 
could be used as a predictor of sensitivity to chemoradiation and in a study by Saw 
[173]  of  60  locally  advanced  rectal  carcinomas  treated  with  pre-operative 
chemoradiation the presence of no TS staining was associated with more significant 
downstaging.
Although  there  is  a  large body of evidence  for the role of TS  as  a prognostic and 
predictive  marker  in  colorectal  cancer,  its  role  in  anal  cancer  remains  largely 
unexplored.
1.23.8  Thymidine phosphorylase
TP  is  an  enzyme,  which  is  involved  in  the  synthesis  of DNA  and  catalyses  the 
reversible  synthesis  of thymidine.  See  Figure  1.7.  It  is  also  identical  to  platelet- 
derived endothelial cell growth factor, a marker of angiogenesis. Takebayashi  [165] 
found that a surrogate marker for microvessel counts was the expression of thymidine 
phosphorylase  and  this  group  demonstrated  that  TP  expression  was  significantly 
associated with a worse outcome in 163 primary colorectal carcinomas. This has been 
shown  in  other  studies  [170,  174].  Metzger  [175]  found  that  a  high  level  of 
expression of TP was associated with a poorer response to 5FU, in a small study of
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colorectal  cancers.  There  is  little  data however  looking  at  the  role  of TP  in  rectal 
cancer alone and in anal cancer.
1.23.9  Dihydropyrimidine dehydrogenase (DPD)
DPD is the initial and rate-limiting enzyme in 5FU catabolism [176]. It is active in a 
circadian pattern  [76,  176].  This  is  associated  with  an  inverse  circadian  pattern  in 
fluorouracil concentrations [76,  177]. There is considerable inter-patient variability in 
DPD  activity in  normal  tissues,  primarily the  liver.  This  variability has  a normal 
distribution with up to a sixfold variation from the lowest to the highest levels  [76, 
176, 177]. Malignant tissues can also vary in their level of DPD activity [178].
The importance of DPD has been demonstrated in several studies. Low levels of DPD 
are  associated  with  higher  response rates  to  5FU  chemotherapy  in  several  tumour 
types  [75,  179,  180]  resulting in  an  improved  prognosis.  It  is  also  an  indicator of 
5FU-related toxicity.
1.23.10  Epidermal growth factor receptor
EGFR is a  170-kD trans-membrane glycoprotein whose gene is located on the short 
arm of chromosome 7pl2. It is one of four members of the erbB family of receptors 
that  has  an  intracellular  domain  possessing  intrinsic  tyrosine  kinase  activity.  On 
binding with its  ligands,  EGF or transforming growth factor alpha (TGF-a),  EGFR 
initiates  transduction  signals  regulating  cell  growth  and  proliferation  [181,  182]. 
EGFR is overexpressed in a wide variety of tumour types and its overexpression has 
been associated with more aggressive tumour behaviour, adverse patient survival and 
poor tumour response to conventional therapy 
[183-186].
A  recent  paper  [187]  examined  tumour  specimens  of patients  with  rectal  cancer 
treated by preoperative chemoradiation. 64% demonstrated EGFR + tumours. EGFR 
positivity was not associated with either the primary stage or the nodal stage of the 
tumour.  However  it  was  significantly  associated  with  a  poorer  response  to 
chemoradiation and a poorer DFS. If this could be validated, EGFR expression could 
identify  patients  at  high  risk  of failure  who  might  benefit  from  novel  therapeutic 
modalities, which target this receptor.
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1.24  The role of molecular markers in anal carcinoma
It can be seen from the information already presented that anal  carcinoma has been 
the subject of little study in terms of molecular markers.  Those studies which have 
been  undertaken  have  found  no  convincing  correlation between  prognostic  marker 
expression and response to therapy or clinical outcome. This is primarily because of 
the small number of patients studied.
Therefore,  there  is  clearly  a  need  to  expand  the  biological  knowledge  of  anal 
carcinoma and to investigate relevant markers related to treatment and outcome.
1.25  The role of molecular markers in rectal carcinoma
Locally advanced rectal  cancer offers  a unique model  for defining histological  and 
genetic changes because access to histological material is relatively easy without the 
requirements of an anaesthetic.  Rectal cancers develop along a variety of molecular 
pathways.  Each  tumour  involves  multiple,  sequential  genetic  alterations  different 
from the next.  Many markers have been studied, however the specific prognostic and 
predictive value of these in rectal cancer has yet to be definitively validated.  This is 
in  part  due  to  the  use  of polyclonal  and  monoclonal  antibodies,  different  scoring 
systems  and  stage of disease and differing treatments.  The majority of studies are 
also  small  and  have  combined  colon with rectal  cancers  and  so  the  effect of these 
markers in rectal cancer, which is often biologically more aggressive, is unclear.
1.26  In conclusion
An evidence-based approach to identifying the most valuable prognostic markers for 
anal  and  rectal  cancer  is  clearly  important.  A  frequent  difficulty  in  assessing  the 
clinical  value  of these  markers  is  the  relatively  small  number  of patients  in  each 
study. What is needed is the study of tumours in large prospective randomised trials 
using similar staining and scoring systems so that results can be compared between 
institutions.  At present, based on the evidence to date it is too early to incorporate 
these predictive markers into the routine diagnostic workup to give information to the 
clinician and help with decisions regarding treatment in these two disease sites.
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The purpose of this study was to expand further the knowledge of the potential use of 
these molecular markers  and in particular with relevance to response to  5FU-based 
chemoradiation  treatment.  In  this  study  a  large  number  of anal  and  rectal  cancer 
specimens have been  analysed and the anal  specimens were from patients who had 
been randomised into a large phase III randomised trial.
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Chapter 2  Methods and Materials
2.1  Immunohistochemistry  (IHC)
2.1.1  Handling of specimens
Formalin fixed, paraffin embedded blocks of rectal and anal cancer specimens were 
received.  Samples  were  requested  for  all  patients  with  squamous  anal  carcinoma 
entered into the ACT I trial and  155 patients with locally advanced carcinoma of the 
rectum  who  had  received pre-operative  5FU  based  chemoradiation.  A  total  of 240 
anal  and  60  rectal  cancer tissue blocks  were received.  Samples  were  cut  into  4pm 
sections using a rotary microtone.  Sections  were then mounted  onto  poly-L-Lysine 
coated microscope slides and dried overnight at 37°C.
2.1.2  Primary antibodies
The  choice  of molecular markers  used  for the  study  of the  rectal  and  anal  cancer
specimens is explained in Chapter 4 of the introduction.
2.1.2.1  P53
IHC staining of p53 was achieved using a mouse monoclonal antibody against human 
p53 protein (DAKO p53, DO-7 clone. Isotype IgG2b) code number M 7001. This is a 
recombinant human wild type protein expressed in E.coli. The DO-7 clone recognises 
an  epitope  in  the  N-terminus  of the human p53  protein.  This  epitope  is  known  to 
reside between amino  acids  19 to 26 and will therefore react with both mutant and 
wild  type protein.  P53  immunohistochemical  staining has  been  widely used  in  the 
study of p53  status in multiple cancers.  The wild-type p53  protein has a short half- 
life  and  is  virtually  undetectable  by  immunohistochemical  staining.  However, 
mutations in the p53 gene often result in stabilisation of the protein, and accumulation 
of p53  protein  has been  demonstrated  to  correlate with p53  mutations  [105].  P53 
staining is nuclear.
2.1.2.2  Ki-67
Staining  was  achieved  using  a  mouse  monoclonal  antibody  (DAKO  Ki-67,  clone 
MIB-1.  Isotype IgGl)  code number M  7240.  This is  a recombinant human peptide 
corresponding to  a  1002 bp Ki-67  cDNA fragment.  The Ki-67  antigen is  a nuclear
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protein, which is defined by its reactivity with monoclonal antibody from the Ki-67 
clone.  It reacts with an epitope encoded by a 66 bp repetitive element in the Ki-67 
gene. During interphase, the antigen can be exclusively detected within the nucleus, 
whereas in mitosis most of the protein is relocated to the surface of the chromosomes.
2.1.2.3  Bcl-2
A  mouse  monoclonal  antibody was  used  (DAKO  bcl-2,  clone  124.  Isotype  IgGl) 
code number M 0887.  This is a synthetic peptide comprising amino  acids 41-54 of 
human  bcl-2  protein.  The  protein  is  associated  with  mitochondria,  smooth 
endoplasmic reticulum and the perinuclear membrane and plays a central role in the 
inhibition  of apoptosis  (programmed  cell  death).  Staining  is  therefore  cytoplasmic 
and perinuclear.
2.1.2.4  Cyclin A
Staining for cyclin A was achieved using a mouse monoclonal antibody (Novocastra 
cyclin  A,  clone  6E6.  Isotype  IgGl),  code  NCL-Cyclin  A.  This  is  a  recombinant 
human  protein  corresponding  to  the  N-terminal  fragment  of the  cyclin  A  protein. 
Cyclin A is a proliferation marker which is detectable in S phase into G2. Expression 
of cyclin A is within the nucleus.
2.1.2.5  Cyclin D1
An antibody derived from a prokaryotic recombinant fusion protein corresponding to 
the human cyclin  D1  molecule was used for staining (Novocastra cyclin Dl,  clone 
P2D11F11.  Isotype  IgG2a).  Cyclin  Dl  is  a  36kD  protein,  which  is  normally 
detectable  in  the  G1  phase  of the  cell  cycle.  Staining  is  predominantly  nuclear; 
however cytoplasmic staining may also be seen,  especially in formalin-fixed tissues 
and when overexpression is present.
2.1.2.6  CD34
Vasculature  staining  was  achieved  using  a  mouse  monoclonal  antibody  against 
human  endothelial  cells  (DAKO  CD34,  clone  QBEnd  10 -  class  II.  Isotype  IgGl) 
code number M7165. The CD34 antigen is a single chain transmembrane protein of 
approximately  116,000  Mr,  expressed  on immature haematopoietic  stem/progenitor 
cells and small-vessel endothelial cells [188]. It appears to be expressed at its highest
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level on the earliest progenitors, and to decrease progressively with maturation [189]. 
It stains  small  and large vessels with  equal  intensity in normal  and tumour tissues. 
However it may also stain some lymphatic and perivascular stroma [190].
2.1.2.7  CA9
Staining  for  hypoxia  was  assessed  using  a  CA9  antibody,  provided  by  Professor 
Adrian Harris, Oxford Radcliffe Hospital. This was a mouse monoclonal anti-human 
antibody M75  [161].  CA9  is  strongly induced by hypoxia in  a broad range of cell 
types  [161]  and is usually associated with  areas  of necrosis  [191].  Membrane  and 
cytoplasmic staining occurs.
2.1.2.8  Thymidine Phosphorylase
TP,  a marker of angiogenesis,  was  stained  for using a mouse monoclonal  antibody 
(Neomarkers thymidine phosphorylase, clone P-GF.44C. Isotype IgGl) code number 
#MS-499-P. This is a recombinant full-length human thymidine phosphorylase. TP is 
both  chemotactic  and  mitogenic  for  endothelial  cells  and  a  non-heparin  binding 
angiogenic factor present in platelets. Its enzymatic activity is crucial for angiogenic 
activity. Its staining occurs in the nucleus, cytoplasm and stroma.
2.1.2.9  Thymidylate Synthase
TS is a marker of DNA synthesis and also plays a critical role in the effect of 5FU 
chemotherapy.  This protein was stained using a polyclonal  antibody supplied by Dr 
Wynne  Aheme,  Institute  of Cancer  Research,  Sutton.  It  was  a  rabbit  anti-human 
antibody [192, 193] and staining occurred predominantly within the cytoplasm.
2.1.2.10  Dihydropyrimidine Dehydrogenase
DPD  is  the  enzyme  responsible  for  the  catabolism  of 5FU  within  the  liver  to  an 
inactive  form.  DPD  was  stained  using  an  antibody  supplied  by  Dr  Masakazu 
Fukushima, Hanno Research Centre, Saitama, Japan. This is a rabbit anti-recombinant 
human DPD polyclonal antibody (IgG) [194]. DPD activity is present exclusively in 
the  cytosol  and  is  expression  is  highest  in  liver  tissue,  but  it  is  also  expressed  in 
variant levels in other normal and cancer tissue.
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2.1.2.11  Epidermal growth factor receptor
Staining for EGFR was assessed using an antibody specific for the external domain of 
the epidermal growth factor receptor. A recombinant fusion protein corresponding to 
the human EGFR molecule was used (Novocastra EGFR, clone 113. Isotype IgG2a), 
code NCL-L-EGFR.  Its  role  is  in  the  regulation  of cell  division,  proliferation  and 
differentiation [181,  182,  195]. The pattern of staining varies between tumour types. 
In  squamous  carcinomas  the  predominant  pattern  is  membrane  staining  but  in 
adenocarcinomas cytoplasmic staining is more common.
2.1.3  Detection systems
2.1.3.1  Avidin-Biotin Complex method
All stains except CA9 and EGFR were performed using the Avidin-Biotin Complex 
method,  see  Figure  2.1.  This  method  depends  on  the  high  affinity  of avidin  or 
streptavidin for biotin through four binding sites. A biotinylated immunoglobulin acts 
as a link antibody, comprising of biotin molecules covalently bound to the constant 
regions of the heavy chain.  Open sites on a separate avidin-biotin complex bind to 
the biotin on the link antibody. The avidin-biotin complex also consists of horseradish 
peroxidase,  which  oxidises  the  chromogen,  diaminobenzine  tetrahydrochloride 
(DAB).
Visualisation of the antigen/antibody reactions is dependent on the ability to produce 
an  insoluble  coloured  product  at  the  site  of  the  reaction.  Peroxidase-conjugated 
antibodies achieve this when in contact with an electron donor and in the presence of 
hydrogen  peroxide.  DAB  is  one of a number of electron  donor molecules  used  as 
chromogens  in  peroxidase-based  immunohistochemistry.  The  staining  procedure 
involves  adding  DAB  and  hydrogen  peroxide  to  the  avidin-biotin  complex;  the 
peroxidase releases atomic oxygen from the hydrogen peroxide that oxidises DAB to 
produce  a  brown  insoluble  end  product.  Prior  to  this,  the  endogenous  cellular 
peroxidases need to be blocked to ensure the stain is specific to bound antibody. This 
is  achieved  by  bathing  samples  in  0.1%  hydrogen  peroxide  before  adding  the 
antibody.
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2.1.3.2  Envision method
This  staining method was used for CA9 and  EGFR (DAKO  Envision-HRP mouse) 
code K4006. This system uses unique chain-polymer based technology, in which the 
peroxidase-labelled polymer is conjugated with secondary antibodies against rabbit or 
mouse.  The  system  is  biotin-ffee,  resulting  in  minimal  background  staining,  and 
consists  of only  two  antibody  stages,  thus  saving  time.  Figure  2.2  illustrates  this 
system.
2.1.4  Control sections
In order to ensure that each immunohistochemical run had been correctly performed a 
positive control sample was stained concurrently for each particular antibody.  These 
were;
■   Tonsil for the proliferative and endothelial cell markers -  CD34, bcl-2, Ki-67, 
cyclin A
■   Mantle cell lymphoma for cyclin Dl
■   Bladder squamous cell carcinoma for CA9 and EGFR
■   Colon adenocarcinoma for DPD and TS
■   Breast adenocarcinoma for p53 and TP
2.1.5  Preparation of antibodies for staining
All  antibodies  were  diluted  to  their  appropriate  concentrations  in  antibody  diluent 
(DAKO chemMate) code S2022.
The dilutions used for each antibody are given below in Table 2.1.
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A vid in -B iotin  C onjugated to  P eroxidase
B iotinylated Secondary A ntibody
Prim ary A ntibody
Figure 2.1 Avidin-Biotin Complex method [196]
STEP 1  Application of primary  STEP 2  Application of EnVisk>n,u. 
antibody. Incubate  Incubate 10 or 30 min.
10 or 30 min.
Figure 2.2 Envision method [196]
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Antibody Dilution
P53 1/300
Ki-67 1/250
Bcl-2 1/300
Cyclin A 1/100
Cyclin Dl 1/60
CD34 1/200
CA9 1/50
TP 1/400
TS 1/300
DPD 1/500
EGFR 1/20
Table 2.1 Antibody dilutions
2.1.6  Slide preparation
■   All slides were dewaxed in xylene (Surgipath code 03665E) for 5 minutes and 
then rehydrated through graded alcohols  100, 90, 70% (Hayman ethyl alcohol 
code 200-578-6) to water
■   Sections  were  then  transferred  to  lOmM  citric  acid  (Merck  277814  N) 
buffered to pH 6.0 using 2M sodium hydroxide (BDH102524X)
■   Depending on the antibody, see Table 2.2, the sections were then microwaved 
for intervals of 4 minutes to unmask the antigens to enable detection
■   Slides were then left to cool for 10-20 minutes depending on the antigen being 
stained and then washed in running tap water for a further 5 minutes
■   Staining was  then performed using an  automated  system or manually using 
the Envision method
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Microwave times Antibody
3x4 minutes P53
Ki-67
Bcl-2
Cyc A
CycD
DPD
CD34
4x 4  minutes TS
EGFR
No pre-treatment TP
microwave CA9
Table 2.2 Pre-treatment microwave times
2.1.7  Staining Methods
2.1.7.1  Automated procedure for staining
An automated system, the Dako Autostainer (universal staining system model LV-1), 
see Figure 2.3, was used for staining all of the antibodies except CA9 and EGFR. The 
automated  system  enabled  an  increased  output  with  improved  reproducibility  and 
quality.  The  system  is  open  and  involves  the  slides  being  secured  in  a  horizontal 
position,  see Figure 2.4.  The reagents  are then dispensed  onto  the tissue by use of 
teflon-coated  pipettes,  thus  mimicking  manual  staining.  The  streptavidin-biotin 
complex method was used in this automated system.
Procedure
■   Endogenous peroxidase was blocked using Dako chemMate peroxidase block, 
code S2023 for 5 minutes
■   Slides  were  then  washed  well  in  distilled  water  and  then  in  Tris  buffered 
saline (TBS) with 0.0004% tween-20 (TBS + T)
■   The slides were incubated for 60 minutes with each primary antibody
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Figure 2.3 Dako Autostainer
Figure 2.4 Positioning of slides in automated system
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■   Slides  were  washed  in  TBS  before  applying  the  biotinylated  secondary 
antibodies  (AB2,  ChemMate  detection  kit  -  Dako,  code  K5001)  for  30 
minutes
■   After washing in  TBS  +  T  the  Streptavidin peroxidase  (HRP)  was  added 
(ChemMate detection kit -  Dako K5001) for 30 minutes
■   Following further washes in TBS + T, DAB  substrate (ChemMate detection 
kit- Dako K5001) was added for five minutes following which further washes 
with TBS-T took place
■   The  slides  were  then  removed  from  the  autostainer  and  washed  well  in 
running water
2.1.7.2  Envision procedure for staining for CA9
■   Endogenous peroxidase was blocked using Dako peroxidase block (Envision 
kit code K4006) for 5 minutes
■   Slides were then washed well in running tap water
■   Dako protein block was then applied (Dako code X0909)  for 5  minutes and 
excess protein block was tipped off
■   CA9 antibody was then applied for 30 minutes
■   Slides were then washed in TBS three times before applying Dako envision 
HRP mouse polymer (code K4006) for 30 minutes
■   Slides were then washed again three times in TBS
■   DAB substrate (Envision kit code K4006) was then applied for 5 minutes
■   Slides were then rinsed in TBS and rinsed well in running tap water
2.1.8  Solutions
2.1.8.1  Tris buffer
O.IMTris (BDH103156)
0.1M Hydrochloric acid (BDH28507)
Adjust to pH 7.4-7.6
2.1.8.2  Tris buffer saline  (TBS)
500ml Tris buffer
4500ml Distilled water
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40.5  grams Sodium chloride (Sigma S-7653)
Adjust pH to 7.4-7.6
2.1.8.3  Tris buffer saline with tween (TBS+T)
5 litres Tris buffer saline pH 7.4-7.6 
2mls Tween (Tween 20- DAKO code SI966)
2.1.9  Mounting slides
All  slides were then counterstained with Gills haematoxylin (Surgipath Gill  1, code 
01500E)  for  5-10  seconds  and  washed  well  in  running tap  water.  They were  then 
dehydrated through graded alcohols and xylene before mounting the coverslips with 
p-Xylene-bis-N-pyridinium bromide (DPX) (Surgipath code number 08600E).
2.1.10  Image analysis
A  Zeiss  Axioscope  trans-illumination  microscope  with  5x,  lOx,  20x  and  40x 
objectives  and  a  lOx  eyepiece  connected to  a 3  CCD  colour camera (JVC  KY55F 
1/3” 6.4 x 4.8mm) was used to visualise and capture tissue section images.  Images 
were  digitised  with  a  Matrox  Meteor™  frame  grabber  in  a  PCI  bus  600MHz 
Pentium™  desktop  PC.  Image  capture  procedures  were  standardised  for  light 
intensity  and  background  subtraction  at  different magnifications,  depending  on  the 
analysis required,  using routines developed in Visilog 5.02  software (Noesis Vision 
Inc.).
2.1.11  Scoring of antibody  expression
All  antibodies  except  for  CD34  were  scored  for  both  intensity  and  percentage  of 
tumour  cells  stained.  Intensity  was  scored  by  assessing  the  variation  across  the 
specimens for each marker and a semi-quantitative scoring system was constructed as 
either negative (score 0), weak (score  1), moderate (score 2) or strong (score 3). The 
percentage of cells stained was scored in  increments, the limits of which varied with 
each marker,  see  Table  2.3.  In the  case of TP,  staining  could occur in  the  stroma, 
cytoplasm or nucleus, for this reason an intensity and percentage score was given for 
each location.
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2 CD34 staining was scored as the average number of vessels per mm  . This involved 
counting the number of vessels on  10 random high power fields (xlO eyepiece and 
x40 objective) and an average calculated from the scores. From the known field size 
at this power the number of vessels per mm  could be calculated. For the purpose of 
the analysis the scores were then subdivided into quartiles.
Three investigators who were blind to the clinical outcome evaluated all the marker 
scores independently. The full scoring system for each marker is given in Table 2.3
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Markers
Field Coding
Grade 1= Well differentiated 
2= Moderate 
3= Poor
Intensity score 0= None
(used for all markers except CD34) 1= Mild 
2= Moderate 
3= Strong
Bcl2 % of cells stained 0= None 
1= <20% 
2= 20-50% 
3= >50%
P53 % of cells stained 0= 0-5%
1= 5-20%
2= >20-50% 
3= >50-75% 
4= >75%
Ki67 pattern 1= Marginal 
2= Random 
3= Mixed
Ki67 % of cells stained 0= None 
1= <5%
2= 5-20%
3= >20-40% 
4= >40%
TS % of cells stained 0=<5%
1=5-20%
2=>20-50%
3=>50-75%
4=>75%
TP % of cells stained 0= None
Nucleus 1= <20%
Cytoplasm 2= 20-50%
Stroma 3= >50%
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DPD % of cells stained 0= 0-5%
1= >5-20% 
2= >20-50% 
3= >50%
CAIX % of cells stained 0= None 
1=<5% 
2= 5-20% 
3= >20%
CD34 score 10 fields at xlO objective and x40 power 
Average number of vessels per mm2
Median Ranee
First quartile 48.30 28-<60
Second quartile 67.85 60-<76
Third quartile 85.10 76-<94
Fourth quartile 105.80 94-233
Cyclin A % of cells stained 0= 0-5%
1= >5-10% 
2= >10-20% 
3= >20-50%
Cyclin D presence of staining 0= None
1= Positive nuclear 
2= positive cytoplasm
EGFR % of cells stained 0=<5%
1=5-20%
2=>20-50%
3=>50-75%
4=>75%
Table 2.3 Scoring of molecular markers
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2.2  Cell lines and culture conditions
2.2.1  Cell culture medium
HT29 and SW48 human colon cancer cells obtained from the European Collection of 
Animal Cell Cultures, were routinely grown and maintained as monolayers in tissue 
culture  flasks.  All  tissue  culture  was  performed  under  sterile  conditions,  using 
EMEMS  (Eagle’s  Minimal  Essential  Medium -   Sigma M4655)  supplemented with 
10% Foetal  Calf Serum (Helena Biosciences),  lx non-essential  amino acids (Sigma 
M7145),  ImM  sodium  pyruvate  (Sigma  S8636),  7.5%  sodium  bicarbonate  (Sigma 
S8761),  200mM  glutamine  (Sigma  G7513)  and  penicillin-streptomycin  solution 
(Sigma code P4333).
Flasks  were  maintained  in  humidified  incubators  at  37°C  in  an  atmosphere  of 5% 
CO2,  5%  O2 and  90%  N2.  Cells  were  collected  for  treatment  or passage  by
trypsinisation:  monolayers  were rinsed  with  sterile phosphate  buffered saline  (PBS
tablets  -   Sigma  P4417)  and  then  incubated  briefly  with  0.05%  trypsin,  0.53mM 
sodium  ethylenediaminetetraacetic  acid  (EDTA)  (Gibco  code  15400-054)  at  37°C. 
Detached  cells  were  diluted  in  EMEMS,  centrifuged  at  lOOOrpm  (revolutions  per 
minute) for 5 minutes and then re-suspended in EMEMS.
2.2.2  Mycoplasma testing
Before  commencement  of  the  experiments  both  cell  lines  were  tested  for 
mycoplasma.
Cells were sub-cultured in antibiotic-free medium in which they were maintained for 
3 days prior to testing. They were then trypsinised and approximately 2xl02 cells, to 
give  a confluence of 20-50%  at 48-72  hours,  in  4mls  antibiotic-free medium  were 
inoculated onto a sterile coverslip in a 5cm Petri dish. The cells were then incubated 
for 72-96 hours.  The medium was then poured off and the cells were washed twice 
with PBS to remove any non-specific DNA and debris. The cell layer was then fixed 
in 70% industrial methylated spirit (IMS) (Sigma),  for 30 minutes and washed with 
PBS.  The  cells  were  then  stained  with  0.5pg/ml  in  PBS  solution  of Hoechst  stain 
(Benzimidazole,  Sigma  HOE33258)  and  left  at  room  temperature  for  20  minutes 
under subdued lighting.  The stain was then washed off with distilled water and the
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cells were inspected using a Nikon UFX-II microscope under UV illumination.  The 
cells  were inspected  for the presence of bright  cytoplasmic  staining in the form  of 
discrete dots which represents mycoplasma contamination.
2.3  X-irradiation
f\  9 Cells from both cell lines were seeded at 5x10  cells per  150cm  flask, in 30mls of 
EMEMS.  They were then  irradiated  on the  fourth  day after  subculture.  The  flasks 
were placed on a perspex baseboard in an incubator maintained at 37°C and irradiated 
using  a Pantak  IV  X-ray  set.  240 kVp X-rays  were delivered  at  13  mA  (dose rate 
0.5Gy min'1 ). In the first set of experiments the cells were exposed to single fractions 
of 2Gy and  1  OGy.  In the second set a fractionated course of 2Gy x 4, each fraction 
delivered 24 hours apart, was given.
2.4  Preparation of cell extracts
For the single fraction doses cell pellets were prepared just after irradiation at 0 hours 
and then at 2, 7, 24 and 48 hours.  The single dose experiments were repeated three 
times  for  each  cell  line  so  that  for  each  time  point,  three  separate  samples  were 
obtained.  Similarly in the fractionated experiments three samples were obtained for 
each 24 hour time point.
Cell pellets were prepared by tipping off the medium from the cells and washing in 
ice cold PBS.  Cells were then scraped from the flasks in 24mls of medium. Half of 
the  sample was  fixed  for flow  cytometry and the remaining was  divided  into three 
samples for western blot analysis, thymidine phosphorylase and thymidylate synthase 
enzyme activity.
2.5  Enzyme activity assays
Once  the  cell  samples  had  been  split  for  TP  and  TS  analysis,  the  cells  were 
centrifuged at 1200rpm at 4°C for five minutes to produce a pellet. Each sample was 
then washed and centrifuged twice more in lOmls of ice cold PBS to remove as much 
of the culture medium as possible from the cells. This was to ensure that the Bradford 
protein assays would be as accurate as possible and not be contaminated by proteins 
within the EMEMS.
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2.5.1  Thymidine phosphorylase activity
After washing, the excess PBS was tipped off. The cell sample was then harvested on 
ice  after  application  for  10  minutes  of a  solution  containing  1%  Triton  xlOO  (t- 
Octylphenoxypolyethoxyethanol, Sigma T9284), 50mM Tris-HCL (pH 8.0),  150mM 
sodium chloride (NACL) (Sigma), lOOpg phenyl methyl sulfoxide fluoride ml (Sigma 
P7626)  and  lmg  aprotinine/ml  (Sigma  A1153).  Cell  suspensions  were  then 
centrifuged at 13,000 rpm for 30 minutes at 4°C. The supernatants were then stored at 
-80°C  until  assayed  for  TP  activity.  TP  enzyme  activity  was  analysed  using  the 
method described by Ciccolini  [197], which calculates the TP enzyme activity from 
the amount of thymidine formed in the presence of thymine and a phosphate cofactor.
2.5.1.1  TP enzyme assay
TP activity was evaluated by incubating 50pl of cell extract in 30mM Tris HCL (pH 
7.4),  ImM EDTA, 5mM magnesium chloride (Sigma M2670), and 0.25mM thymine 
(Sigma T0376).  2.5mM  deoxyribose-1-  phosphate was  added  as  a  cofactor (Sigma 
D6539).  Reactions  were  stopped after 60 minutes  by boiling in  a  water bath  for 5 
minutes.  The samples were then stored  at -20°C  for 30 minutes.  Cell  extracts were 
then centrifuged at 10,000 rpm for 10 minutes.  150pl of supernatant from each of the 
samples was then loaded onto a Phenomenex Aqua C l8 250 x 3.0mm column.  Full 
HPLC  conditions are described below.  TP  activity was expressed  as the amount of 
thymidine formed per mg protein per minute.
2.5.1.2  High performance liquid chromatography analysis
Detection  and  separation  of the  thymidine  from  thymine  was  achieved by ion-pair 
reverse phase chromatography, see Figure 2.5. The HPLC consisted of a Waters 2695 
with  a  2996  diode  array  detector.  Data  was  processed  using  Waters  Millennium 
software.  Separation was achieved using a Phenomenex Aqua C l8  column at 40°C, 
eluted  by  (a)  5mM  heptane  sulphonic  acid,  5mM  potassium  dihydrogen 
orthophosphate  (KH2PO4),  5mM  orthophosphoric  acid  (H3PO4)  and  (b)  75% 
acetonitrile (all  from Fisher  Scientific).  The  separation conditions  involved using a 
gradient  of 4-20%b  in  9  minutes  with  a  flow  rate  of 0.6mls/minute.  Comparing 
retention  times  with  standards  for  thymine  and  thymidine  identified  the  different 
peaks.
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Figure 2.5 HPLC separation of thymidine from thymine
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2.5.2  Thymidylate synthase activity
After washing, the excess PBS was tipped off. The cell sample was then harvested on 
ice after resuspending in a solution of 50mM Tris HCL buffer (pH  7.3),  containing 
2mM dithiothreitol (Sigma D8255). After sonication on an ice bed (three times at  10 
second intervals), the cell suspension was immediately centrifuged at  13,000 rpm for 
30 minutes at 4°C. The supernatants were then stored at -80°C until assayed for TS 
activity.
2.5.2.1  TS enzyme assay
TS enzyme activity was measured according to the tritium release assay described by
'y
Spears  [198].  This  assay  consisted  of  incubating  25pl  of  cytosol  with  HdUMP 
(llOnM final concentration) (obtained from Amersham Pharmacia Biotech, UK) and 
5-10 methylenetetrahydrofolate  (mTHF  (Sigma)  (0.62mM  final  concentration)  in  a 
total  volume  of  50pl  (in  the  previous  Tris-HCL  buffer).  After  30  minutes  of 
incubation  at  37°C  the  reaction  was  stopped  on  ice.  The  excess  of 3HdUMP  was 
removed by the addition of 300pl of activated charcoal (Sigma) (15%) containing 4% 
trichloracetic  acid  (Sigma)  and  5  minutes  centrifugation  at  10,000  rpm  (room 
temperature). The  H2O  formed during the incubation was then counted in an aliquot 
of 150pl of the supernatant, to which lOmls of scintillant had been added (Beckman). 
The  scintillation  process  is  described  below.  Results  were  expressed  as  ffnoles  of 
H2O formed per minute per mg of protein.
The mTHF was prepared from tetrahydrofolic acid according to the method by Moran 
[199].  This  required  50pl  of  1M  ascorbate  (pH6.5),  2.2pl  of  37%  (vol/vol) 
formaldehyde  and  9.5mls  buffer  A  [1ml  of  1M  phosphate  (pH  7.2),  14pl  2- 
mercaptoethanol, 2ml of a solution containing lOmg of bovine serum albumin per ml 
and  17mls  of distilled  water]  to  an  ampoule  containing  3.1pmol  of tetrahydro folic 
acid (all chemicals from Sigma).
2.5.2.2  Scintillation system
The  amount  of  H2O   formed  was  counted  using  a  Beckman  LS  6500  Scintillation 
System. This system features a Motorola 68000 series microprocessor, a digital signal 
processor and a 32,768  channel Multichannel Analyser.  A user programme specific
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for 3H was used and he instrument calculates counts per minute (CPM). The counts 
per second can then be calculated and this is equivalent to the amount of radioactivity 
formed in Becquerels (Bq).
2.5.3  Bradford protein assay
Enzyme  activity  was  calculated  as  fmoles  per  minute  per  mg  of  protein.  The 
normalisation to the protein content was estimated, in duplicate, using the Bradford 
protein assay [200]. This uses albumin as a standard. Serial dilutions of both albumin 
and the enzyme samples were made in a 96 well plate. The Bradford reagent (Sigma) 
was then added and the plate was analysed on a Labsystems Multiscan MCC/340 MK
II.  This is an 8 channel vertical light path filter photometer. The absorbance readings 
were  taken  at  620nm.  The  amount  of absorption  produced  is  proportional  to  the 
protein concentration. A standard curve for protein concentration against absorbance 
is  calculated  for  albumin.  From this  curve  an  estimate can be made  of the protein 
concentration in the enzyme samples.
2.6  Protein expression and cell cycle analysis
In  addition  to  studying  the  changes  in  enzyme  activity  following  radiation,  the 
changes  in  protein  expression  were  also  analysed.  Flow  cytometric  analysis  was 
chosen as not only could the relative levels of protein expression be assessed but also 
the changes in the expression throughout the cell cycle. This is particularly important 
as cell cycle changes will occur in response to the radiation. The antibodies used for 
TP  (Neomarkers  P-GF.44C)  and  TS  (Chemicon  International  clone  TS  106)  were 
mouse  monoclonals  and  in  the  case  of  the  TP  antibody  it  had  not  been  used 
previously in flow cytometric analysis. For this reason, prior to commencing the flow 
analysis,  western blots  were performed on the earlier samples,  in both cell  lines to 
ensure that protein expression was detectable with each antibody.
2.6.1  Western blot analysis
After scraping cells into cold PBS the samples were then centrifuged for 5 minutes at 
1200 rpm.  The PBS was then tipped off and the pellets resuspended in  1ml of cold 
PBS and transferred to an eppendorf tube. After further centrifugation at 2000 rpm for 
5 minutes the pellets were stored at -80°C until analysis.
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2.6.1.1  Western blot
Pellets  were  resuspended  in  150pl  of cold  lysis  buffer  (150mM  NaCl,  1%  Triton 
XI00,  1%  sodium  deoxycholate,  0.1%  sodium  dodecyl  sulphate  (SDS),  20mM 
EDTA, distilled water and Tris HCL (pH 7.4) (all Sigma)) and incubated for 1  hour at 
4°C.  Samples were then sonicated at  100% for one minute prior to resuspending in 
150pl  of  Laemelli  Sample  buffer  (Bio-Rad)  containing  10%  mercapto-ethanol 
(Sigma).  Samples were then heated at  100°C in a water bath for 3 minutes and then 
stored on ice.
Samples (20pl) were then loaded into lanes in a stacking gel (4% acrylamide, 0.1% 
bisacrylamide (both National  Diagnostics),  10%  SDS,  10%  ammonium persulphate 
(Sigma),  0.1%  temed  (Sigma)  and  0.5M  Tris  HCL  buffer  (pH  6.8))  and  then 
subjected to elecrophoresis in a separating gel (10% acrylamide, 0.1% bisacrylamide, 
0.05%  N,N,N’,N’-Tetramethyl ethyl enediamine  (TEMED),  10%  ammonium 
persulphate, 10% SDS and 1.5M Tris HCL buffer). 20pl of a pre-stained, broad range 
protein marker (Rainbow marker -  Amersham Life Science) was loaded to facilitate 
identification of the protein bands by molecular weight.  Electrophoresis was carried 
out in a running buffer (lOx Tris/Glycine/SDS 0.25mM Tris-1.92M glycine-1% SDS 
(National Diagnostics)) at 50mA for 4 hours, until the bands were well separated.
Gels  were then  equilibrated in  a pre-chilled transfer buffer (TB)  (lOx  Tris/Glycine 
0.2MTris-1.5M  Glycine  (National  Diagnostics))  at  4°C  for  ten  minutes  then 
positioned on nitrocellulose filters for transfer blotting of protein bands. The cassettes 
holding the  gels  and  nitrocellulose membrane  sandwiched  between  sheets  of filter 
paper  and  fibre  pads  were  inserted  into  an  electrophoresis  tank  filled  with  TB. 
Transfer electrophoresis was then applied at 47mA overnight at 4°C.
Once transfer to the nitrocellulose membrane had taken place, the membranes were 
dried.  They  were  then  incubated  for  30  minutes  in  a  non-fat  milk  solution  (5% 
Marvel,  0.2%  Tween-20  in  PBS)  to block  non-specific  protein binding  sites.  Each 
was  then  incubated  for  90  minutes  with  the  appropriate  diluted  antibody  in  2.5% 
Marvel/PBS-T  solution,  1/200  for both  TS  and  TP,  and  1/2000  for murine  p-actin 
monoclonal AC-40 (Sigma). The actin was to ensure equal loading of protein. After 
three washes in 0.2% PBS-T the blots were incubated with secondary goat anti-mouse
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IgG antibody conjugated to horseradish peroxidase (DAKO) at 1:1000 dilution in the 
2.5% marvel  solution,  for 45  minutes.  The blots  were then  washed  a  further three 
times.
2.6.1.2  Chemiluminescent detection
An  enhanced  chemiluminescence  (ECL)  detection  protocol  was  employed  for 
detection  of labelled  proteins  (Amersham  Pharmacia  Biotech  ECL  Kit).  The  ECL 
solutions  are  activated  by horseradish  peroxidase  to  emit  visible  light  that  can  be 
detected by high performance chemiluminescence film (Hyperfilm ECL, Amersham 
Pharmacia Biotech).  In a dark room,  the blots were exposed  for 60  seconds to  the 
ECL solutions prior to placing them beneath the hyperfilm. They were then left for 15 
minutes and then the film was developed.
2.6.2  Flow cytometry
After scraping the cells in cold PBS the sample was centrifuged at  1200 rpm  for 5 
minutes.  The cell pellet was then resuspended in  0.5mls of cold  PBS  and  syringed 
gently  to  break  up  any  clumps.  For  fixation,  lOmls  of 70%  cold  methanol  (BDH 
101586  B)  was  added  whilst vortexing and the  samples were stored  at  -20°C  until 
analysis.
Prior to analysing the experimental samples, titration experiments with both the TS 
and TP antibodies were performed to determine the optimal concentration of antibody 
for  analysis.  This  was  defined  as  the  dilution  at  which  maximum  fluorescence 
occurred,  showing  saturation  of the  antibody.  In  the  case  of TP  this  was  at  a  1:5 
dilution and in TS 1:25.
A further preliminary analysis was carried out to  assess the influence of confluency 
on  protein  expression  of both  proteins  in  each  cell  line.  This  was  important  to 
determine the appropriate growth conditions of each cell line for the radiation studies.
2.6.2.1  Flow cytometric analysis
Approximately lxlO6 cells at each time point were placed in two centrifuge tubes; the 
experiment  sample  and  its  control.  The  cells  were  then  washed  twice  by
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centrifugation at 2000 rpm for 5 minutes in PBS. The remaining PBS was pippetted 
off and  the  cell  pellets  were  resuspended  with  lOOpl  of the  primary  antibody  or 
isotypic control  for 90 minutes.  The antibodies  and isotypic  control  (DAKO)  were 
diluted in  1  OOjul  of PBS  with 0.5% normal  goat  serum  and  0.5%  Tween-20  (PBS- 
NGS-T (Sigma)).  The dilutions are given above.  After primary antibody incubation 
the cells were washed with PBS  and incubated for 45 minutes with secondary anti­
mouse  antibody  conjugated  to  Sigma  Fluorescein  Isothiocyanate  (FITC),  in  PBS- 
NGS-T,  at a dilution of 1:50.  The cells were then washed a further time with PBS 
prior  to  resuspending  in  0.5mls  of a  solution  of propidium  iodide  (Sigma)  at  a 
concentration of 20pg/ml  and ribonuclease  at  1  mg/ml  (Sigma).  Samples were then 
left at 4°C for 5 minutes and then analysed.
2.6.2.2  Description of the FACscan
The  flow  cytometer  system  used  was  a  Becton  Dickinson’s  FACScan,  which  is  a 
laser-based, five-parameter flow cytometry analyser. It consists of a bench-top sensor 
module and computer system, which controls both acquisition and analysis of data. 
Cells enter the flow chamber in single file and are irradiated by a 15mW, 488nm air- 
cooled argon-ion laser. Dichroic mirrors spectrally filter emitted light, separating and 
deflecting longer wavelengths whilst transmitting shorter wavelengths. Scattered laser 
light is collected in both the forward (narrow angle) and side direction.  The longer 
wavelengths are further separated by a series of long pass and bend pass filters and 
directed to three photomultiplier detectors, FL1,  FL2,  and FL3.  Having reached the 
photomultiplier  the  signal  is  amplified,  digitised,  processed  and  stored  on  the 
computer module. The FL1 detector measures light in the green range of the spectrum 
(515 to 545nm) and is optimised for FITC detection. FL2 measures orange-red light 
(564-606nm) emitted by phycoerythrin whilst the FL3 detector transmits wavelengths 
in excess of 650nm, suitable for detection of red light emitted by propidium iodide, 
which binds to DNA.
2.6.2.3  Data analysis
Data  was  analysed  using  a  computer  acquisition/analysis  programme,  Cellquest 
(Becton  Dickinson,  San  Jose,  Calif).  Events  were  quantified  by  the  imposition  of 
computer generated windows (CGW) to define specific regions on the histogram or 
two-dimensional  dot  plot.  CGW  allows  the  definition  of  specific  populations  of
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nuclei  or  cells  and  required  phases  of the  cell  cycle.  Regions  can  be  set  around 
populations of cells to omit extraneous interference from debris or from populations 
of  cells  whose  data  is  not  required.  In  this  analysis,  the  doublet  discrimination 
capability of the FACScan was used to exclude debris and cell doublets from further 
analysis. This was achieved by creating a dot plot of FL3 area versus FL3 width, see 
Figure 2.6. A region was placed around the single cell population as shown and this 
was  used  to  gate  the  data.  Analysis  was  carried  out  on  a  gated  dot  plot  of DNA 
content (FL3-area)  against FITC (FL1-height) for each protein,  see Figures 2.7  and 
2.8.
2.6.2.4  Calculation of TS and TP protein levels
Using  Cellquest,  TS  and  TP  positivity was  calculated  from  the  comparison  of the 
number of events within regions applied to the dot plots of both the control and test 
sample. Initially a region is set around the control dot plot of FL3 area v FL1  height. 
This  region  demarcates  labelled  from  unlabelled  nuclei.  This  same  region  is 
superimposed on the antibody-labelled dot plot of the same specimen and the event 
count is subtracted from that of the control.  This gives the overall number of nuclei 
showing specific labelling due to TS or TP protein expression. Further regions can be 
set around populations of nuclei, which lie within different phases of the cell-cycle, to 
allow  analysis  of oncoprotein  expression  within  each phase  of the  cell  cycle.  The 
median  fluorescence  of the  FITC-labelled  nuclei  gives  an  estimate  of the  relative 
amount of protein contained within each cell cycle phase and this can be represented 
numerically as a ratio of the median fluorescence of the positive cells compared to the 
isotypic control (unlabelled) cells.
For the purpose of this study the computer system was programmed to collect 5000 
cell events and generate a dot plot of FL3-area v FL3-width for each test sample and 
control. A region was then set around those nuclei adhering specifically to the FITC 
secondary  antibody.  This  was  done  by  excluding  the  small  proportion  of nuclei 
staining  non-specifically  and  the  labelled  cell  debris  exhibiting  the  highest 
fluorescence values, which is estimated to be less than 2% of the whole population of 
labelled material. The median fluorescence of the test and control was then calculated 
for each. A histogram of FL3 area v counts was then generated and regions were then 
set on each phase of the cell cycle, see Figure 2.9, this histogram gives the cell cycle
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profile  of the  labelled  nuclei,  see  Figure  2.10.  The  number  of events  and  median 
fluorescence  were  then  calculated  for  each  phase  of the  cell  cycle  and  compared 
between test and control samples.
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Chapter 3:
Molecular Markers in Anal Carcinoma
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Chapter 3
Defining potential predictive and prognostic 
molecular markers in anal carcinoma
3.1  Aims
■   Define predictive molecular markers for the effectiveness of chemoradiation
■   Develop  a panel  of biological  and  clinical  parameters,  that  will  predict  the 
outcome of sub-groups of patients within each arm of the trial
■   Identify new prognostic indices that will predict the outcome to treatments, 
indicating  the  best  choice  of treatment  or  the  need  to  find  an  alternative 
treatment in anal carcinoma
3.2  Introduction
The ACT I trial was one of the largest randomised phase III trials undertaken in anal 
carcinoma,  recruiting  a  total  of 585  patients  with  squamous  cell  carcinoma  of the 
anus. The patients were randomised to receive radiotherapy alone or in combination 
with 5FU and MMC, see Introduction for trial algorithm.  Permission from the CRC 
trials office (Cancer Research Campaign) was given to collect and study histological 
material obtained from the trial.
A  panel  of  10  molecular  markers  were  examined.  These  markers  were  chosen  as 
indices  of  proliferation,  vascularity  and  cell  cycle  control.  The  contribution  of 
thymidylate  synthase  (TS),  thymidine  phosphorylase  (TP)  and  dihydropyrimidine 
dehydrogenase were also studied in the context of the 5FU chemotherapy.
Proliferation:
Recruitment:
Redistribution:
Apoptosis:
Hypoxia:
Tumour structure:
Ki-67 and cyclin A
Cyclin D1 and p53
Cyclin A
P53 and bcl-2
CA9
Grade
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Vascularity:  CD34
5FU:  TS, TP and DPD
The  panel  of molecular  markers  were  examined  to  provide  a  basic  profile  of the 
tumours.  This  profile  was  analysed  in  conjunction  with  known  prognostic 
pathological  and clinical  indices, which were recorded as part of the trial database. 
These  included  sex,  age,  site  of  disease;  canal  or  margin,  tumour  stage,  grade,
treatment  arm  and tumour response to treatment.  The markers  were also  augmented
with drug and radiation specific parameters.
3.2.1  Marker Staining
Figure 3.1  demonstrates the staining patterns for each marker in the anal carcinoma 
specimens.  The patterns of staining for each marker were discussed in the methods 
and materials chapter.
3.3  Handling  of specimens
Formalin fixed, paraffin embedded blocks from the original diagnostic biopsies were 
requested from the relevant pathology centres. Samples were requested for all patients 
entered into the ACT I trial. A total of 240 tissue blocks were received. Samples were 
cut  into  4pm  sections  using  a rotary microtone.  Sections  were then  mounted  onto 
poly-L-Lysine coated microscope slides and dried overnight at 37°C.
3.4  Statistical analysis
The  main  endpoint  was  relapse-free  survival  (RFS),  with  secondary  endpoints  of 
cause-specific survival (CSS) and response to chemoradiation.
A univariate analysis was performed using Kaplan-Meier curves for the association 
between  each  of the  markers  and  known  pathological  prognostic  indices  for  RFS, 
CSS and overall survival (OS).  Comparison between the different marker scores with 
the endpoints was  compared by the  logrank test  and  associations between markers 
were assessed using the Spearmans Rank Correlation Coefficient.
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CA9  Cyclin D1
Cyclin A  CD34
DPD
Figure 3.1 Examples of molecular marker expression patterns in anal cancer
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A  multivariate  analysis  was  then  undertaken  using  the  Cox  proportional  hazards 
model.  Those  indices,  which  were  positive  on  multivariate  analysis,  were  then 
compared between  the  two  treatment  arms.  Hazard  ratios  were  calculated  and  an 
estimate  of benefit  from  chemoradiation  was  calculated  (±  1  standard  error of the 
estimate).
For the  analysis  the  statistics  package  used  was  SPSS  for windows  release  11.5.0 
(Statistical package for Social Sciences).
3.4.1  Cox proportional hazards model  (PHM)
This is a multiple regression analysis of survival data [201]. The basic assumption in 
the PHM is that at time (t) the hazard rate (death rate) for a patient with prognostic 
factors or covariates zi, Z2,.. ..,Zp is given by
X(t; zi,..., zp) = Xo(t). exp(pizi +,...,+ ppzp) 
where  Xo(t)  is  an  unspecified  baseline  hazard  function,  and  pi,  p2,....,pp  are  the 
regression variables to be estimated from the analysis.
The  sign  of  a  regression  variable  (Pi)  indicates  whether  an  increase  in  the 
corresponding  covariate  (Z j)  results  in an improved  (Pi  negative)  or a worsened  (pi 
positive) prognosis. If Pi is not significantly different from zero, the i’th covariate has 
no significant influence on prognosis.
3.5  RESULTS
3.5.1  Patient characteristics
Of the  240  blocks  received  there  was  missing data  on  10  patients;  therefore these 
were excluded from the analysis. The median age was 63 years (range 29-88) with a 
maleifemale  ratio  99:131  (43%:57%).  The  predominant  site  was  anal  canal  and 
palpable nodes were present in 16%. The majority of anal carcinomas (211/230) had a 
complete or >50% response to treatment. The median follow-up was 42 months and 
in this time 100 patients died. The majority of these deaths (76%) were related to their 
anal carcinoma. Patient and tumour characteristics within each treatment group, and 
comparisons with the original ACT  I trial  data,  are shown in Table 3.1.  This table 
demonstrates that the clinical characteristics of the cohort of patients obtained for this
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study, were comparable with the characteristics of the complete ACT I trial dataset. 
In  the  ACT  I  trial,  tumour  grade  was  not  documented  and  the  addition  of 
chemotherapy did not impact upon treatment compliance.
3.5.2  Distribution of molecular markers in the study
The  following  sections  describe  the  distribution  of staining  positivity  and  staining 
intensity  for  each  of the  groups  of markers  investigated  in  the  study.  Correlation 
analysis was used to assess the significance of any associations between intensity and 
positivity.
The distribution of marker scores between the individual treatment groups is shown 
and demonstrates that there is an equal distribution of scores for each marker between 
the two treatment arms.
3.5.2.1  Proliferation markers: Ki-67 and cyclin A
Fig. 3. 2 shows that Ki-67  expression was detectable in nearly all patients (94%) as 
was cyclin A.  The majority of tumours had Ki-67 indices that exceeded 20%. In most 
patients (>70%) the distribution of proliferation was random. The percentage of cells 
staining correlated  significantly with both Ki67  pattern (r2=  0.239,  p=<0.001)  and 
intensity (r2= 0.522, p=<0.001). Cyclin A staining was less than 20% in about 90% of 
the  tumours  in  agreement  with  its  expression  pattern  confined  to  S  and  G2  cells. 
Greater positivity for cyclin A correlated with the intensity of staining (r2=  0.719, 
p=<0.001).
3.5.2.2  Apoptosis markers: bcl-2 and p53
The  anti-apoptotic  protein,  bcl-2,  was  detected  in  38%  of the  anal  tumours  with 
variable levels of staining intensity (Fig. 3.3). Of the tumours that were positive, the 
majority  showed  positivity  in  over  50%  of the  tumour  cells.  There  was  a  strong 
correlation between positivity and intensity of staining  (r2=  0.966,  P=<0.001).  P53 
staining  occurred  in  the  majority  of  cases  (78%)  with  most  tumours  showing  a 
sporadic staining pattern with between 5  and 50% of cells staining in the specimen 
(Fig. 3.5.2.2). The degree of p53 intensity correlated significantly with the percentage 
of cells staining positively (r2= 0.667, p=<0.001).
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Patient Characteristics RT ACT I CMT ACT I
n=124 n=106
Age median 63 65 63 63
Sex M:F 47:53% 47:53% 38:62% 43:57%
Canal 103(83%) 218(77%) 86(81%) 213(73%)
Margin 21 67 20 79
T1 18(14%) 13% 15(14%) 13%
T2 48(39%) 37% 32(30%) 32%
T3 43(35%) 39% 45(43%) 40%
T4 15(12%) 11% 14(13%) 15%
Nodes impalpable 107(86%) 82% 86(81%) 77%
Nodes palpable N1 16 16
N2 4 1
Response
Clinical response 6  CR 32(27%) 30% 36(36%) 39%
weeks after initial  >50% 78(66%) 62% 59(59%) 53%
treatment  <50% 9(7%) 9% 5(5%) 8%
Died before assessment 2 6 3 9
Missing 4 2
Deaths -106
Anal 50(79%) 26(70%)
Not anal 13 11
Grade
Well 28 26
Moderate 72 58
Poor 24 22
Table  3.1  A  comparison  of patient  and  tumour  characteristics  for  RT  alone  and 
combined modality treatment between the ACT I trial and the present study
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Fig. 3.2 The distribution of proliferation markers
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3.5.2.3  Cell cycle control markers: cyclin D1
Cyclin D1  is frequently overexpressed in other squamous cell  carcinomas, yet only 
18% of the anal carcinomas stained positively for this protein (Fig. 3.4). Interestingly 
the staining was both nuclear and cytoplasmic.
3.5.2.4  Hypoxia markers: Carbonic anhydrase IX
Carbonic anhydrase-9 is considered as a surrogate marker for hypoxia within tissues. 
Over 80% of anal  carcinomas  showed some degree of positivity for CA9  and high 
levels (>5%) were observed in approximately 50% of all tumours (Fig. 3.5).
3.5.2.5  Vascular markers: CD34
CD34  expression  was  used  to  identify  blood  vessels  within  the  tumours  and  the 
vascular  density  was  calculated  per  mm .  Figure  3.6  shows  the  distribution  of 
vascular densities among the tumours and the categorization of the data into quartiles 
for  statistical  analysis.  The  mean  and  median  vascular  densities  were  78  and  74 
vessels/mm  respectively; the range spanned from a low as 9 to 232 vessels/mm .
3.5.2.6  Markers of 5-FU response: TS, TP and DPD
Very few tumours were negative for TS and expression was widespread throughout 
each  tumour.  As  a  result  only the  intensity  was  scored.  The  majority  of tumours 
showed weak to moderate intensity (Fig.  3.7.A).  Over 93% of anal tumours stained 
positively for DPD. Almost half (47%) had greater than 50% of tumour cells staining 
positive (Fig. 3.7). The majority of staining however was weak. The DPD percentage 
score correlated with intensity of staining (r = 0.589, p=<0.001).
87% of cases stained positive for TP and staining occurred in the nucleus, stroma and 
cytoplasm (Fig. 3.8). Most samples stained positively in at least two areas. TP nuclear 
percentage  correlated  strongly  with  nuclear  intensity  (r2=  0.868,  p=<0.001).  TP 
cytoplasmic  percentage  also  correlated  strongly  with  cytoplasmic  intensity  (r2= 
0.785,  p=<0.001).  There  was  also  a  positive  correlation  between  the  TP  nuclear 
intensity  score  and  the  cytoplasmic  percentage  and  intensity  scores  (1^=0.539, 
p=<0.001, r2= 0.533, p=<0.001).  Only 9% of cases  stained  for stroma alone.  There 
were no correlations between the nuclear/cytoplasmic staining with stromal staining.
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3.5.3  Correlation between markers and clinicopathological
variables
As  part  of the  trial  database  several  clinicopathological  variables  were  recorded. 
These included  the  sex  of the patient,  site  of disease,  and  T  and  N  stage.  For  the 
current series of patients, an experienced pathologist also classified the tumour grade.
Table  3.2,  shows  those  significant  correlations  which  were  identified  between  the 
clinicopathological features and the biological markers. Only CA-9 expression, of the 
biological  variables  showed  a correlation with increasing tumour  stage.  In  contrast 
tumour  grade  correlated  with  several  biological  parameters  including  increased 
expression of bcl-2, Ki-67 and stromal expression of TP; negative correlations were 
noted with p53 and cytoplasmic TP expression. Anal tumours of male subjects had a 
higher expression of p53.  Carcinomas of the anal canal correlated with an increased 
bcl-2, Ki-67 and cyclin A expression compared to anal margin tumours.
ClinicoDath Bv variable Soearmans Rank P value
T stage N stage 0.218 0.001
T stage Grade 0.159 0.015
T stage CA9 0.150 0.022
Grade Bcl-2% & Int 0.361/0.368 <0.001/<0.001
Grade P53% & Int -.218/-. 194 0.048/0.003
Grade Ki-67% 0.137 0.034
Grade TS Int 0.191 0.003
Grade TP Cyt Int -.164 0.011
Grade TP Str % & Int 0.217/0.228 0.001/0 .0 0 1
Sex: 1  male P53% & Int -.155/-. 132 0.019/0.045
2 female
Site: 1  canal Bcl-2% &  Int -.163/-. 170 0.013/0.010
2 margin
Site Ki-67% -.166 0.012
Site Cyc A% -.158 0.017
Table 3.2 Correlation between markers & clinical characteristics
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3.5.4  Correlations between individual markers
Several hypotheses were generated to look at the associations between some of the 
markers and determine their predominant role.
3.5.4.1  Thymidylate synthase
Thymidylate synthase is an enzyme involved in DNA synthesis. As a result it would 
be expected that TS  would correlate with the proliferation markers.  From the table 
below, see Table 3.3, it is clear that TS does correlate significantly with other markers 
of proliferation, Ki-67 and cyclin A.
There  is  also  a  positive  correlation  with  bcl-2  intensity  and  percentage.  This  is 
consistent with the observation that TS  expression is strongly correlated with grade 
and bcl-2 expression also correlates with grade. An increase in bcl-2 with increasing 
proliferation may be expected if cell death/loss mechanisms also show a proliferation- 
associated increase.
There was no correlation between TS and the other proteins thought to be associated 
with  5FU  metabolism.  There  was  also  no  association  with  p53,  which  has  been 
hypothesized  in  other  studies  to  modulate  expression  of  TS  [202].  The  lack  of 
correlation  with  markers  of vascularity and  hypoxia  suggests  that  in  this  group  of 
patients  TS  may purely  be  acting  as  a  marker  of DNA  synthesis  and  not  have  a 
significant role in influencing the effect of 5FU.
3.5.4.2  Dihydropyrimidine dehydrogenase
DPD is the enzyme responsible for metabolizing 5FU. High tumour levels have been 
associated with an increased resistance to 5FU-based chemotherapy.  In this analysis 
DPD did not appear to be associated with the other 5FU-dependent enzyme markers. 
However,  there  was  an  association  with  the  markers  of proliferation,  hypoxia  and 
vascularity, see Table 3.4.
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Variable Spearmans P-value
Cyclin D 0.249 p=<0.001
Cyclin A% 0.290 p=<0.001
Cyclin A Int 0.313 p=<0.001
Ki67% 0.253 p=<0.001
Ki67 Int 0.197 p=0.002
Bcl2 Int 0.236 p=<0.001
Bcl2% 0.243 p=<0.001
Table 3.3 Major correlations between TS expression and other molecular markers
Variable SDearmans P value
CA-9 0.171 0.008
CD34 -.139 0.032
Cyc A% 0.174 0.008
Cyc A Int 0.201 0.002
Ki67 Int 0.188 0.004
TP Cyt Int 0.158 0.015
Table 3.4 Major correlations between DPD expression and other molecular markers
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3.5.4.3  Thymidine phosphorylase
TP  is  multi-faceted  and  is  involved  in  DNA  metabolism,  increased  tumour 
angiogenicity  and  increased  intrinsic  cancer  cell  aggressiveness.  It  activates 
capecitabine,  an  oral  5FU  pro-drug  and  is  also  a  marker  of angiogenesis.  TP  is 
complicated by the fact that staining can occur within the tumour stroma, nucleus and 
cytoplasm.  It  is  not  clear  whether  in  all  of these  sites  TP’s  role  is  predominantly 
angiogenic.  One hypothesis is that the stromal  staining is most representative of the 
angiogenic activity and that nuclear staining may represent the form of TP involved 
in capecitabine activation.
From  the  earlier  analysis,  it was  noted that  cytoplasmic  expression  correlates  with 
nuclear  expression  but  neither  of  these  correlate  with  the  degree  of  stromal 
expression,  suggesting a different role for cytoplasmic and nuclear TP  from that of 
stromal  TP.  From  Table  3.5,  it  can  be  seen  that  TP  staining  correlated  with  the 
expression  of  cyclin  A  irrespective  of  the  cell  or  tissue  localization  probably 
reflecting its function in DNA metabolism. There was a positive correlation between 
nuclear  and  cytoplasmic  TP  expression  and  p53  but  this  was  not  observed  with 
stromal  TP  expression.  The  association  with  p53  has  been  noted  previously  [203] 
suggesting  that  TP  expression  might  be  modulated  by  p53.  Interestingly  TP 
expression did not appear to correlate with vascularity nor the hypoxic marker CA-9. 
CD34 also did not correlate with CA-9.
3.5.4.4  Proliferation markers
Cyclin A and ki67 were both strongly correlated with TS (see above) and each other 
(r =0.216,  p=0.001),  as  expected.  Cyclin  A  also  correlated  with  p53  expression 
(r =0.142,  p=0.03),  which may purely be due to  the  cell-cycle dependence of each 
protein.  There  was  also  a  positive  correlation  between  cyclin  A  and  increasing 
expression of CA-9 (r2= 0.134, p=0.04); this was not seen with Ki67.
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TP Bv variable SDearmans P-value
TP Nuc% Cyc A% & Int 0.212/0.163 p=0.001/0.013
TP Nuc% P53% & Int 0.193/0.169 p=0.003/0.009
TP Nuc Int Cyc A% & Int 0.201/0.208 p=0.002/0.001
TP Nuc Int P53% & Int 0.163/0.186 p=0.012/0.004
TP Cyt% Cyc A% & Int 0.160/0.190 p=0.015/0.004
TP Cyt% P53% & Int 0.139/0.174 p=0.033/0.007
TP Cyt Int CycA Int 0.209 p=0.001
TP Cyt Int P53% & Int 0.214/0.253 p=0.001/<0.001
TP Str% Cyc A% & Int 0.158/0.188 p=0.016/0.004
TP Str Int Cyc A Int 0.172 p=0.008
Table 3.5 Major correlations between TP expression and other molecular markers
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3.5.5  Survival analysis
The RFS rate at 5  years was estimated to be 61% ± 5.2% (1  standard error),  (95% 
confidence intervals (Cl)  50.8-71.2),  in the chemoradiation arm and 38.3% ± 4.6%, 
(95% Cl 29.3-47.3), in the radiotherapy alone arm.  This difference in RFS between 
the two treatment groups was  statistically significant on log rank testing p=0.0001. 
(Fig. 3.9).
The overall  survival  rate between the two  arms  was  55.4% ± 6.2%  (95%  Cl 43.2- 
67.6) for CMT and 45.1% ± 5.2% (95% Cl 34.9-55.3), for RT at 5  years. This was 
statistically  significant  p=0.0301,  see  Figure  3.9,  this  was  not  significant  in  the 
original ACT I trial. When cause-specific survival (CSS) was analysed at 5 years the 
difference between the two treatment arms was more striking. The CSS for RT alone 
was 54.1% ± 5.3% (95% Cl 43.7-64.5) and for the CMT arm 66.9% ± 6.0% (95% Cl 
55.1-78.7), p=0.0128. (Fig. 3.9).
3.5.5.1  Progression -free survival
On univariate analysis, for the entire group, treatment arm, increasing T and N stage, 
and  increasing TP  cytoplasmic  intensity were  statistically associated  with  a poorer 
RFS. In the case of CD34 a decreasing score was significant for a poorer RFS rate at 
5  years,  see  Table  3.6.  Increasing  p53  intensity  was  of  borderline  significance
p=0.062.
Using the Cox proportional hazards model these factors remained significant on 
multivariate analysis, see Table 3.7.
Using this same model the markers and tumour indices were compared between the 
two  treatment  arms.  In  a univariate analysis  increasing tumour T  and  N  stage,  TP 
cytoplasmic  intensity,  Ki-67  intensity  and  percentage,  and  CAIX  score,  were 
associated with  an improved  survival  in the  CMT  arm.  On multivariate  analysis  T 
stage, CD34 score and TP cytoplasmic intensity remained independently significant.
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Figure 3.9 Clinical outcome of the cohort of patients studied. The data are presented 
as progression-free (upper), overall (middle) and cause-specific survival (lower)
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Variable Code % 5vr RFS ± 1SE 95% Cl
T stage: T1 1 14% 59.1% ± 10.8 37.9-80.3
T2 2 35% 56.2% ± 6.3 43.9-68.5
T3 3 38% 44.3% ±5.5 33.5-55.1
T4 4 13% 25.0% ±8.2 8.9-41.
P=0.000*
N stage: NO 0 84% 52.1% ±3.9 44.4-59.8
N1 1 14% 34.2% ± 8.7 17.1-51.3
N2 2 2% 20.0% ± 17.9 -15-55.
P=0.002*
TP Cyt Int: None 0 28% 53.9% ±6.6 40.9-66.8
Weak 1 41% 53.9% ±5.8 42.5-65.3
Moderate 2 18% 39.7% ± 7.7 24.6-54.8
Strong 3 13% 32.0% ± 10.3 11.8-52.2
P=0.035*
CD34 score: 1st Quartile 1 27% 40.0% ± 6.6 27.1-52.9
2nd Quartile 2 24% 45.3% ±6.8 32.0-58.6
3rd Quartile 3 23% 49.1% ±7.2 35.0-63.2
4th Quartile 4 26% 61.9% ±7.0 48.2-75.6
P=0.003*
Table 3.6 Significant indices associated with progression-free survival on univariate
analysis
Variable P SE P value HR 95% Cl
T stage 0.571 0.122 0.000* 1.769 1.39-2.25
N stage 0.531 0.199 0.008* 1.701 1.15-2.51
CD34 -.008 0.004 0.038* 0.992 0.98-1.00
TP cyt I 0.376 0.107 0.000* 1.457 1.18-1.80
Group 1.031 0.214 0.000* 2.804 1.84-4.26
Table 3.7 Cox’s proportional hazards model for significant indices on multivariate 
analysis with progression-free survival
SE = Standard error 
HR = Hazard Ratio 
Cl = Confidence interval
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3.5.5.1.1  T stage
Increasing T stage was associated with an improved RFS in the CMT arm compared 
with a significantly poorer RFS in the RT alone treatment arm (p=0.383,  SE 0.060, 
p<0.001, hazard ratio  1.466), see Figure 3.10. This might suggest that treatment with 
chemoradiation eliminates the prognostic effect of T stage. The finding that there was 
no significant difference in RFS between the different T stages for the CMT arm but 
it  was  significantly  different  for  those  patients  having  RT  alone  supports  this 
hypothesis. In particular T4 tumours do very poorly with RT alone.
Table 3.8 shows the RFS for the two treatment arms according to T stage, and Figure 
3.11  shows the estimated benefit from CMT over RT alone assuming a RFS rate of 
40% at  5 years in the RT arm, as calculated in the survival analysis. This shows that 
patients with T4 tumours benefit most from CMT.
T Stage  5 year relapse-free survival ± 1SE
CMT 95% Cl RT 95% Cl
T1 62.7% ± 19.8 23.9-100 55.6% ± 11.7 32.7-78.5
T2 64.4% ± 10.4 44.0-84.8 50.6% ± 7.8 35.3-65.9
T3 58.1% ±7.6 43.2-73.0 29.8% ± 7.2 15.7-43.9
T4 50.0% ± 13.4 23.7-76.3 All progressed
Table 3.8  5 year RFS - T stage versus treatment arm
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Figure  3.10  Effect  of T  stage  on  progression-free  survival;  chemoradiation  arm 
(upper) and RT alone arm (lower)E
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Figure 3.11 Estimated benefit from CMT for each T stage
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3.5.5.1.2  TP cytoplasmic intensity
The cytoplasmic expression of TP was associated with an improved RFS in the CMT 
arm  compared  with  a  significantly  poorer  RFS  in  the  RT  alone  treatment  arm 
(P=0.226,  SE 0.056, p=<0.001, hazard ratio  1.254),  see Figure  3.12.  The influence 
was absent in those tumours with low expression of TS in the cytoplasm.
These results suggest that with chemoradiation treatment the effect of TP cytoplasmic 
intensity is not  as  important with regards to prognosis  as  it is with  RT  alone,  in  a 
similar way to the effect of T stage. This is demonstrated in Figure 3.13, where there 
is  no  significant  difference  in  progression-free  rate  between  the  different  TP 
expressing tumours for the CMT arm, however it is significantly different for those 
patients having RT alone.
Table  3.9  shows  the  RFS  for  the  two  treatment  arms  according  to  increasing  TP 
cytoplasmic intensity, and Figure 3.14 shows the estimated benefit from CMT over 
RT  alone,  once  again  assuming  a  RFS  rate  of 40%  at  5  years  in  the  RT  arm,  as 
calculated in the survival analysis.
T P cvt int 5 vear relapse-free survival ± 1SE
CMT 95% Cl RT 95% Cl
H
I
I
o 54.5% ± 10.3 34.3-74.7 50.6% ± 8.8 33.4-67.8
TP = 1 65.3% ± 8.3 49.0-81.6 41.3% ±7.4 26.8-55.8
TP = 2 54.2% ± 11.3 32.1-76.3 28.6% ± 9.4 10.2-47.0
TP = 3 64.2% ± 14.4 36.0-92.4 11.8% ±9.8 -7.4-31.0
Table 3.9 5 year RFS - TP cytoplasmic intensity versus treatment arm
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Fig. 3.12 The influence of cytoplasmic expression of TP on  the outcome of ACT  I 
trial  patients.  The  green  lines  are those treated  with  combined  chemoradiation  and 
the pink are those treated by radiation alone.
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Figure 3.13 The influence of treatment arm on the clinical significance of cytoplasmic 
TP  expression.  The  upper  panel  shows  those  patients  treated  by  chemoradiation, 
whilst the lower represents radiation alone. The lines in both panels follow the same 
colours.
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Figure 3.14 Estimated benefit from CMT for TP cytoplasmic intensity
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3.5.5.1.3  CD34
A decreasing CD34 ((3=-.005, SE 0.002, p=0.014, hazard ratio 0.995) was associated 
with an improved RFS in the CMT treatment arm compared to RT alone.  This was 
only significant however,  for those tumours where the CD34 count was  in the first 
quartile, see Figure 3.15. Tumours that express a low CD34 score in the first quartile 
benefit significantly from combined modality treatment. In a previous study in rectal 
tumours  [108]  a  low  micro-vessel  density  was  prognostic  for  increased  tumour 
recurrence.
These results  suggest that with chemoradiation treatment the effect of a decreasing 
CD34 score is not as important with regards to prognosis as it is with RT alone. This 
is  demonstrated  in  Figure  3.15,  where  there  is  no  significant  difference  in 
progression-free rate between the different CD34 quartiles for the CMT arm, however 
it is significantly different for those patients receiving RT alone. RFS in the RT arm 
significantly  improved  with  increasing  CD34  count,  see  Table  3.10.  Figure  3.16 
shows the estimated benefit from CMT over RT alone.
CD34  5 year relapse-free survival ± 1SE
CMT 95% Cl RT 95% Cl
1st Quartile 61.0% ±9.3 42.8-79.2 20.0% ± 7.6 5.1-34.9
2nd Quartile 57.7% ±9.7 38.7-76.7 34.1% ±8.9 16.7-51.5
3rd Quartile 58.2% ± 12.7 33.3-83.1 44.6% ± 8.6 27.7-61.5
4th Quartile 67.4% ± 8.6 50.5-84.3 55.7% ± 10.2 35.7-75.7
Table 3.10 5 year RFS stratified by CD34 count and treatment arm
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Figure 3.15  The influence on vascularity on the outcome of patients treated in the 
ACT I trial. The upper panel compares tumours within the lowest vascular score (28- 
59  vessels/mm2)  between  the  two  arms  of the  trial.  The  middle  panel  shows  the 
influence  of differing  vascularity  in  the  chemoradiation  arm  and  the  lower  panel 
demonstrates the clinical  significance of vascularity in the radiation alone arm.  The 
middle and lower panel use the same colours and lines.
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Figure 3.16 Estimated benefit from CMT for CD34 count
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3.5.5.2  Cause-specific survival
On  univariate  analysis,  RT  treatment  arm,  increasing  tumour  T  and  N  stage, 
increasing P53 expression and a decreasing CD34 score were significant for a poorer 
CSS, see Table 3.11.
Using  the  Cox  proportional  hazards  model  these  indices  remained  independently 
significant on multivariate analyses, except for CD34, see Table 3.12.
As would be expected an increasing T and N stage and RT treatment arm indicates a 
poorer CSS  as  seen  in  the RFS  data.  However,  an increasing P53  intensity is  also 
significant for a poorer CSS, which was not seen for RFS.
3.5.5.2.1  P53
A decreasing P53  (P=-.273,  SE 0.138, p=0.048,  hazard ratio  0.761) was  associated 
with a significantly improved CSS in the CMT treatment arm compared to RT alone. 
This was only significant however, for those tumours, which were negative for P53, 
see Figure 3.17.
CSS  in  the  both  treatment  arms  worsened  with  increasing  P53  intensity.  This 
demonstrates that P53  remains  an independent prognostic  factor irrespective of the 
treatment received.
Table 3.13  shows the CSS  for the two treatment arms  according to  increasing P53 
intensity, and Figure 3.18 shows the estimated benefit from CMT over RT alone.
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Variable Code % 5vr RFS ± 1SE 95% Cl
Site: Canal 1 84% 55.9% ±4.5 47.1-64.7
Margin 2 16% 81.2% ±6.5 68.5-93.9
P=0.053*
T stage: T1 1 14% 59.7% ± 12.9 34.4-85.0
T2 2 35% 73.0% ±6.5 60.3-85.7
T3 3 38% 56.5% ± 6.2 44.3-68.7
T4 4 13% 31.2% ±9.0 13.6-48.8
P=0.000*
N stage: NO 0 84% 64.1% ±4.3 55.7-72.5
N1 1 14% 37.2% ± 10.6 16.4-58.0
N2 2 2% 40.0% ±21.9 -2.9-82.9
P=0.003*
P53 Int: None 0 27% 68.6% ±6.3 56.3-80.9
Weak 1 22% 65.1% ±7.9 49.6-80.6
Moderate 2 28% 59.6% ± 8.3 43.3-75.9
Strong 3 23% 42.0% ± 9.7 23.0-61.0
P=0.030*
CD34 score: 1st Quartile 1 27% 49.4% ± 7.6 12.1-64.3
2n d  Quartile 2 24% 57.7% ± 7.8 42.4-73.0
3 rd  Quartile 3 23% 62.1% ±8.1 46.2-78.0
4th  Quartile 4 26% 71.5% ±7.8 56.2-86.8
P=0.009*
Table 3.11 Significant indices associated with cause-specific survival on univariate 
analysis
Variable P SE P value HR 95% Cl
T stage 0.713 0.150 0.000* 2.040 1.52-2.73
N stage 0.553 0.210 0.008* 1.739 1.15-2.62
P53 Int 0.244 0.107 0.021* 1.277 1.03-1.57
Group 0.849 0.218 0.000* 2.337 1.52-3.58
Table 3.12 Cox’s proportional hazards model for significant indices on multivariate 
analysis with progression-free survival
125Chapter 3
100 CMT
80
60
RT
40
20
0
4 6 7 3 5 0 1 2
Follow-up (years)
1  0 0
Q .
P53=2
P53=l
P53=0
P53=3
P=0.098
2  3  4
Follow -  up (years)
1  0 0
8 0
6  0
4 0
P=0.072 2  0
0
Follow -  up (years)
Figure 3.17 The influence of p53 on CSS. The upper panel compares tumours within 
the lowest p53  score between the two arms of the trial.  The middle panel  shows the 
influence  of  differing  p53  in  the  chemoradiation  arm  and  the  lower  panel 
demonstrates the clinical  significance of p53  in the radiation alone arm.  The middle 
and lower panel use the same colours and lines.
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P53 intensity  5 year cause-specific survival ± 1SE
CMT 95% Cl RT 95% Cl P
P53 = 0 81.5% ±8.4 65.0-98.0 60.0% ± 8.6 43.1-76.9 0.010
P53 = 1 70.7% ± 11.8 47.6-93.8 57.8% ± 10.8 36.6-79.0 0.098
P53 = 2 64.0% ± 11.1 42.2-85.8 57.8% ± 11 36.2-79.4 0.867
P53 = 3 50.3% ± 14.6 21.7-78.9 33.6% ± 12.5 9.1-58.1 0.089
Table 3.13 5 year CSS -  P53 intensity versus treatment arm
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3.5.5.3  Response to chemoradiation
For the purpose  of this  analysis  response was  divided into  three  subgroups.  These 
were complete response, >50% response and <50% response or progressive disease. 
Only one patient progressed during treatment, so they were grouped with the <50% 
responders.
3.5.5.3.1  Survival analysis
RFS  and  CSS  were  analysed  for  the  different  response  groups.  This  showed  a 
significant difference at 5 years for both parameters for each group.  See Table 3.14. 
Figure 3.19 clearly demonstrates the importance of a good response to treatment in 
achieving a prolonged survival.
3.5.5.3.2  Correlation with other parameters
For  the  entire  study  group,  using  Spearman’s  Correlation  Coefficient,  significant 
associations were found between a poorer response and increasing T and N stage and 
p53  percentage of cells stained,  see Table 3.15.  In the CMT  alone group the same 
significant associations were found. However, in the RT treatment group, increasing 
T stage, decreasing cyclin A intensity, increasing bcl2% and intensity correlated with 
a poorer response to radiation.
3.5.5.3.3  Response as a prognostic marker
If response is analysed as an indices in the Cox proportional hazards model it is an 
independent, highly significant prognostic indicator marker for both RFS and CSS. 
See Table 3.16.
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Response 5 vear CSS ± 1SE 95% Cl
Complete 75.6% ± 6.3 63.3-87.9
>50% 60.1% ±5.0 50.3-69.9
<50%/ PD 17.0% ± 10.8 -4.2-38.2
5 vear RFS ± 1SE 95% Cl
Complete 63.0% ±6.3 50.7-75.3
>50% 48.5% ± 4.4 39.9-57.1
<50%/ PD None at 5 years
Table 3.14 RFS & CSS association with response to treatment
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Figure 3.19  Effect  of  clinical  response  to  treatment  on  cause-specific  survival 
(upper); and progression-free survival (lower)
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Bv Variable Correlation Coefficient P value
Entire group: T stage 0.262 0.000*
N stage 0.149 0.026*
P53% 0.145 0.030*
CMT arm: T stage 0.232 0.018*
N stage 0.268 0.006*
P53% 0.207 0.036*
RT arm: T stage 0.306 0.001*
Cyc A int -0.217 0.018*
Bcl2% 0.193 0.034*
Table 3.15 Spearmans rank correlation coefficients - response
CSS
Variable P SE P value HR 95% Cl
Response 0.563 0.227 0.013* 1.755 1.13-2.74
RFS
Response 1.221 0.278 0.000* 3.392 1.97-5.85
Table 3.16 Response as an independent prognostic indicator of both survival 
outcomes on multivariate analysis
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3.6  Discussion
Carcinoma of the anus is primarily a loco-regional disease with a low rate of distant 
metastasis  [13,  204].  Adequate  control  of the  primary  site  is  therefore  extremely 
important,  to  optimise  the  chances  of cure  while,  if possible,  preserving  anorectal 
function.  With current chemoradiation and surgical techniques  locoregional  failure 
still  occurs  in  up  to  35%  of patients  [15,  16].  Unfortunately,  most  patients  with 
tumours that fail to respond to chemoradiation will die of their disease [205, 206].
To  improve  upon  the  current  situation  it  is  becoming  increasingly  important  to 
identify other factors which may help in predicting response to treatment and clinical 
outcome; the use of biological markers is an area receiving growing attention in many 
cancers.  It is important to  determine which pre-treatment  factors  are predictive of 
patients’  responses  to  chemoradiation.  This  could  help  identify patients  who  need 
more aggressive treatment with a more intensive chemoradiation regimen or possibly 
a primary surgical approach.
There  have  been  few  studies  investigating  the  role  of molecular  markers  in  the 
management of patients with anal carcinoma.  To date, indicators of patient outcome 
have  been  derived  from  clinicopathological  features  including  tumour  stage/size, 
extent  of lymph  node  involvement  and  anatomical  site  [15,  207,  208].  However, 
despite  careful  assessment of these features  it is  still  difficult to  accurately predict 
outcome in individual patients with this disease.
In this current series of 230 anal carcinomas, a panel of 10 molecular markers were 
studied.  The aim was to identify potential markers which could predict outcome and 
response to treatment independently of the clinicopathological factors. Markers were 
stained  for  intensity  and  percentage  of  cells  staining  positive.  In  all  cases  the 
intensity scoring  correlated  significantly with percentage,  in  each  of the  molecular 
markers.
3.6.1  Correlation between molecular markers and clinicopathological variables
The  first  part  of the  study  was  to  analyse  the  association  between  the  molecular 
markers  and  the  clinicopathological  characteristics.  This  demonstrated  that  an
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increasing T stage was associated with an increasing N stage, as might be expected. 
Increasing T stage also correlated with grade and CA9, implying that the larger, faster 
growing  tumours  were  of a  higher  grade  and  more  hypoxic.  This  has  also  been 
demonstrated in a study of [191] non-small cell lung carcinomas. In this series, grade 
also correlated with increasing Ki-67 and bcl-2, indicating the degree of proliferation 
correlated with a higher grade. This may explain the positive correlation of Ki-67 and 
bcl-2 with carcinomas of the anal canal, because these are usually of a higher grade 
than  margin  carcinomas.  This  association  between  grade  and  Ki67  has  also  been 
demonstrated in breast carcinomas [209].
Grade  also  positively  correlated  with  TS,  a  marker of 5FU  metabolism  and  DNA 
synthesis,  and  with  the  stromal  expression  of the  angiogenic  factor TP.  However, 
there  was  a  negative  correlation  with  tumour  TP  expression.  This  variation  in 
association of grade with different TP locations has been noted previously [210]  in 
both breast  carcinomas  and bladder carcinomas  [211].  Grade  negatively  correlated 
with p53  staining,  indicating that the  well  differentiated  tumours  expressed  higher 
levels of p53. This association is illustrated in the correlation between sex and p53. 
Lower levels of p53 positivity were seen in females, who are known to have a higher 
incidence of anal  canal  tumours, which are usually more poorly differentiated than 
those found at the anal margin.
In  this  series  there  was  no  association  between  DPD  and  any  of  the 
clinicopathological factors, in particular grade and stage.  This is interesting because 
more  data  is  becoming  available  on  the  relevance  of DPD  expression  in  tumours 
detected by IHC. In a study [212] of bladder carcinomas, the DPD level paralleled the 
tumour stage and grade and activity of DPD was 2 fold higher in carcinoma tissues 
compared  to  normal  tissues.  The  activity  was  also  2  fold  higher  in  invasive 
carcinomas compared to  superficial bladder cancers.  This suggests that the level of 
DPD might be associated with the malignant potential.  This higher level of DPD in 
tumour tissues has also been found in head and neck cancers with a 6.6 fold increase 
[75]  and  in  colorectal  carcinomas  with  a 3.3  fold  increase  [213].  This high  DPD 
activity  in  the  cancer  tissues  compared  with  normal  tissues  may  contribute  to  the 
unfavourable differential between the anticancer effect and the adverse effect of 5FU.
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A  higher  degree  of degradation  may  occur  in  cancer  tissues  compared  to  normal 
tissues.
3.6.2  Correlations between molecular markers
The  role  and  expression  of molecular  markers  in  anal  carcinoma  remains  largely 
unstudied.  In this series there was a high proliferation index and expression of p53, 
CA9, and markers of 5FU metabolism DPD, TP and TS.  Over a third expressed bcl- 
2, however only 18% stained positively for cyclin Dl, in other series this figure has 
been much higher at 50-80% in breast and head and neck cancers [149, 214].
The significant associations between the molecular markers were studied. Ki-67 and 
cyclin A strongly correlated as markers of proliferation and as might be expected they 
also  correlated with  TS,  a marker of DNA  synthesis.  TS  also  correlated positively 
with bcl-2 intensity and percentage. This is consistent with the observation that both 
TS  and bcl-2  expression correlated  strongly with  grade.  An  increase  in bcl-2  with 
increasing proliferation may be expected if cell death/loss mechanisms  also show a 
proliferation-associated increase. There was no correlation between TS and the other 
proteins  thought  to  be  associated  with  5FU  metabolism.  There  was  also  no 
association  with  p53,  which  has  been  hypothesized  in  other  studies  to  modulate 
expression  of TS  [202].  The  lack  of correlation  with  markers  of vascularity  and 
hypoxia suggests that in this group of patients TS may purely be acting as a marker of 
DNA synthesis and not have a significant role in influencing the effect of 5FU.  TS 
did  however,  correlate  strongly  with  cyclin  Dl.  This  may  well  be  due  to  the 
expression  of  both  these  proteins  predominantly  at  G1  into  S  phase.  Equally 
overexpression  of  cyclin  Dl  shortens  the  G1  phase  and  reduces  dependence  on 
growth  factors  [215],  which  in  turn  may  result  in  loss  of cell  cycle  control  and 
increased cell proliferation.  As a result TS may increase as a marker of proliferation.
TP  cytoplasmic  expression  correlated  with  nuclear  expression  but  neither  of these 
correlated  with  the  degree  of  stromal  expression,  suggesting  different  roles.  TP 
staining correlated with the expression of cyclin A irrespective of the cell or tissue 
localization probably reflecting its function in DNA metabolism. There was a positive 
correlation between nuclear and cytoplasmic TP expression and p53 but this was not
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observed  with  stromal  TP  expression.  The  association  with  p53  has  been  noted 
previously  [203]  suggesting  that  TP  expression  might  be  modulated  by  p53. 
Interestingly TP expression did not appear to correlate with vascularity or CA-9. This 
is in direct contrast to a study in lung cancer [191], where there was significant co­
expression of CA9 with TP and a higher MVD.  Recently hypoxia has been identified 
as  a  microenvironment  factor,  which  can  up-regulate  TP  expression  and  enzyme 
activity  in  breast  carcinoma  cells  [216].  However,  other  studies  have  produced 
contrasting data, with increased expression of TP associated with high blood velocity 
as measured by Doppler imaging, which is presumably a measure of vascularity and 
therefore high oxygen tension [217].
The lack of correlation in this current series between TP and CD34 is also interesting 
as  TP  has been found to be correlated with MVD  in many tumour sites including, 
gastric  [218,  219],  cervical  [220,  221],  endometrial  [222],  breast  [223],  renal  cell 
[224]  and  colorectal  carcinomas  [165,  174,  225].  Interestingly  in  a  study  [226]  of 
endometrial carcinomas only stromal TP correlated with increased MVD and not the 
tumour staining.
Cyclin A correlated with p53  expression, which may purely be due to the cell-cycle 
dependence of each protein. There was also a positive correlation between cyclin A 
and  increasing  expression  of CA-9,  suggesting  increasing  levels  of hypoxia  with 
increased tumour proliferation, however this association was not seen with Ki67.  In 
contrast  previous  reports  have  [227]  demonstrated  that  CA9  correlated  with  Ki-67 
expression, suggesting a growth advantage in CA9 positive areas.
3.6.3  Survival outcome
In this series of anal carcinomas there was a significant improvement in RFS, OS and 
CSS for those patients who received combined modality treatment. One of the most 
significant factors for predicting survival was T stage, however this effect was most 
prominent in the RT alone treatment arm, T4 tumours in particular had a very poor 
survival  outcome  if treated  by radiation  alone.  However,  all  T  stages  had  similar 
survivals in the CMT arm and a benefit for CMT  even in T1  and T2  tumours was 
demonstrated.
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A series from the Princess Margaret Hospital  also  showed that tumour size did not 
appear to be significant in those patients who received combined modality treatment 
[228].  Salmon and colleagues [229] found that tumour size was significantly related 
to survival, in which radiation therapy alone was the primary treatment, this fits with 
the current study.  This finding has also been supported in multivariate analyses in 
other anal carcinoma series [230-232].  In a series of 118 patients treated by external 
beam and brachytherapy there was an increase in local failure with T stage (Tl, 11%; 
T2,  24%;  T3,  45%  and  T4,  43%)  and  a corresponding decrease  in  5-year survival 
[233].
In contrast to T stage, the reported effect of positive lymph nodes on survival is less 
clear.  In this current series increasing N stage was associated with both a poorer DFS 
and  CSS  and  this  fits  with  the  Intergroup  trial  [18],  which  reported  a  higher 
colostomy rate, which is an indirect measurement of local  failure,  in N1  versus NO 
patients  (28%  vs.  13%).  The  EORTC  [17]  trial  also  reported  that  patients  with 
positive  nodes  experienced  significantly  higher  local  failure  and  lower  survival. 
However,  there  was  no  difference  in  prognosis  between  N1  versus  N2  versus  N3 
disease.  In  the  Princess  Margaret  series  [228]  patients  with  negative  nodes  who 
received  combined  modality  therapy  had  a  higher  5-year  cause-specific  survival 
compared with those with positive nodes (81% vs.  57%).  In contrast other studies 
have  [207,  234]  reported  no  significant  difference  in  5-year  colostomy-free  and 
overall survival in patients with node positive compared with node negative disease, 
using multivariate analyses.
Grade has been shown to be a prognostic factor in some anal carcinoma studies [235], 
with low grade tumours resulting in 5-year survivals of 75% compared with only 24% 
for high grade tumours,  however these patients  did not receive combined modality 
treatment.  In contrast in this  series grade did not impact upon survival, which is in 
agreement  with  other  studies  [236].  No  association  was  found  between  sex  of the 
patient and outcome.  However,  male  gender has been  shown to be associated with 
poorer  local  control  [237].  A  retrospective  cohort  of  1050  patients  with  anal 
carcinoma  found  that  females  had  a  more  favourable  5  year  survival  [236],  The 
EORTC study also [17] identified male sex as an independent poor prognostic factor 
for DFS and OS on multivariate analysis.
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The  high  proliferation  index  in  this  series  has  been  noted  previously  [136,  138]. 
However, no significant association was found with either of the survival endpoints. 
This  lack  of impact  upon  survival  has  been  demonstrated  in  other  studies  of anal 
carcinomas  [138]  but  associations  with  depth  of  invasion  and  lymph  node 
involvement  have been  shown  [139].  A  positive  correlation between  a high  Ki-67 
index  and  poor  prognosis  however,  has  been  reported  for  upper  urinary  tract 
carcinomas  [238],  astrocytomas  [239]  and  hepatocellular  carcinomas  [240]. 
However, inconclusive or contradictory results have been reported for other tumour 
types, namely oesophageal squamous cell carcinomas [241, 242], gastric carcinomas 
[243, 244], and lung carcinomas [245, 246].
In  this  series  78%  stained  positive  for  p53,  similar  to  other  studies  [123,  128]. 
Alterations  in p53  protein  function may result  from  either mutations  in its gene or 
sequestration by other cellular proteins such as the E6 viral oncoprotein of the HPV 
virus [247].  HPV E6 protein has a direct effect on p53 in the basal layers of the anal 
epithelium, allowing the continuous proliferation of the host cells and increasing their 
risk  of mutation  [248].  Several  studies  have  looked  at  the  association  of p53  and 
HPV.  The product of HPV E6 and E7 genes is able to inactivate the p53  and pRb 
proteins.  P53 nuclear accumulation has been found to be associated with the presence 
of HPV without an effect on clinical outcome [129].  However, in other studies p53 
was not found to be associated with HPV and coexpression of p53  and the HPV E6 
oncoprotein  was  uncommon  [123,  124,  128].  Mullerat  et  al  [127]  studied  samples 
from 70 patients with anal warts, low grade anal intraepithelial neoplasia (AIN), high 
grade  anal  intraepithelial  neoplasia  and  anal  squamous  cell  carcinoma.  Both  the 
expression  of Ki67  and  p53  increased  significantly  and  gradually  as  the  lesions 
became  dysplastic  and  invasive.  The main  increase  in p53  expression  was  as the 
lesions progressed from anal warts to low grade AIN.  A similar expression of p53 
and Ki67 has been reported to increase with the level of dysplasia in pre-invasive anal 
lesions  [249,  250].  The  average  S-phase  fraction  has  been  demonstrated  to  be 
significantly  higher  in  HPV  positive  versus  HPV  negative  lesions  with  a  higher 
PCNA index  [136].  Expression of p53  protein in anal cancer is thus influenced not 
only by alterations in the p53 gene alone, but may also be dependent on HPV status 
and this may explain the high levels of expression in anal carcinomas.
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In this  current  series  an  increased  percentage  of p53  staining  was  found  to  be  an 
independent  factor,  on  multivariate  analysis,  for  a  poorer  CSS  (p=0.01)  and  of 
borderline  significance  for  a poorer  RFS,  irrespective  of the  treatment  arm.  In  a 
similar smaller  study of [125] 49 patients, p53 expression also predicted for a poorer 
DFS.  Other studies however, have been contradictory [124].  The RTOG study [18], 
of 64 patient found there was a trend for patients whose tumours over-expressed p53 
to  have  an  inferior  outcome  however  stage  was  the  only  predictive  factor  in 
multivariate analysis. A further small study of 18 patients also concluded that p53 had 
no prognostic impact and the authors concluded that p53  gene overexpression may 
confer a more aggressive growth pattern, but does not impact upon prognosis [251].
In anal carcinoma there is little data on the potential role of angiogenic markers.  A 
study  of  CD31  [168],  a  platelet  endothelial  cell  adhesion  molecule,  like  CD34, 
showed no correlation with neoplastic relapse but there was a significant correlation 
with  the  depth  of tumour  invasion,  supporting  the  concept  that  tumour  growth  is 
angiogenesis-dependent.  Increasing MVD  has  also  been  demonstrated to  correlate 
with increasing grade of intra-epithelial anal neoplasia [252], suggesting angiogenesis 
is a pre-malignant event  [253, 254].  The significant  finding in this  study was that 
decreasing  CD34  was  significantly  associated  with  a  poorer  RFS,  in  multivariate 
analysis and CSS in univariate analysis. This was prominent in the RT alone arm but 
not in those patients  who received combined modality treatment.  A  similar finding 
has been reported  in rectal  carcinomas receiving  5FU-based  chemoradiation  [108], 
where a low micro-vessel density was prognostic for increased tumour recurrence. It 
has been suggested that higher vessel densities may facilitate higher concentrations of 
chemotherapeutic drug reaching the tumour and  that  radiation  may increase  vessel 
leakage also resulting in increased delivery of the chemotherapy to the tumour.
In this  series  TP  expression  in  the  tumour  correlated  with  a  poorer  RFS  overall. 
However in the  CMT  group, this  survival  difference was not  seen  and the patients 
with tumours expressing high levels of TP expression had a similar outcome to those 
that were negative or with low levels of TP expression. The role of TP is complicated 
by the fact that staining can occur within the tumour stroma, nucleus and cytoplasm. 
It has been suggested that stromal staining is most representative of TP’s angiogenic 
activity promoting microvessel growth supported by the observation of a correlation
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with  increased  MVD  [210,  255].  These  observations  are  in  contrast  to  the present 
study.  It  has  also  been  proposed  that  a  nuclear  location  might  indicate  a  role  of 
regulating thymidine levels for DNA synthesis, while its cytoplasmic location might 
be required to regulate other enzymes such as TS and thymidine kinase [256].
As a consequence of its involvement in angiogenesis, TP has been identified as a poor 
prognostic  factor  in  several  tumour  sites.  In  a  report  of  patients  with  gastric 
carcinoma,  [257]  TP positive tumours had a significantly worse prognosis.  Another 
study demonstrated the promotion of angiogenesis and a significantly higher rate of 
incidence of hepatic metastasis in patients with TP positive gastric carcinomas [258]. 
However, in carcinomas of the breast [259] and bladder [211], no correlation between 
TP expression and recurrence free survival, or overall survival was found.
In this current series, TP may well be acting as a poor prognostic factor as a direct 
result of its role as an angiogenic factor;  although this does not explain the lack of 
influence  seen  in  the  CMT  arm.  The CMT  is  a more  effective  treatment  and the 
prognostic effect may be lost in the same way as the effect of T stage, alternatively 
there could be an interaction between the 5FU  and TP.  The latter has already been 
suggested  in other studies  [260, 261] where TP was found to potentiate commonly 
used  cytotoxic  drugs  such  as  5-Fluorouracil  (5FU)  and  other thymidylate  synthase 
inhibitors as well as methotrexate. Fox et al [259, 262] has previously shown that TP 
is  upregulated  in  breast  cancer  epithelium  by  20  fold  and  also  showed  that  TP 
expression  was  associated  with  treatment  response  in  a  series  of  328  breast 
carcinomas treated with adjuvant CMF (cyclophosphamide,  5FU  and methotrexate) 
[263]. In the latter study univariate analysis revealed an association between TP and 
RFS but not OS in all patients and the node positive sub-group, no influence of TP 
was  observed  in  the  node  negative  group.  Patients  treated  with  CMF  showed  a 
significant increase in RFS  and OS  in TP positive tumours; this was not evident in 
patients not treated with CMF.
These  results  suggest  that  patients  with  TP-positive  tumours  have  a  significant 
survival benefit when treated with CMF.  The advantage of TP positivity may be due 
to  TP  enhancing tumour  sensitivity to  cytotoxic  therapy,  particularly methotrexate 
and 5FU.  Since the enzymic pathway of TP is reversible, the activation of 5FU may
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be enhanced with increased conversion to 5FdUMP  [261, 264], an active metabolite 
of 5FU.
In a reported study of 98 patients, 51 of whom received combined modality treatment, 
lack of bcl-2 expression was associated with lower local control and overall survival, 
this remained significant on multivariate analysis [146].  Patients with positive bcl-2 
and negative p53 tumours had a significantly higher 5-year LC compared to patients 
with negative bcl-2 and positive p53 (93% vs. 53%). In contrast in this present series 
no association between outcome and bcl-2 was demonstrated.
Data on the prognostic value of cyclin Dl  is rare, although overexpression has been 
reported to be an adverse factor in hypopharyngeal carcinomas [265] and carcinomas 
of the anterior tongue [149] predicting for an increased lymph node status and poor 
DFS and OS.  In this study cyclin Dl did not predict for outcome.
C A9 is a marker of hypoxia and although expression of CA9 has been noted in other 
tumour  sites;  cervical  [266],  oesophageal  [267],  colorectal  [227]  and  lung  cancer 
[268], its clinical and prognostic role in human malignancies is unclear.  Hypoxia in 
other  carcinomas  especially  squamous  cell  carcinomas,  has  been  shown  to  be 
important in predicting response to treatment and influencing clinical outcome [162]. 
The  role  of hypoxia  in  anal  squamous  cell  carcinomas  and  how  it  may  influence 
response to  chemoradiation is  largely unexplored.  In a study of lung cancer  [191], 
multivariate  analysis  showed  that  CA9  was  a  significant  prognostic  factor 
independent of angiogenesis.  In this  series of anal  squamous  cell  carcinomas  CA9 
stained positively in 80% of cases.  However, unlike in other squamous carcinomas, 
there was no significant correlation with either of the survival indices or response to 
chemoradiation on multivariate analyses.
There are few reports on IHC studies to evaluate the tumour expression of DPD [269, 
270]  or the relationship between  clinical  outcome  and  DPD  expression  in humans 
[269, 271-273]. Therefore, the clinical implication of intra-tumoral DPD levels is not 
clear. Recently in non-small cell lung carcinoma a poorer survival was demonstrated 
in those patients whose tumours had a high expression of DPD  [271].  However,  in 
this  series,  DPD  expression did not correlate with survival.  The lack of correlation
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with  DPD  in  the  CMT  arm  was  an  interesting  finding  because  a  recent  study  in 
bladder  carcinomas  has  demonstrated  that  the  activity  of  DPD  was  inversely 
correlated with sensitivity to 5FU [212] and a low DPD intratumoral gene expression 
in colorectal tumours was associated with tumour response to 5FU  [274].  This has 
also been demonstrated in colorectal cancer cell lines [275].
3.6.4  Treatment response
This  current  series  has  demonstrated  that  response  to  treatment  is  an  important 
prognostic factor.  Outcome is significantly improved with a CPR or >50% response 
to treatment.  Similar findings were reported  [233]  in  118  patients where the initial 
response to radiotherapy was also evaluated after a 6-8 week interval. Response was 
shown to influence locoregional control as much as survival, and appeared to be the 
main prognostic factor, this group also found that a cut-off of <50% response to be a 
good selection criteria to assess poor responders.
Patients in this study who did not achieve a greater than 50% response and went on to 
salvage surgery did not do well, with the majority of patients surviving no longer than 
18 months. However, this contrasts with the results of a small review of 21  patients, 
who  underwent  an  abdominoperineal  resection  for  persistent  disease  following 
RT/CMT who had a 72% 3  year survival [276].  An explanation for the disparity in 
survival for this group of patients is that in the current series a significant proportion 
of the poorer responders were of higher T stage and in a retrospective study [277] of 
T4 tumours, salvage surgery did not influence outcome, due to higher rates of distant 
recurrence.  This  same  retrospective  study  also  found  T4  tumours  benefited more 
from chemoradiation  as found in this current study.  Leichman et al  [206]  noted no 
recurrence of tumour in 38/45  patients who  were tumour free after chemoradiation 
with  5FU  and  MMC.  All  those  with  persistent  disease  developed  recurrence  at 
distant  sites.  This  stresses  the  importance  of achieving  eradication  of disease with 
CMT.
For all the anal carcinoma patients taken together, increasing T stage, N stage and p53 
predicted for a poorer response to treatment.  The same factors predicted response in 
the CMT treatment  arm.  In the  RT  alone  arm  associations between  response  and
142Chapter 3
several other factors also became apparent.  Increasing bcl-2 and decreasing cyclin A 
predicted for a poorer response to radiation alone.
The association of response with tumour T stage has been noted previously in anal 
carcinomas  [234].  In  a  study  of [278]  35  patients  treated  with  chemoradiation  a 
100% complete response rate was reported in T1/2 tumours and 60% in T3 tumours. 
The Intergroup and EORTC trials [17,  18]  also reported a higher complete response 
rate  by  tumour  size.  Unlike  in  this  current  series  these  results  were  based  on 
univariate  analyses.  The  association  of  response  with  N  stage  is  not  as  well 
documented and previous reported studies have  found no difference between node 
positive and node negative tumours [278].
A higher expression of cyclin A predicted  for an improved response to  irradiation. 
Willett  et  al  [279]  reported  a  marked  pathological  downstaging  after preoperative 
irradiation  of  rectal  adenocarcinomas  with  higher  Ki-67  indices  compared  with 
tumours  with  low  indices  and  an improved  survival  has  been  observed  in patients 
with  high  grade  lymphomas  receiving  chemotherapy,  whose  Ki-67  indices  were 
greater than 80% [280].
P53 in this series also predicted for a poorer response to treatment overall and in the 
chemoradiation  arm.  In  a  previously  reported  study  of  rectal  carcinomas  p53 
expression  correlated  inversely  with  response  to  chemoradiation  and  a  CPR,  and 
directly with  an  increased  likelihood  of residual  cancer in the  lymph nodes  of the 
surgical  specimens  [107].  A correlation between p53  immunohistochemical staining 
and a poor response to chemotherapy has also been observed in patients with lung and 
ovarian  cancers  [102,  103].  Recent  studies  have  confirmed  that  induction  of 
apoptosis by the agents  commonly used in cancer treatment is highly dependent on 
normal p53 function [281-284].
Bcl-2  inhibits  the  induction  of apoptosis  from  a  wide  variety  of stimuli  including 
radiation and chemotherapy [144]. Overexpression potentially promotes resistance to 
both treatment modalities. However, in this group of patients overexpression of bcl-2 
only predicted for a poorer response in the RT alone arm.
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This series demonstrates that certain molecular markers have been identified which 
may  predict  outcome  and  response  to  treatment  in  patients  with  squamous  cell 
carcinoma of the anus.  In particular this group of patients were randomised to one of 
two treatments, with differing outcomes.  This enabled a more detailed investigation 
of the role of these molecular markers in response to different treatment modalities. 
This  is  also  one  of the  first  studies  to  comprehensively  investigate  the  role  of 
biological molecular markers and their degree of expression in this carcinoma site.
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Chapter 4:
Molecular Markers in Rectal Carcinoma
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Chapter 4
Defining potential predictive and prognostic 
molecular markers in locally advanced rectal carcinoma
4.1  Aims
■   Determine the overall survival and relapse-free survival for a cohort of locally 
advanced rectal cancer patients treated with 5FU chemoradiation
■   Determine the importance of downstaging and an RO resection
■   Define predictive molecular markers for the effectiveness of chemoradiation 
in rectal carcinoma
■   Identify new prognostic indices that will predict the outcome in this group of 
rectal carcinomas
■   Identify  whether molecular markers  are  up-regulated  or  down-regulated  by 
chemoradiation
4.2  Introduction
The  Mount  Vernon  Hospital  Cancer  Centre  serves  a population  of  1.8  million.  A 
prospective  database  has  collected  information  on  all  the  locally  advanced  rectal 
cancer  patients,  who  have  been  treated  with  5FU-based  chemoradiation  prior  to 
surgery. Tumours were defined as rectal if the lower limit was located within 12cm of 
the anal verge on rigid sigmoidoscopy. Information on all these patients was retrieved 
from the database.
4.3  Patients
Between  January  1995  and  December 2002,  patients  with  locally  advanced  rectal 
cancer  were  identified.  Initial  staging  by  digital  rectal  examination  (DRE), 
computerised  tomography  (CT)  and  more  recently  magnetic  resonance  imaging 
(MRI), defined these patients as locally advanced or unresectable (stage T3/4) rectal 
cancers. A total of 155 patients had been treated with 5FU and low dose folinic acid 
in combination with radiotherapy. All patients had confirmed adenocarcinoma of the
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rectum and they were considered unresectable by the referring surgeons.  There was 
no evidence of distant metastases at the commencement of treatment.
4.4  Treatment
The patients received chemotherapy with bolus low dose folinic acid (20mg/m ) and 
5FU (350mg/m2 over a 60 minute infusion) on days  1-5  and 29-33  of radiotherapy. 
Pelvic radiotherapy delivered a dose in the majority of cases of 45Gy in 25 fractions 
over 33 days, to a planned volume.
Surgery  was  performed  6-8  weeks  after  finishing  chemoradiation.  After 
histopathological  examination  of the  resected  specimen,  patients  with  a  positive 
circumferential resection margin (< 1mm), extra-nodal deposits or Dukes C histology 
went on to receive post-operative adjuvant 5FU-based chemotherapy.
Resection margins were defined using UICC criteria:
R0:  No microscopic residual tumour
R1:  Microscopic residual tumour
R2:  Macroscopic residual tumour
4.5  Handling of specimens
Formalin  fixed,  paraffin  embedded tissue blocks  from  both  the  original  diagnostic 
biopsy and surgical specimens were requested for all of the 155 patients. A total of 60 
biopsy  and  33  surgical  tissue  blocks  were  received.  Samples  were  cut  into  4pm 
sections  using a rotary microtone.  Sections were then mounted  onto  poly-L-Lysine 
coated microscope slides and dried overnight at 37°C.
4.6  Molecular markers
A  panel  of 6  molecular  markers  were  examined.  These  markers  were  chosen  as 
indices  of proliferation,  differentiation  and  cell  cycle  control.  The  contribution  of 
thymidylate synthase (TS) and thymidine phosphorylase (TP) were also studied in the 
context  of the  5FU  chemotherapy.  All  of these  markers  have  been  implicated  as 
prognostic or predictive indices in rectal carcinoma, in previous studies.
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Recruitment:
Proliferation: Cyclin A & EGFR 
P53
Redistribution:  Cyclin A
Apoptosis:  P53 and bcl2
Tumour structure:  Grade
5FU: TS and TP
Differentiation: EGFR
The  panel  of molecular  markers  were  examined  to  provide  a basic  profile  of the 
tumours.  This  profile  was  analysed  in  conjunction  with  known  prognostic 
pathological  and  clinical  indices,  which  were  recorded  as  part  of the  prospective 
database.
Figure 4.1  demonstrates the staining patterns for each marker in the rectal carcinoma 
specimens.  The common distributions of staining for each marker were discussed in 
the methods and materials chapter.
The  main  endpoint  was  relapse-free  survival  (RFS),  with  secondary  endpoints  of 
overall survival (OS) and response to chemoradiation.
A univariate analysis was performed using Kaplan-Meier curves for the association 
between  each  of the  markers  and  known pathological  prognostic  indices  for RFS, 
CSS and overall survival (OS).  Comparison between the different marker scores with 
the endpoints  was  compared by the logrank test  and  associations between markers 
were  analysed  using  the  Spearmans  Rank  correlation  coefficient.  A  multivariate 
analysis was then undertaken using the Cox proportional hazards model. This method 
has been described in Chapter 3.
For  the  analysis  the  statistics  package  used  was  JMP  version  5.0  (Statistical 
Discovery Software, SAS Institute) and SPSS for windows release  11.5.0 (Statistical 
package for Social Sciences).
4.6.1 Marker Staining
4.7 Statistical analysis
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EGFR  TP
TS P53
Figure 4.1 Examples of molecular marker expression patterns in rectal cancer
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4.8  Results
4.8.1  Patient characteristics
The median age for the  155 patients was 67 years (range 21-85) with a male:female 
ratio  113:42 (73%:27%). The T stages were: T2:2 patients, T3:59 patients and T4:94 
patients. In the case of the two T2 patients the tumours were low and bulky. Curative 
surgery was performed in 122 patients. The median follow-up was 25 months and in 
this time 67 (43%) patients died.
4.8.2  Survival
4.8.2.1  Relapse-free survival
The median RFS was 28 months (2.33 years) and 31% were disease-free at 5 years of 
follow-up, see Figure 4.2. The median time to local recurrence (LR) was 22 months 
and 19 months for the median time to distant metastases (DM).
The median overall survival (OS) was 37 months (3.08 years) and 34% were alive at 
5 years of follow-up. From these results it is clear that this group of patients have a 
poor OS with a high risk of both LR and DM.
4.8.2.2  DFS and OS for an R0 resection
All of the 155 patients were deemed unresectable and therefore likely to have an R1/2 
resection  margin,  by  the  referring  surgeons.  Of the  155  patients  who  underwent 
chemoradiation 122 had undergone surgery with curative intent, see Figure 4.3.
After completing chemoradiation  15 patients were still unable to undergo a curative 
resection  and  underwent  palliative  surgery.  No  resection had been performed  on  a 
further 18 patients for various reasons, 4 patients died shortly after completing CRT 
or during surgery,  3  had been lost to follow-up, 5 patients refused surgery who had 
had a complete pathological response (CPR), 2 patients who had prior cardiac disease 
were  felt  unsuitable  to  undergo  surgery  and  5  patients  were  still  awaiting  their 
surgical resection.
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Figure 4.2 Progression-free and overall survival in the study patients
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Study group 
n=155
Unresectable
n=15
No resection
n=18
Potentially curative 
resection 
n=122 (79%)
CRM -ve(RO)
n=98
CPR 15/122 
(12%)
CRM +ve 
(R1/2)
n=24
Figure 4.3 Clinical outcome and management of study group
Of the 122 patients who underwent curative surgery, an RO resection was achieved in 
98/122 cases (80%), with an overall RO resection rate for the entire group (98/155) of 
63%.  The importance of achieving an RO resection in terms of survival can be seen 
in Figure 4.4 below.
As can be seen in Figures 4.5.A and B, both the LR and DM rates are higher in the 
Rl/2 resection group. This results in a significant difference between the two groups 
in both DFS and OS. The median DFS in the RO resection group was 38 months with 
a  3  year  DFS  of 52%.  This  is  in  contrast  to  the  Rl/2  resection  group  where  the 
median DFS is 16 months with a 3 year DFS of only 9%. The difference between the 
two groups is strongly significant log rank p=<0.001.
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Figure 4.4  Importance of achieving a clear circumferential  margin and progression- 
free (upper) and overall survival (lower)
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CRM +ve 
(R1/2)
n=24
CRM -ve 
(RO)
n=98
Local
recurrence
15/24
(62%)
Local
recurrence
10/98
(10%)
Potentially curative 
resection 
n=122
23/122 = 20% Local Recurrence
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28/98
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resection 
n=122
38/122 = 37% Distant metastases
Figures  4.5.A  and  B  Incidence  of local  recurrence  (upper)  and  distant metastases 
(lower) in relation to the circumferential margin
154Cl lap  ter 4
The median OS was 59 months in the RO resection group and the 3 year OS was 64%. 
In the Rl/2 resection group the median OS was 25 months with a 3 year OS of 25%. 
The  difference  in  OS  between  the  two  groups  was  strongly  significant  log  rank
p=0.0001.
It is clearly important from these figures to achieve an RO resection in this group of 
patients.  With  this  chemoradiation  regimen  62%  of  patients  previously  deemed 
unresectable  had  a  curative  RO  resection.  Pathological  downstaging  to  pTO/1/2 
occurred  in  28%  of  cases  and  15/122  (12%)  achieved  a  complete  pathological 
response  (CPR),  however  at  least  a  further  5  patients  who  refused  surgery  also 
appeared to have had a complete response.
4.8.2.3  Response to chemoradiation
For the purpose of this analysis response was divided into two groups, those whose 
tumours  had  been  downstaged  to  pTO/1/2  by  chemoradiation  and  those  whose 
tumours had not.
4.8.2.3.1  Survival analysis
RFS and OS were analysed for the different response groups. This showed there was 
a  significant  difference  at  5  years  follow-up  for  both  parameters.  See  Table  4.1. 
Figure 4.6 clearly demonstrates the impact of downstaging on survival.
Downstage 5 vear OS ± 1SE 95% Cl
Yes 71.9% ±9.6 53.1-90.7
No 30.4% ± 6.6 17.5-43.3
5 vear RFS ± 1SE 95% Cl
Yes 67.6% ± 9.2 49.6-85.6
No 24.7% ±5.9 13.1-36.3
Table 4.1 Survival outcome in relation to pathological downstaging of the primary 
rectal tumour
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Figure 4.6 The effect of downstaging on overall and progression-free survival
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4.8.2.3.2  Importance of a complete pathological response
The  results  show  that  it  is  important  in  terms  of both  RFS  and  OS  to  achieve 
downstaging of the primary tumour. As a result of these findings the importance of 
achieving  a  complete  pathological  response  was  also  examined.  It  has  been 
hypothesised that  those who  achieve a CPR in their primary tumour will  do better 
overall.
This analysis revealed that those patients whose tumours had a CPR did not have a 
better OS or RFS compared to those who downstaged to pTl/2.  In fact their survival 
rates were worse;  although not  significantly,  see Table 4.2.  Overall patients whose 
tumours were downstaged did better, see Figure 4.7.
Downstage 5 vear OS ± 1SE 95% Cl
CPR 63.2% ± 13.8 36.2-90.2
DS 80.3% ± 13.4 54.0-106.6
No 30.4 % ± 6.6 17.4-43.4
5 vear RFS ± 1SE 95% Cl
CPR 57.7% ± 13.8 30.7-84.7
DS 78.7% ± 11.2 56.7-100.7
No 24.7% ± 5.9 13.1-36.3
Table 4. 2 The effect of response on survival
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Figure 4.7 The influence of downstaging or complete pathological response on 
overall and progression-free survival
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4.8.3  Biopsy marker frequencies
From  the  original  155  patients,  60  biopsy  samples  were  received.  From  these  60 
patients,  surgical  samples were also received  in  33  cases.  The median  age for this 
group was 68 years with a male:female ratio of 48:12 (80%:20%). The T stages were: 
T3:21  patients  and  T4:39  patients  and  the  majority  of tumours  were  of moderate 
grade (65%). These are all similar to the larger cohort of 155 patients. At the time of 
the analysis 26 patients had died (43%). A survival analysis on these 60 patients was 
also very similar to the original group of 155 patients. The median OS was 40 months 
and  the  median  DFS  was  31  months.  Pathological  downstaging  occurred  in  28% 
(16/60) of cases with a CPR in 10% (6/60).
The  following  sections  describe  the  distribution  of staining  positivity  and  staining 
intensity  for  each  of the  groups  of markers  investigated  in  the  study.  Correlation 
analysis was used to assess the significance of any associations between intensity and 
positivity.
4.8.3.1  Apoptotic markers bcl-2 and p53
52%  of  the  rectal  tumours  stained  positive  for  bcl-2  and  an  increasing  bcl-2% 
correlated strongly with an increasing bcl-2 intensity score (r2= 0.877, p=<0.001).
P53  staining  occurred  in  67%  of  cases.  The  degree  of p53  intensity  correlated 
significantly  with  the  percentage  of  cells  staining  positive  for  P53  (r2=0.775, 
p=<0.001).  A  large  proportion  (-50%)  had  strong  staining  intensity  for  p53,  see 
Figure 4.8.
4.8.3.2  Thymidylate synthase and thymidine  phosphorylase
Staining  for  TS  in  the  rectal  samples  was  different  from  that  in  the  anal  cancer 
samples.  Although most of the rectal biopsies  stained positive for TS  (95%),  there 
was quite a variation in the percentage of cells stained and so this was also scored for 
the rectal tumours. The majority of the TS staining was of weak to moderate intensity. 
TS intensity correlated strongly with TS percentage (r2= 0.592, p=<0.001). See Figure 
4.9.
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Figure 4.8 The distribution of apoptosis-related proteins
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In contrast to the anal cancer biopsies only 60% of cases stained positive for TP and 
staining  appeared  to  only  occur  in  the  tumour  stroma.  TP  stromal  percentage 
correlated strongly with intensity (r2= 0.898, p=<0.001). See Figure 4.9.
4.8.3.3  EGFR and Cyclin A
EGFR staining can be cytoplasmic and membranous.  In the rectal cancer specimens 
the  staining  was  only  present  in  the  cytoplasm.  To  check  that  the  antibody  was 
working  several  other types  of tumour were  stained  and  membranous  staining  did 
occur  in  the  squamous  cell  carcinoma  controls.  There  was  a  strong  positive 
correlation between the EGFR intensity score and the percentage of cells stained (r2= 
0.843, p=<0.001). See Figure 4.10.
Over 78% of cases stained for cyclin A. The majority of samples, >95% scored 1   on 
intensity so the percentage of cells stained was the scoring used. See Figure 4.11.
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Figure 4.9. The distribution of TS and TP
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Figure 4.10 The distribution of EGFR
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Figure 4.11 The distribution of cyclin A
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4.8.4  Surgical marker frequencies
For 33 of the patients in the study, surgical sample specimens were also received. The 
aim of analysing these was to see if the expression of the markers changed following 
chemoradiation  and  whether this  influences  their value  as potential  prognostic  and 
predictive  markers.  The  following  analysis  shows  the  changes  in  intensity  of 
expression  and  percentage  of cells  staining  for  each  of the  markers  pre  and  post 
surgery.
4.8.4.1  Markers of 5FU response:  TP and TS
Figures 4.12 and 4.13 demonstrate that there is a no significant difference in TP or TS 
expression between the biopsy and surgical specimens.
4.8.4.2  EGFR expression
Figure  4.14  shows  that  there  is  a trend  for  an  increased  EGFR  expression  in  the 
surgical specimen post chemoradiation. Suggesting an upregulation in expression.
4.8.4.3  Proliferation marker: Cyclin A
Figure 4.15 demonstrates that there is an overall decrease in the expression of cyclin 
A  following  chemoradiation,  suggesting  an  overall  downregulation  in  tumour
proliferation. This has been confirmed in other series.
4.8.4.4  Apoptosis markers: bcl-2 and p53
Figure  4.16  shows  there  appears  to  be  an  increase  in  bcl-2  expression  following
chemoradiation but there is no  similar change in p53  which remains  unchanged  in 
expression, see Figure 4.17.
164T
P
 
s
u
r
g
e
r
y
-
b
i
o
p
s
y
 
s
c
o
r
e
 
T
P
 
s
u
r
g
e
r
y
-
b
i
o
p
s
y
 
s
c
o
r
e
Chapter 4
3   -
2  -
1  -
Increase at surgery
o -
-1  -
-2  -
oooooooooo oo
ooooooo
oo
ooo
- 3 - Decrease at surgery
TP biopsy score intensity
oo
ooo oo
ooooooooooooo ooooo
ooooo
-2  -
- 3 -
0
TP biopsy score %
Figure 4.12 Changes in TP intensity (upper) and % (lower) expression between 
biopsy and surgical specimens
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Figure 4.13 Changes in TS intensity (upper) and % (lower) expression between
biopsy and surgical specimens
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Figure 4.14 Changes in EGFR intensity (upper) and % (lower) expression between
biopsy and surgical specimens
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Figure 4.15 Changes in cyclin A % expression between biopsy and surgical 
specimens
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Figure 4.16 Changes in bcl-2 intensity (upper) and % (lower) expression between
biopsy and surgical specimens
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Figure 4.17 Changes in p53 intensity (upper) and % (lower) expression between 
biopsy and surgical specimens
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4.8.5  Correlation between biopsy and surgical markers and
clinicopathological variables
As  part  of the  Mount  Vernon  database  several  clinicopathological  variables  were 
recorded. These included the sex of the patient, T and N stage, tumour grade, patient 
age and degree of tumour downstaging. Table 4.3, shows the significant correlations 
between these clinicopathological features and the biopsy and surgical markers.
In the biopsy specimens there were several correlations with T and N stage, however 
the rectal tumours were all locally advanced T3 or T4 and more than two thirds were 
T4 tumours.  So any positive associations with staging may not be reliable, because 
there is  little variability in these two  clinical  characteristics.  T stage was positively 
correlated with increasing cyclin A% indicating that proliferation increases with the 
higher the T stage. Interestingly there were negative correlations between N stage and 
bcl2 intensity and TS and TP percentage.
Grade  correlated  with  cyclin  A,  a  marker  of  proliferation.  But  there  was  no 
association with bcl2, p53 or TS, as seen with the anal samples.
There were strong correlations between increased tumour downstaging and a higher 
TP intensity and percentage. A higher cyclin A percentage was also associated with 
improved tumour downstaging.  This indicates that in rectal cancer, the more highly 
proliferating  tumours  with  an  increased  expression  of stromal  TP  respond  best  to 
chemoradiation.
Age  correlated  with  a  number  of biopsy markers.  These  included  increasing bcl2 
intensity and percentage, increasing cyclin A percentage and an increasing percentage 
of cells staining for TS.
Compared  to  the  biopsy  markers  there  were  few  significant  correlations  with 
clinicopathological variables  for the surgical marker expression.  Those correlations, 
which were significant, were not the same as those seen with the biopsy samples.
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ClinicoDath By variable SDearmans Rho P value
Biopsy
T stage Cyc A% 0.2674 0.041
N stage Bcl2 Int -0.263 0.048
N stage TS% & Int -.330/-.348 0.012/0.007
N stage TP% -0.305 0.019
Age TS% 0.270 0.039
Age Cyc A% 0.280 0.032
Age Bcl2 int 0.392 0.002
Age Bcl2% 0.427 0.0008
Grade Cyc A% 0.288 0.049
Downstaging TP int -0.339 0.008
Downstaging TP% -0.331 0.010
Downstaging Cyc A% -0.287 0.028
Surserv
N stage EGFR% 0.369 0.049
N stage P53% & Int 0.417/0.348 0.011/0.038
Grade Bcl2 Int -0.338 0.044
Grade Bcl2% -0.318 0.058
Downstaging P53 Int 0.335 0.046
Table 4.3 Correlation between biopsy and surgical markers with the clinical 
characteristics
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Bcl2  was  negatively  correlated  with  grade  and  increasing  p53  intensity  was 
associated with a poorer response to chemoradiation, and an increasing N stage. The 
correlation with bcl2  maybe explained by the difference in expression between the 
surgical and biopsy specimens, see Figure 4.16; however this correlation was seen in 
the  anal  samples.  In  this  analysis  surgical  EGFR%  also  correlated positively  with 
increasing N stage.
Unlike in the biopsy samples there was no  correlation between any of the surgical 
markers  and  the  age  of the  patient.  There  was  also  no  correlation  between  the 
proliferation and angiogenic markers with downstaging.
4.8.6  Correlations between individual biopsy markers
Several hypotheses were generated to look at the associations between some of the 
markers and determine what their predominant role is.
4.8.6.1  Markers of 5FU response:  TP and TS
Table 4.4 shows the correlations for TS and TP with the other markers. Unlike in the 
anal  samples  TS  did  not  correlate  with  cyclin  A,  another marker  of proliferation. 
However it did correlate strongly with TP stromal intensity and percentage and with 
EGFR intensity and percentage. The correlation with TP and lack of correlation with 
cyclin A may indicate that in rectal tumours TS may have a more significant role in 
influencing the  effect  of 5FU.  There is  a borderline positive  association with p53, 
which may give support to the hypothesis that in rectal tumours at least p53 may be 
involved in the modulation of TS [202]. There is a positive correlation with EGFR, a 
marker  of differentiation  and  proliferation.  This  marker  has  been  associated  with 
more aggressive tumours in several studies [187].
The physiological  role of TP  is  complex  and  is  involved  in  DNA metabolism  and 
angiogenesis.  In  contrast  to  the staining pattern  seen in  anal  cancer,  rectal  cancers 
showed mainly stromal localisation, with no obvious staining within the rectal tumour 
cells  themselves.  This  staining  within  the  stroma  may  well  be  the  predominant 
angiogenic component of TP.
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TS Bv variable Spearmans P-value
TS Int TP% & Int 0.407/0.343 p=0.001/0.008
TS% TP% & Int 0.413/0.413 p=0.001/0.001
TS Int EGFR % & Int 0.255/0.272 p=0.054/0.039
TS% EGFR% & Int 0.303/0.351 p=0.021/0.007
TS Int P53% & Int 0.244/0.245 p=0.067/0.066
TP Bv variable Soearmans P-value
TP% EGFR% & Int 0.339/0.416 p=0.009/0.001
TP Int EGFR% & Int 0.354/0.423 p=0.006/<0.001
TP% TS% & Int 0.413/0.407 p=0.001/0.001
TP Int TS% & Int 0.413/0.343 p=0.001/0.008
TP% P53% 0.278 p=0.037
TP Int P53% 0.294/0.174 p=0.027
Table 4.4 Thymidylate synthase and thymidine phosphorylase correlations
The association with p53 has been noted previously [203].  It has been hypothesized 
that TP  expression might be modulated by p53.  The association with TS may well 
suggest that this is due to the angiogenic component. More DNA synthesis occurring 
in those tumours with a high expression of TP, this would also explain the association 
with  EGFR.  It may  also  be possible that  the positive  correlation between  the two 
markers may show a role for influencing the response to 5FU based chemotherapies.
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4.8.6.2  Epidermal growth factor receptor
EGFR strongly correlated with a number of markers, see Table 4.5. There were strong 
positive correlations with TP, TS and P53.
4.8.6.3  P53
It can be seen that p53 has significant positive correlations with TS and TP. This may 
be explained by the fact that P53 has been implicated in the modulation of expression 
of both of these proteins. There is also a positive correlation between EGFR intensity 
and percentage of cells stained with the number of p53 cells staining positively.
EGFR Bv variable Spearmans P-value
EGFR% TP% & Int 0.339/0.354 p-0.009/0.006
EGFR Int TP% & Int 0.416/0.423 p=0.001/<0.001
EGFR% TS% & Int 0.303/0.256 p=0.021/0.054
EGFR Int TS% & Int 0.351/0.272 p=0.007/0.039
EGFR% P53% 0.314 p=0.018
EGFR Int P53% 0.253 p=0.060
Table 4.5 EGFR correlations
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4.8.7  Correlations between individual surgical markers
All  the  marker  variables  correlated  significantly  between  their  intensity  and 
percentage  scores.  See  appendix  G  for the  full  list  of correlations.  The  significant 
correlations  are  shown  below  in  Table  4.6.  There  are  clearly  fewer  significant 
correlations between the surgical markers than in the biopsy markers.
The correlations between bcl-2  and  cyclin A were not  seen in the biopsy analysis. 
There is a significant correlation between an increasing bcl-2 with a decreasing cyclin 
A expression. There is also a positive correlation between cyclin A and TP.
TS  correlates  with  cyclin  A,  another  marker  of proliferation,  as  seen  in  the  anal 
samples but not in the rectal biopsy markers. However there is no correlation with TP 
or p53. The same correlation between TS stromal intensity with EGFR intensity and 
percentage is seen and there is also a positive correlation between TS and bcl-2.
Variable Bv variable
TS Int EGFR% & Int
Cyc A% TP% & Int
Cyc A% TS%
Bcl2% Cyc A%
Bcl2 Int Cyc A
Bcl2% TS%
Spearmans P-value
0.373/0.442 p=0.050/0.019
0.437/0.491 p=0.013/0.004
-0.359 p=0.048
-0.457 p=0.005
-0.449 p=0.006
0.377 p=0.033
Table 4.6 Correlations between surgical markers
176Chapter 4
4.8.8  Marker survival analysis
4.8.8.1  Relapse-free survival
With univariate analysis increasing N  stage was statistically significant for a poorer 
RFS. The lack of significance for T stage is likely in view of the fact that all were T3 
or T4  tumours.  The  degree  of downstaging (DS)  also  correlated  significantly with 
RFS.  Table 4.7  shows  all  the significant univariate correlations.  P53  expression in 
both the surgical and biopsy specimens was significant for a poorer RFS. Increasing 
TP  expression in the surgical  sample was also  associated with a poorer RFS,  there 
were no survivors at 5 years in patients whose tumours expressed TP in over 50% of 
tumour cells. Increasing EGFR intensity in the biopsy sample was associated with an 
improved RFS.
Using  the  Cox  proportional  hazards  model;  N  stage  (x2=5.81,p=0.016)  degree  of 
tumour  downstaging  (% 2=7.97,p=0.019)  EGFR  biopsy  intensity  (x2=10.79,p=0.049) 
and P53 biopsy percentage (x2=10.11,p=0.039), remained significant on multivariate 
analysis. In particular p53 of moderate staining had a very poor RFS. In view of the 
number of variables in the analysis and the smaller number of patients the EGFR and 
p53  scoring were condensed into fewer scoring groups. This resulted in an increased 
statistical  significance for EGFR and less significance for p53  and is likely to be a 
more appropriate reflection of the statistical relevance.
Figure  4.18  demonstrates  the  RFS  survival  differences  for  the  clinicopathological 
variables downstaging and nodal status each of these variables and Figures 4.19 and 
4.20 demonstrate the RFS differences for p53 and EGFR.
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Variable Code % 5vr RFS ± 1SE 95% Cl
N stage: NO 0 68% 56.0% ± 10.3 35.8-76.2
N1 1 32% 18.3% ±9.5 -0.3-36.9
P=0.011*
Downstage: CPR 1 10% 80.0% ± 17.9 44.9-115.1
DS 2 17% 88.0% ± 10.5 67.4-108.6
None 3 73% 30.6% ±8.7 13.5-47.7
P=0.018*
EGFR Int: None 0 35% 28.0% ± 11.5 5.5-50.5
(biopsy) Weak 1 48% 41.0% ± 10.0 21.4-60.6
Moderate
Strong
2
3
15%
2%
66.6% ± 27.2 
100%
13.3-119.9
P=0.045*
P53 Int: None 0 34% 61.1% ± 11.5 38.6-83.6
(biopsy) Weak 1 5% None None
Moderate 2 13% None None
Strong 3 48% 50.9% ± 12.0 27.4-74.4
P=0.034*
P53%: 0-5% 0 34% 62.0% ± 11.4 39.7-84.3
(biopsy) 5-20% 1 10% 100%
20-50% 2 23% 15.5% ±20.4 -24.5-55.5
50-75% 3 13% 52.5% ± 20.4 12.5-92.5
>75% 4 20% 43.2% ±20.8 3.2-83.2
P=0.02*
TP%: 0-5% 0 58% 38.1% ± 11.6 15.4-60.8
(surgery) 5-20% 1 24% 65.6% ±20.9 24.7-106.5
20-50% 2 15% 40.0% ±21.9 -2.9-82.9
>50% 3 3% None None
P=0.019*
Table 4.7 Log rank univariate analysis RFS and significant indices
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Figure 4.18 Relapse-free survival for nodal status (upper) and degree of downstaging
(lower)
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Figure 4.19 Relapse-free survival for EGFR expression, scored 1-2 (upper) and 1-4
(lower)
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Figure 4.20 Relapse-free survival for p53 expression, scored 0-1  (upper) and 2-4
(lower)
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4.8.8.2  Overall survival
On univariate analysis increasing N stage was statistically significant for a poorer OS. 
The degree of downstaging however was not, in this sample of 60 patients, but for the 
group of 155 patients it was significant.
Table  4.8  shows  all  the  significant  univariate  correlations.  P53  expression  in  the 
surgical  and  biopsy  specimens  was  significant  for  a  poorer  OS.  Increasing  TP 
expression in the surgical sample was also associated with a poorer OS. There were 
no  survivors  at  5  years,  in  patients  whose  tumours  expressed  TP  in  over  20%  of 
tumour cells. There was no correlation between EGFR expression and OS, in contrast 
to RFS.
Using the Cox proportional hazards model increasing N stage (x2=5.26, p=0.022) and 
p53 biopsy intensity (x2=8.21, p=0.041) remained significant on multivariate analysis. 
Figure 4.21  demonstrates the OS  survival differences for each of these variables.  If 
However, p53 intensity was divided into just two groups 0-1  and 2-3, the association 
with p53  was no  longer significant,  in the same way as with the RFS  analysis (p= 
0.905).
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Variable Code % 5vr RFS ± 1SE 95% Cl
N stage: NO 0 68% 64.6% ± 8.6 47.8-81.4
N1 1 32% 28.4% ± 11.1 6.7-50.1
P=0.016*
P53 Int: None 0 34% 57.7% ± 12.4 33.4-82.0
(biopsy) Weak 1 5% 66.6% ± 27.2 13.3-119.9
Moderate 2 13% None None
Strong 3 48% 64.6% ± 10.7 43.7-85.5
P=0.006*
TP%: 0-5% 0 58% 42.0% ± 12.5 17.5-66.5
(surgery) 5-20% 1 24% 87.5% ± 11.7 64.6-110.4
20-50% 2 15% None None
>50% 3 3% None None
P=0.006*
P53 Int: None 0 39% 62.6% ± 13.5 36.1-89.1
(surgery) Weak 1 0% 0
Moderate 2 22% 19.1% ± 16.8 -13.8-52.0
Strong 3 39% 36.7% ± 17.6 2.2-71.2
P=0.025*
Table 4.8 Log rank univariate analysis OS and significant indices
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Figure 4.21 Overall survival for nodal status (upper) and p53 expression, (lower)
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4.8.8.3  Response & correlation with other parameters
Downstaging in response to  chemoradiation has  already been shown  earlier in this 
chapter,  to be a significant marker of both OS  and RFS  in locally advanced rectal 
cancer.
For  the  entire  study  group,  using  Spearman’s  Rank  coefficient,  significant 
associations were found between an improved response and increasing TP expression 
and cyclin A percentage in the initial biopsy specimen, see Table 4.9.
Bv Variable Correlation Coefficient P value
TP Int(biopsy) -0.339 0.008
TP%(biopsy) -0.331 0.010
Cyc A%(biopsy) -0.287 0.028
P53 Int (surgery) 0.335 0.046
Table 4.9 Major correlations between response and molecular markers
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4.9  Discussion
Following a curative surgical resection, the prognosis of rectal cancer remains poor. 
5-year survival rates fall from 85% in stage I disease to 60% in stage II and 40% in 
stage III  [285].  First recurrence sites in stage II  and III cancer occur to  an almost 
equal extent in the pelvis, liver and lung [286].  Because of the anatomical constraints 
of the  pelvis,  achieving  local  control  while  preserving  sphincter  function  can  be 
challenging.  Local recurrence rates can be as high as 25% and they are associated 
with significant morbidity [51, 287-291].  The social and psychological consequences 
of a permanent colostomy are obvious.
The  difficulty  in  obtaining  a  negative  radial  resection  margin  is  one  of the  main 
causes  of local  recurrence  [292-295].  Multivariate  analyses  have  suggested  that 
tumour involvement  of the radial  margin may be  the most  critical  single  factor in 
predicting local recurrence in rectal cancer [294].  One recent technique, which has 
improved  local  control  rates by reducing the incidence of a positive CRM,  is total 
mesorectal excision.  Local recurrence rates of less than 10% have been reported with 
this procedure, in selected patients [40].
There has been  considerable  oncological  interest in ways  of further improving the 
local  recurrence  rates  and  survival  in  rectal  cancer.  Adjuvant  radiation  with  or 
without  5FU  based  chemotherapy  delivered  before  or  after  surgery  has  been 
demonstrated to improve local  control in patients with high risk rectal cancers  [51, 
287-289] and pre-operative radiotherapy has been used successfully as an adjuvant to 
surgery,  providing  good  local  control  and  potentially  enhancing  sphincter 
preservation rates [42,  51, 287-289, 291, 296].  Initial experience with pre-operative 
treatment  was  with  radiation  alone.  Several  studies  compared  pre-operative 
radiotherapy at moderate doses (25-40Gy) to  surgery only [42, 297-303].  Analysis 
showed  a  significant  reduction  in  local  recurrences.  Three  of these  studies  also 
demonstrated  a  survival  benefit.  In  a meta-analysis,  the benefit  in  terms  of local 
control  with  preoperative  radiotherapy  was  much  greater  than  that  observed  with 
postoperative  radiotherapy  [304].  The  addition  of  chemotherapy  reduces  local 
recurrences even further [305]  and toxicity rates and compliance do not seem to be 
significantly affected [306].  A recent randomised phase III trial has confirmed [307]
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an  improvement  in  local  control  with  preoperative  chemoradiation  compared  to 
postoperative.  Almost  800  patients  were  randomised  to  either  preoperative  or 
postoperative  chemoradiation  in  T3/4  rectal  tumours.  There  was  a  significant 
improvement in local control (P=0.02) and in improved sphincter preservation in low 
rectal tumours (P=0.004).  The results of the EORTC 22921  are also awaited, which 
has randomised patients between preoperative radiotherapy alone versus preoperative 
chemoradiation..
Preoperative treatment potentially downstages locally advanced tumours such that a 
negative resection margin can be achieved with surgery.  The preoperative approach 
also  has  several  other  potential  benefits,  enabling  an  enhanced  effect  on 
micrometastatic  disease  and  an  enhanced  compliance,  since  the  treatment  is 
administered to previously untreated patients.  Sauer et al  [307]  showed a trend for 
reduced acute toxicity and significantly less chronic toxicity at the anastomotic site 
for preoperative treatment.
The purpose of this study was to analyse outcome data, in conjunction with tumour 
molecular marker expression in a group of patients with locally advanced carcinoma 
of the rectum, treated with pre-operative 5FU based chemoradiation prior to definitive 
curative  surgery.  All  these  patients  underwent  chemoradiation  for  the  purpose  of 
downstaging, as the referring surgeons felt there was a high risk of achieving an R1/2 
resection margin.
The first part of the analysis was to confirm the previously reported poor survival in 
this  group  of patients  [285]  and  determine  the  incidence  of local  recurrence  and 
metastatic disease. Only 31% of patients in this current series were disease-free at 5 
years. The median time to the development of a local recurrence was 22 months and 
19 months for distant metastases.  Therefore, at least half the recurrences occurred in 
the first two years following treatment. The overall median survival for the group was 
37 months and only 34% were alive at 5  years of follow-up. This confirms that this 
group  of patients  does  have  a  poor  survival  with  high  incidences  of both  local 
recurrence and metastatic disease.
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The importance of a positive circumferential  (CRM) margin (Rl/2)  in determining 
the incidence of local recurrence has been noted earlier.  In this analysis data on the 
surgical  resection  margins  had  been  collected  on  all  the  patients  who  underwent 
surgery.  It was therefore possible to determine outcome according to the resection 
margin as defined by UICC  criteria.  From the original  group of 155  patients,  122 
patients  at the time of this  analysis had undergone surgery with curative intent.  A 
negative  CRM  was  achieved  in  80%  of surgical  cases  giving  an  overall  negative 
CRM  for  the  whole  group  of 63%.  The  importance  of a  positive  CRM  became 
evident in the recurrence  and  survival  analysis.  Only  10%  of patients, who had  a 
negative CRM,  developed a local recurrence, in comparison to  62% in the positive 
CRM group. Similarly, 29% of patients in the negative CRM group developed distant 
metastases  compared  to  75%  in  the  positive  CRM  group.  This  resulted  in  a 
significant  difference  in  terms  of both relapse-free  survival  (P<0.001)  and  overall 
survival  (P=0.0001)  between  the  two  groups.  At  3  years  52%  of patients  with  a 
negative  CRM  were  relapse-free  compared  to  9%  in the positive  CRM  group  and 
overall survival at 3 years was 64% vs. 25%. It is therefore important in this group of 
patients to achieve where possible a negative circumferential margin. A recent phase 
II  trial,  Socrates  [308],  has  reported negative  CRM’s  of greater than  80% using a 
combination of oxaliplatin and 5FU and similar trials looking at irinotecan and 5FU 
are underway.
The  incidence  of  a  complete  pathological  response  was  12%  with  pathological 
downstaging to a pTO/1/2 tumour in 28% of cases, this is in line with other reported 
series [307, 309]. Response to chemoradiation was important in terms of survival and 
this  has  also  been  found  previously  [135,  173].  For this  series,  the patients  were 
divided  into  those  whose  tumours  had  been  pathologically  downstaged  and  those 
whose  tumours  had  not.  There  was  a  significant  improvement  in  terms  of RFS 
(P=0.0032) and OS (P=0.020) in those who were downstaged. This may in part be a 
reflection  of a  good  response  to  chemoradiation  acting  as  a  surrogate  marker  for 
achieving a negative CRM.  If response to chemoradiation can predict outcome as in 
this  series,  can  a  complete  pathological  response  predict  for  an  even  greater 
improvement in survival outcomes.  This has been postulated but there have been no 
trials  which  have  established  this.  Rich  et  al  [53]  reported  a  non-significant 
improvement in patients with a CPR but did not report local recurrence data.  In this
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series of patients this was not the case.  Patients with a CPR did not do better than the 
group of patients who had been pathologically downstaged.
The main prognostic factors in rectal cancer remain the extent of the primary tumour 
(T  stage),  regional  lymph  node  status  (N  stage)  [310],  the  histological  grade,  the 
presence  of  vascular  invasion  and  whether  there  is  a  sufficient  circumferential 
resection margin. These factors however, are not easy to predict preoperatively. Thus 
there have been considerable efforts to define accurate histological, pathological and 
molecular  information  preoperatively,  which  have  a  bearing  on  proliferation, 
apoptosis  and  other  molecular  targets  and  can  hence  predict  future  outcome. 
Presently little is known about pre-treatment characteristics that may predict response 
to chemoradiation in patients with rectal cancer.  For this reason the second part of 
this  study  analysed  a  panel  of biological  molecular  markers,  which  in  previous 
reported series of colorectal carcinomas have been implicated as predictive markers 
of treatment response, outcome or both.  From the initial series of 155 patients, pre- 
chemoradiation  biopsy  specimens  were  received  on  60  patients  and  from  these; 
surgical  operative  specimens were also received  on 33  patients.  Six markers were 
chosen to reflect previous published series and to give a biological overview of the 
different processes involved in tumour growth, cell cycle regulation and angiogenesis.
4.9.1  Correlation between molecular markers and clinicopathological variables
Analogous to the anal  carcinoma series, the rectal samples expressed a high rate of 
the proliferation marker cyclin A and over half (52%) were bcl-2 positive; this is in 
line with other reported series [110,  117,  135,  145]. Over two thirds (67%) were p53 
positive, which is slightly higher than some quoted series of 40-50% [107,  113,  118, 
121,  122,  145,  151].  However,  only  60%  expressed  TP  and,  unlike  in  the  anal 
carcinomas,  the expression was predominantly in the stroma.  Over 90% of tumours 
expressed TS  with considerable variation in the percentage of tumour cells staining 
positively.  This  degree  of expression  is higher than  some reported  series  of  69% 
[171]  and  65%  [173].  In  this  present  study  65%  of tumour  samples  were  EGFR 
positive but the staining was cytoplasmic with very little membrane expression.
T  stage  correlated  with  increasing  cyclin  A  percentage  and  TS,  both  markers  of 
proliferation.  Cyclin A also  correlated with increasing tumour grade indicating that
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the higher grade  and T  stage tumours  are proliferating more rapidly.  Proliferative 
activity has been shown previously to be correlated with tumour stage in colorectal 
carcinoma [279].
P53 has also been shown to correlate with T stage [113] however in this analysis p53 
did not  correlate significantly with any of the clinicopathological variables.  This is 
not  surprising  as  only locally advanced tumours  were in the analysis.  This  lack of 
association has however, been found in other rectal cancer series [151].
Bcl-2  in previous reported studies has correlated with stage and lymph node status 
[117, 311], this correlation was found in this analysis. A significant association was 
also found between TS, cyclin A, bcl-2 and age. This association between TS and age 
has been demonstrated previously [312]. The explanation for this is unclear.
In this  series,  a negative correlation between increasing N  stage and increasing TP 
was found. This negative correlation has been found in other series, including breast 
carcinomas, [210] postulating that TP mediates its angiogenic activity early in breast 
carcinoma  progression  by remodelling the  existing vasculature  within  the  affected 
breast  lobules,  as  high  TP  expression was  also  found  in  low-grade invasive breast 
carcinomas.  This  hypothesis  may  also  explain  the  association  seen  in  this  study. 
However this is  contradicted in previous studies  [313]  in which TP expression has 
correlated  with  both  the  size  of  the  tumour  and  the  incidence  of  lymph  node 
metastasis.
4.9.2  Correlations between molecular markers
When  the  correlations  between  the  markers  were  studied  p53  staining  correlated 
significantly  with  TS  staining.  This  association  has  been  noted  in  a  series  of 25 
patients with stage II colon cancer, in which nuclear expression of p53 was observed 
to be associated with high levels of TS and 91% of recurrences occurred in patients 
whose tumours had mutated p53 and high levels of TS [314].  An interaction between 
TS and p53  occurs at the translational level as TS can bind  to the mRNAs of both 
p53 and c-myc [315, 316].  This finding is important because it suggests that mutated 
p53  may increase  TS  levels  and  cause resistance  to  chemotherapy.  However,  TS 
expression in this  series of rectal carcinomas was not prognostic for either survival
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outcome in multivariate analyses. TS also strongly correlated with TP, unlike in the 
anal carcinoma series. This suggests in the rectal carcinomas the 5FU markers may 
play a more significant role in influencing response.
Positive correlations between TP and bcl-2  expression have been shown previously 
and  both  were  inversely  correlated  with  increasing  tumour  grade  [210].  This 
association between grade and bcl-2 was found in the present series and TP was also 
strongly correlated with p53, which has been addressed previously [203]  suggesting 
that TP expression might be modulated by p53. Shomori’s study [203] found that the 
frequency of TP expression in colorectal carcinomas was significantly higher in those 
with p53 expression, than in those without.
EGFR  significantly  correlated with p53,  TS  and TP.  This  association has not been 
demonstrated previously.  Binding to the extra-cellular domain of EGFR  causes the 
activation  (phosphorylation)  of a number of downstream  effectors  involved  in  the 
ras/raf-\/mitogen-activated protein kinase, and the phatidylinositol-3-kinase, and the 
phospholipase Cy pathways [317].  Activation of these cascades ultimately results in 
the transcription of other genes responsible for cell growth co-ordination, regulating 
cell division, proliferation and differentiation.  This may well explain the associations 
with TP, TS and p53 seen in this study.
Another factor analysed in this study was the difference in expression of each of the 
molecular markers pre and post chemoradiation. Previous reported series of Ki-67  in 
rectal  carcinomas  have  demonstrated  that  expression  in  the  surgical  specimen was 
lower than in the biopsy specimen [130,  131,  133]. This was also true of cyclin A in 
this  series  with  22%  of pre-chemoradiation  biopsy  specimens  being  negative  for 
cyclin A and 40% negativity in the surgical specimens.  It is not unexpected that a 
course of CRT will alter cell kinetics.  The therapy should preferentially affect rapidly 
dividing cells, leaving behind a population biased toward slow proliferation [318].
P53  expression  did  not  alter  significantly  between  the  biopsy  and  the  surgical 
specimens.  Previous  studies  have  demonstrated  that  [106]  p53  is  upregulated  in 
normal human cells after short course pre-operative RT but not in rectal tumour cells.
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This indicates that the p53 in rectal tumours does not respond to radiation, suggesting 
a high frequency of p53 abnormalities.
In this study EGFR was upregulated in response to chemoradiation. Lammering et al 
have  demonstrated  that  the  exposure  of tumour  cells  to  ionising  radiation  in  the 
therapeutic dose range (l-5Gy) results in the immediate activation of EGFR [319] and 
that repeated radiation exposures of 2Gy lead to increased EGFR expression.  Bcl-2 
expression also increased following chemoradiation.  This may be expected as most 
chemotherapeutic agents and radiation, induce cell death through the triggering of the 
apoptotic pathway [320].
Several  associations  were  identified between the  surgical markers,  which were not 
seen in the biopsy specimen markers. However, the sample group was much smaller 
and  their  correlations  therefore  may  not  be  as  significant.  EGFR  correlated  with 
increasing N stage, suggesting a more advanced stage of presentation with increasing 
expression of EGFR. EGFR is often expressed at high levels in human cancer and has 
been associated with more aggressive tumours. Cyclin A correlated with TS both of 
which are proliferation markers, and cyclin A also correlated with bcl-2 which may 
be explained by their upregulation in response to chemoradiation.
4.9.3  Survival outcome
The  pathological  stage  after  complete  surgical  resection  is  probably  the  most 
important  prognostic  factor  in  rectal  cancer  [321].  It  also  determines  the 
appropriateness  of adjuvant treatment.  In this  study T  stage was not prognostic of 
outcome and this is likely to be because all the tumours were locally advanced.  N 
stage however was of prognostic significance, predicting for both a poorer RFS and 
OS on multivariate analyses.  The database did not extend to histopathological detail 
with reference to the presence of perineural invasion or extra-mural extension, so the 
prognostic effect of these histopathological variables was not assessed.
The  evaluation  of grade  is  largely subjective  and no  one grading  system has been 
widely accepted and uniformly employed.  In this series grade was reported as well, 
moderate or poorly differentiated on the basis of the degree of glandular formation, 
presence  of mitoses  etc.  It  has  been  noted  in  the  literature  that  the  pathologic
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diagnosis of poorly differentiated or undifferentiated tumours is relatively consistent, 
but  discrimination  between  well  and  moderately  differentiated  carcinomas  is 
associated with  a  significant  degree of interobserver variability  [322].  Despite the 
absence  of standardised  assessment,  it  has  repeatedly  been  shown  on  multivariate 
analyses that grade is a stage dependent prognostic factor [323-328]. However, in this 
series the grade of tumour did not correlate with any of the outcome indices; this may 
be due to the fact that all the tumours were locally advanced in stage.
No  association  between  the  proliferation  markers  was  observed  with  regard  to 
survival.  Similarly bcl-2 expression did not correlate with survival, which is in direct 
contrast  to  a  study  [117]  of 160  rectal  carcinomas  in  which  bcl-2  expression  was 
associated  with  a  longer  disease  free  interval  and  was  an  independent  predictive 
factor of recurrence.
P53  staining of moderate intensity however, did predict for a poorer RFS  (P=0.039) 
and OS (p=0.041). This result however may be due to sample size and the number of 
staining variables rather than a true association.  The prognostic  significance of p53 
has  been  identified  in  other  rectal  carcinoma  studies  receiving  different  treatment 
modalities,  including surgery alone, pre-operative radiotherapy and CRT,  [112-114, 
117, 329]. In a study [111] of pre-operative RT, the presence of a p53 mutation was 
associated with a significantly shorter 5 year survival and in a series of 166 resected 
Dukes’  B2  [330]  rectal  carcinomas,  overexpression  of  p53  was  significant  on 
multivariate analysis for an increased risk of recurrence.  The results however, remain 
conflicting with several studies reporting negative results [119-122].
TS expression in this study did not predict for clinical outcome.  The studies to date 
also  show  conflicting  data  regarding  the  prognostic  significance  of  TS.  Its 
importance  is  predominantly  governed  by  whether  treatment  has  included  5FU, 
because TS overexpression has been shown to correlate with high rates of recurrence 
and  decreased  survival  in  those  treated  with  5FU  [170,  171].  In  one  previously 
reported  study  [171]  49%  of patients  with low  TS  levels  were  free of disease  at  5 
years compared to 27% in those with high TS  levels.  A high TS protein expression 
has also been shown to predict for a poorer disease-free survival and overall survival 
independently of Dukes stage and 5FU treatment [169, 314]. However, many series in
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colorectal carcinoma do not report an association between TS and clinical outcome or 
subsequent response to 5FU chemotherapy [312, 331].
EGFR is being increasingly investigated as a potential marker of prognosis in several 
carcinoma sites. There is evidence to support that the overexpression of EGFR is an 
independent  prognostic  factor  in  squamous  cell  carcinomas  of the  head  and  neck 
[332-335].  In  this  current  series  of 60  rectal  carcinoma  patients  the  presence  of 
EGFR expression correlated significantly with increasing N stage,  suggesting a role 
in the progression of disease.  There  are  few previous reported  studies  of EGFR in 
rectal  cancer.  A  recent  study  of  45  patients  who  received  either  preoperative 
radiotherapy alone or preoperative 5FU-based chemoradiation, showed that increased 
EGFR expression correlated with a poor prognosis.  However, this series recruited a 
mixed group of patients receiving two different pre-operative treatments.
The interesting finding in this current series is that although  EGFR  correlated with 
increasing N stage, DFS improved with increased EGFR expression. This may be due 
to  an  enhanced  radiosensitisation  effect.  Lammering  et  al  [319]  have  shown  that 
EGFR  is  upregulated  in  response  to  radiation  and  this  radiation-induced  EGFR 
activation resulted in a pronounced dose-dependent, proliferative response that could 
be  quantified  in  vitro  after  both  single  and  repeated  radiation  exposures.  They 
hypothesise that radiation-induced EGFR activation contributes, at least in part, to the 
mechanism  of accelerated  repopulation.  This  cellular proliferation  response  during 
repeated radiation exposures, as used in clinical radiotherapy,  can lead to  increased 
renewal  of tumour clonogens.  This has led to the concept that disruption of EGFR 
function  should  prevent  the  repopulation  response  and  mediate  tumour  cell 
radiosensitisation.  In  a  recent  study  in  head  and  neck  cancer  the  addition  of 
cetuximab,  an  EGFR  inhibitor,  with radiation  led to  an  improved  clinical  outcome 
[336].  Indeed,  radiosensitivity was  shown to be  enhanced  in  a dominant-negative 
EGFR  mutant,  EGFR-CD533,  after  both  single  and  repeated  radiation  exposures 
[319].
4.9.4  Downstaging
Increased cyclin A expression correlated strongly with improved downstaging of the 
primary  tumour.  This  association  between  increased  expression  of proliferation
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markers and response has been noted previously in colorectal carcinomas.  In rectal 
cancer fast proliferating tumours have been shown to demonstrate a high immediate 
response  to  high  dose  radiation  therapy  [130]  and  an  improved  response  to 
chemoradiation [131, 132].
P53 expression correlated strongly with a poorer response to chemoradiation and this 
has  been  noted  previously  in  other  rectal  cancer  studies  [108,  109].  It  has  been 
suggested  that  this  is  due  to  increasing  radio-  and  chemoresistance  by  p53  gene 
mutations [283, 337]. One study found that P53 expression correlated inversely with 
response to chemoradiation and a CPR, and directly with an increased likelihood of 
residual  cancer  in  the  lymph  nodes  of the  surgical  specimens  [107].  However  no 
significant correlation has been noted in other rectal carcinoma series [110, 338].  The 
postulated resistance to the treatment modalities of chemotherapy and radiotherapy, 
which has been  discussed in the previous  chapter may well  explain the  finding by 
Goh [115], who demonstrated a lower likelihood of benefiting from adjuvant therapy 
in colorectal carcinoma when a mutation in the p53 gene was present.
In  this  current  study  TS  did  not  appear  to  predict  for  tumour  downstaging.  This 
contradicts  previous  reports  in  which  [110,  173],  TS  expression  did  predict  for  a 
poorer  response  to  5FU  CRT,  however  this  is  likely  to  be  due  to  the  known 
interactions of TS with 5FU; as the lack of TS expression was only associated with 
tumour downstaging after combined CRT and not with just radiation alone. Although 
no association between TS and response to chemoradiation in this study was found, 
increasing  TP  expression  did  predict  for  an  improved  response.  A  plausible 
explanation could be attributed to the angiogenic properties of the protein resulting in 
increased chemotherapy delivery to the tumour. Alternatively, it may also be a result 
of increasing  sensitivity to  5FU,  which has been demonstrated  in  a study  [263]  of 
breast  carcinomas,  in  which  patients  with  TP-positive  tumours  had  a  significant 
survival  benefit  when  treated  with  5FU  combination  chemotherapy.  Therefore 
several studies, including the present one suggest that tumour levels of TP may give 
an indication of patient response to treatment.
This study confirms that this group of locally advanced rectal carcinoma patients have 
a poor outcome.  The importance of achieving a negative circumferential  margin is
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demonstrated.  Higher rates  of a negative CRM  can be achieved by the use of pre­
operative  long  course  5FU-based  chemoradiation.  If pathological  downstaging  is 
achieved there is a significant improvement in both DFS  and OS.  However,  further 
efforts are needed to improve patient outcome. This has led to the search for potential 
prognostic molecular markers, which  could help  identify patients who  are  likely to 
have a poor response to treatment or outcome. Although this is a small series several 
markers do appear attractive in this respect but larger randomised controlled series are 
required to clearly define their role in this disease site.
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Chapter 5:
The Effect of Radiation on Thymidylate 
Synthase and Thymidine Phosphorylase
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Chapter 5
Assessment of the effect of radiation on thymidine 
phosphorylase and thymidylate synthase enzyme activity in 
HT29 and SW48 colon cancer cell lines
5.1  Aims
■   Investigate  HT29  and  SW48  colon  cancer  cell  lines  in  vitro  and  study  the 
effect  of radiation  on  the  enzyme  levels  of thymidine  phosphorylase  and 
thymidylate synthase
■   Establish a dose-time relationship for thymidine phosphorylase
■   Establish a dose-time relationship for thymidylate synthase
■   Investigate the effect of a clinical fractionated course at 2Gy per day
5.2  Introduction
HT29  and  SW48  are  well  established  human  colon  cancer  cell  lines.  HT29  is 
relatively radioresistant and has mutated p53 whilst SW48 is relatively radiosensitive 
and  is  p53  wild-type.  The  cell  culture  conditions  and  preparation  are  described  in 
Chapter  2  as  are  the  enzyme  activity  assays  and  protein  expression  of thymidine 
phosphorylase  and  thymidylate  synthase.  The  details  of the  fractionation,  radiation 
and timing of the experiments are in appendix I.
5.3  Single dose experiments enzyme activities
Both cell lines were exposed to single doses of 2Gy and 1  OGy. Enzyme activities and
protein expression were then measured at 0, 2, 7, 24, and 48 hours after irradiation. 
These measurements were performed in triplicate and at each dose and time point a 
sham irradiation (RT) was given to a control sample.
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5.3.1  Thymidylate synthase activity
5.3.1.1  HT29
Figure  5.1  shows  the  TS  enzyme  activities  for  the  three  HT29  experiments  in 
response to single doses of radiation.
TS activity in the HT29 cells rose at 7 hours, on average to 1.5 times the control level. 
This change did not appear to be dose dependent with similar differences occurring at 
both 2 and  1  OGy. TS activity then fell at 24 to 48 hours, with a more prominent drop 
occurring  at  lOGy,  to  50%  of the control  activity.  It  is  interesting to  note that  TS 
levels fell in the unirradiated controls over time and as will been seen later in the flow 
cytometry results, this is likely to be due to an increase in cell confluence.
Figure  5.2  shows the ratio to  OGy,  of each of the time points  combined from  each 
experiment,  for the 2 and  lOGy. This shows the changes in enzyme activities more 
clearly. It also shows that there was an initial drop in activity at 2 hours after RT.
The TS activities were then analysed at each time point for each radiation dose. Table
5.1  shows  the  significant  changes  in  TS  activity between  different  time  points,  as 
measured by Anova’s T test.
This  shows  that  following a radiation dose of 2Gy and  lOGy there is  a significant 
increase  in  TS  levels  at  7 hours  and a significant  decrease  from  7  to  24 hours.  At 
lOGy there was also a significant drop overall from 0 to 48 hours.
A comparison of TS activities was also made between the time points for the different 
doses of RT, using the one way anova T test. There were no significant differences 
between the TS activities for the two different radiation doses at each time point. This 
is  consistent  in  the  HT29  cell  line  with  the  TS  activity  changes  not  being  dose 
dependent.
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Figure 5.1 TS activity over time following single dose irradiation in the HT29 cell
line
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Area under curve:
2Gy  45.2 
lOGy  39.3
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o
is
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E
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OGy
2Gy
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Figure 5.2 Comparison of the ratios of TS activity after 2 and lOGy normalised to 
OGy (HT29)
TS activity at Time T test P value
2Gv
0 to 7 5.37 0.006
2 to 7 5.03 0.007  :
7 to 24 -4.13 0.015
lOGy
0 to 7 4.53 0.011
0 to 2 -6.318 0.003
2 to 7 6.149 0.004
7 to 24 -6.06 0.004
Oto 48 -15.15 <0.001
Table 5.1 Significant changes in TS activity levels in the HT29 cell line
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5.3.1.2  SW48
Figure  5.3  shows  the  TS  enzyme  activities  for  the  three  SW48  experiments  in 
response to single doses of radiation. Similar changes in the levels of TS activity are 
seen in the SW48 cells, with a dose independent increase at 7 hours following RT and 
a  gradual  decrease  at  24-48  hours  compared  to  the  sham  irradiated  controls.  The 
decrease however is more prominent following the  1  OGy dose, which is also seen in 
the HT29 cell line.
Figure 5.4 shows the TS activities at 2 and lOGy normalised to the OGy values. This 
again  shows  the changes  in enzyme activities  more clearly.  It similarly shows  that 
there was also an initial drop in activity at 2 hours after RT but this was not as clear 
as with the HT29 cell line. Table 5.2 shows the changes in TS activities between the 
time points for each radiation dose, which were significant.
The  comparison  of TS  activities  at  each  time  point,  between  the  two  RT  doses, 
revealed that in SW48 there was a significant difference between the activities at 24 
hours  following RT  (T test -6.601,  p=0.0012).  The  lOGy TS  activity levels  at this 
time  point  were  significantly  lower  than  in  the  2Gy.  There  was  also  a  borderline 
significant difference at 2 hours with a more prominent drop in the  lOGy samples (T 
test -2.324, p=0.068).
These results confirm that there is a drop in TS activity levels at 2 hours after RT, in 
both cell lines; however this is only statistically significant after  lOGy.  This change 
would therefore appear to be dose dependent. There is a significant rise in TS activity 
levels in both cell lines at both doses of RT at 7 hours, which does not appear to be 
dose dependent. The final significant change is a drop in TS activity levels over 24-48 
hours  after  RT.  This  again  is  more  significant  at  the  lOGy  dose.  A  difference  in 
activity between the  two  different RT  doses  was  only detectable  in the  SW48  cell 
line. It is also interesting to note that SW48 cells appear to have higher levels of TS 
than  HT29  cells.  There  is  no  significant  difference  in  TS  activity response  to  RT 
between the two cell  lines as demonstrated by the similar values for area under the 
curve.
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Figure 5.3 TS activity over time following single dose irradiation in the SW48 cell
line
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Area under curve:
2Gy  52.6 
lOGy  35.4
2.0
w o
OGy
■ O < D N
0.8 o 2
0.6
0.4
0.2
30 0 20 40 50 10
Time (hours)
Figure 5.4 Comparison of the ratios of TS activity after 2 and  lOGy normalised to 
OGy (SW48)
TS activity at Time T test P value
2Gv
0 to 7 2.18 0.053
2 to 7 3.37 0.028
7 to 24 -2.70 0.054
lOGy
0 to 7 3.32 0.030
0 to 2 -3.92 0.017
2 to 7 4.97 0.008
7 to 24 -6.01 0.004
0 to 48 -2.83 0.047
Table 5.2 Significant changes in TS activity levels in the SW48 cell line
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5.3.2  Thymidine phosphoryiase
5.3.2.1  HT29
Figure  5.5  shows  the  TP  enzyme  activities  for  the  three  HT29  experiments  in 
response  to  single  doses  of radiation.  This  demonstrates  that  a rise  in  TP  enzyme 
activity levels starts at 24 hours continuing to rise further at 48 hours after RT. This 
does  appear  to  be  more  prominent  following  lOGy,  indicating  a  possible  dose 
dependent response.
Figure 5.6 shows the TP activities at 2 and lOGy normalised to the OGy values. This 
clearly demonstrates that there is a rise in activity levels which starts from 24 hours. 
The level at 48 hours after 2Gy is on average 1.5 times higher and after lOGy, 3 times 
higher  than  the  equivalent  control.  Table  5.3  shows  the  changes  in  TP  activities 
between the time points for each radiation dose. Only the 48 hour time points at lOGy 
were significantly different from the sham irradiated controls. The 24 hour time point 
at  lOGy  was  of  borderline  significance.  No  significant  differences  were  seen 
following the 2Gy dose.
The comparison of TP activities between the time points for the different doses of RT 
showed that the only significant difference in TP levels between the two doses of RT 
occurred at the 48 hour time point (T test 3.262, p=0.031), with a significantly higher 
rise  in  TP  activity  following  lOGy.  It  would  therefore  appear  that  the  rise  in  TP 
activity following RT may occur in a dose dependent manner in the HT29 cell line.
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Figure 5.5 TP activity over time following single dose irradiation in the HT29 cell
line
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Area under curve:
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Figure 5.6 Comparison of the ratios of TP activity after 2 and lOGy normalised to 
OGy (HT29)
TP activity at Time T test P value
lOGy
0° to 24° 2.38 0.070
0° to 48° 4.39 0.012
Table 5.3 Significant changes in TP activity levels in the HT29 cell line
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5.3.2.2  SW48
Figure 5.7 shows the TP enzyme activities for the SW48 cell line. This demonstrates 
the same changes in TP levels in response to RT that were seen in the HT29 cell line. 
Again this appears to be more prominent following 1  OGy.
In the SW48 cell line the TS levels at 48 hours after 2Gy was on average  1. 5 times 
higher and after lOGy, 3.75 times higher than the equivalent control. Table 5.4 shows 
the changes in TP activities between the time points for each radiation dose. As with 
the HT29 experiment the 48 hour time point at 1  OGy was significantly different from 
the  sham  irradiated  control but  also the 24 hour time point and the increase in TP 
activity  from  24  to  48  hours  were  also  significant,  see  Figure  5.8.  No  significant 
differences were found following 2Gy.
The comparison of TP activities between the time points for the different doses of RT 
showed that the only significant difference in TP levels between the two doses of RT 
occurred at the 48 hour time point (T test 3.37, p=0.028). This finding is the same in 
the HT29 cell line demonstrating that the rise in TP activity following RT may occur 
in a dose dependent manner in both cell lines.
These results confirm that there is a significant rise in TP activity after RT, in both 
cell lines.  This becomes most apparent at  lOGy and is statistically significant at the 
48 hour time point. This change would therefore appear to be dose dependent. There 
also appears to be a higher TP enzyme activity in the HT29 cell line compared to the 
SW48  cell  line but no significant difference in TP activity response to RT between 
the two cell  lines was demonstrated, which can be seen from the similar values for 
area under the curve.
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Figure 5.7 TP activity over time following single dose irradiation in the SW48 cell 
line
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Area under curve:
2Gy  60.73 
lOGy  93.92 4 lOGy
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OGy 1
o
30 20 40 50 0 10
Time (hours)
Figure 5.8 Comparison of the ratios of TP activity after 2 and 1  OGy normalised to 
OGy (SW48)
TP activity at Time T test P value
lOGy
0° to 24° 3.25 0.031
0° to 48° 4.79 0.009
24° to 48° 2.96 0.042
Table 5.4 Significant changes in TP activity levels in the SW48 cell line
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5.4  Fractionated experiments enzyme activities
Following  completion  of  the  single  dose  experiments  both  cell  lines  were  then 
exposed to a fractionated course of RT. This consisted of four fractions of 2Gy over 4 
days.  Each 2Gy fraction was given exactly 24 hours apart thus aiming to mirror as 
much  as  possible,  a  clinical  fractionated  RT  treatment.  Enzyme  activities  were 
measured 24 hours after each 2Gy dose of RT.
5.4.1  Thymidylate synthase
5.4.1.1  HT29
Figure 5.9 shows the ratio of TS activities after 2, 4, 6 and 8Gy (equivalent to 24, 48, 
72 and 96 hour time points) normalised to the control levels at each time point. This 
demonstrates that TS  levels fall over the fractionated course of RT, to  a maximum 
low at 72 hours before showing signs of recovery.
The changes in TS enzyme activities between fractions were then analysed using the 
Anova  T  test.  Table  5.5  shows  those  changes  which  were  significant.  This 
demonstrates that there is a significant drop of TS after consecutive fractions of RT. 
Some recovery starts to occur after 8Gy but this is not significant.
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Area under curve:
TS fractionation 59.77
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Figure 5.9 Comparison of the ratios of TS activity after a fractionated course of 
radiation normalised to OGy controls (HT29)
TS activitv at Fraction T test P value
2 to 6Gy -12.14 <0.001  1
4 to 6Gy -4.08 0.015
2 to 8Gy -5.00 0.008
Table 5.5 Significant changes in TS between fractions (HT29)
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5.4.1.2  SW48
Figure 5.10 shows the ratio of TS  activities after 2, 4,  6 and 8Gy normalised to the 
control  levels at each time point for the SW48  cell line.  This demonstrates that TS 
levels fall over the fractionated course of RT, to a maximum low at 72 hours before 
showing signs of recovery which is exactly the same as in the HT29  cell  line.  The 
changes in TS enzyme activities between fractions were analysed, significant changes 
are shown in Table 5.6. There is clearly a significant drop in TS levels over 6Gy, with 
some recovery at 8Gy which is not significant.
The results show that TS levels fall during a fractionated course to 6Gy in both cell 
lines.  The  levels  then  show  a  slight  rise  at  8Gy,  which  is  not  significant.  There 
appears to be no significant difference between the responses in each cell line. This 
can be seen in the very similar values for area under the curve.
Area under curve:
TS fractionation 67.17
(o
o
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Figure 5.10 Comparison of the ratios of TS activity after a fractionated course of 
radiation normalised to OGy controls (SW48)
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TS activity at Fraction T test P value
2 to 4Gy -2.20 0.090
2 to 6Gy -4.63 0.010
4 to 6Gy -5.53 0.005
Table 5.6 Significant changes in TS between fractions (SW48)
5.4.2  Thymidine  phosphorylase
5.4.2.1  HT29
Figure 5.11  shows the ratio of TP activities after 2, 4, 6 and 8Gy (equivalent to 24, 
48, 72 and 96 hour time points) normalised to the controls levels at each time point.
This  demonstrates  that  there  is  a  continuous  increase  in  TP  levels  following  each 
fraction of RT. On analysis of the differences between TP levels at different doses the 
rise  of TP  after  8Gy is  significantly higher than  the  level  after 2Gy  (T  test  7.91,
p=0.001).
5.4.2.2  SW48
In the SW48 cell line there is an increase in TP throughout the fractionated course of 
RT,  see  figure  5.12.  However,  unlike the HT29  cell  line where the maximum rise 
occurs at the end of the RT (8Gy), in the SW48 the most significant rise occurs after 
the cells have received 4Gy (T test 3.54, p=0.024). There is then a significant drop 
after 6Gy (T test 3.25, p=0.031).
In both cell lines however TP clearly increases in response to radiation but it is more 
prominent in the HT29 cell line; this is demonstrated by the clear difference in area 
under the curve between each cell line.
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Figure 5.11 Comparison of the ratios of TP activity after a fractionated course of 
radiation normalised to OGy controls (HT29)
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Figure 5.12 Comparison of the ratios of TP activity after a fractionated course of 
radiation normalised to OGy controls (SW48)
215Chapter 5
5.5  Comparison of enzyme activities between single dose &
fractionated RT
A comparison was made between the ratio of enzyme levels for TS and TP to OGy, 
after a single  lOGy dose at 24 hours and an 8Gy fractionated dose. In the case of TS 
this revealed that in both cell lines the drop in TS levels at 24 hours after 1  OGy was 
more than after the fractionated 8Gy. This was more prominent however in the SW48 
cell line, see Figure 5.13.
TP levels in the HT29 cell line were higher after the fractionated 8Gy, however in the 
SW48 cells the TP levels were higher after the single  lOGy dose. These differences 
may  be  partly  explained  by  the  finding  that  HT29  cells  appear  to  have  a  higher 
enzyme level of TP, and SW48 have similar higher enzyme levels of TS.
216Chapter 5
□ 10Gy
HT29  SW48
□ 10Gy
HT29  SW48
Figure 5.13 Comparison of single lOGy and fractionated 8Gy for Thymidylate 
Synthase (upper) and Thymidine Phosphorylase (lower)
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5.6  Single dose experiments protein  expression
5.6.1  Western analysis
Prior to  commencing the flow cytometry analysis western blots were performed on 
both cell  lines to ensure that protein expression was detectable with each antibody. 
Figure 5.14 shows western blots demonstrating that TP and TS were detectable using 
the chosen monoclonal antibodies.  It was also apparent that for the same number of 
cells the expression of TP was definitely more prominent in the HT29 cell line, and 
the expression of TS was slightly more prominent in the SW48 cell line.
5.6.2  Confluence experiments
Figure  5.15  demonstrates  the  effect  of  increasing  cell  confluence  on  median 
fluorescence, in the different phases of the cell cycle.  TP expression increases with 
increasing confluence and there is no point at which the expression levels start to fall, 
this is true for both cell lines. The increase is seen throughout all phases of the cell 
cycle.  TS  expression  initially  increases  with  confluence  and  then  falls  off
7   3 dramatically after a confluence of xlO  cells per 75cm  flask.  This again is true for 
both  cell  lines  in  all  phase  of the  cell  cycle.  This  is  particularly  relevant  when 
analysing the TS protein expression over time after irradiation in the control samples, 
which  have  undergone  sham  irradiation.  In  these  flasks  the  cells  will  continue 
growing to a confluence at which the TS expression will start to fall. This is seen in 
the  flow  cytometry  results  where  the  TS  does  fall  over  time  in  the  unirradiated 
controls.
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Thymidine phosphorylase  Thymidylate Synthase
SW48  HT29  SW48  HT29
Actin  Actin
SW48  HT29  SW48  HT29
Figure 5.14 Western blots for TS and TP (upper) and Actin controls showing equal 
loading of samples (lower)
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Figure 5.15 Effect of confluence on TP (upper) and TS (lower) expression
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5.6.3  Thymidylate synthase expression
5.6.3.1  HT29
Figure  5.16  shows  the  TS  protein  expressions  for  the  three  HT29  experiments  in 
response to single doses of radiation. The amount of protein expression is determined 
by the ratio of fluorescence between the cell sample incubated with antibody and the 
cell sample incubated with control immunoglobulin.
This demonstrates that the TS protein expression results with flow cytometry are not 
as  consistent between the  experiments  as  that  found  with  the  enzyme  activities  in 
HT29 cells. Each flow experiment result is different.
When  the  experiments  are  analysed  together  in  Figure  5.17,  the  overall  response 
becomes  clearer.  This figure shows the ratio to  OGy,  of each of the time points for 
each  dose  combined  for  the  three  experiments.  The  error  bars  are  large  with 
considerable overlap at the time points.
However,  overall there appears to be a rise in TS  levels  at 24 hours which start to 
return to  OGy values  at 48  hours.  This rise  is  more prominent  for the  lOGy dose. 
There  is  little  variation  in  protein  expression  between  the  two  doses  of  RT  as 
demonstrated by the similar area under the curve values. The overlapping error bars 
also  explains  why  there  were  no  significant  differences  in  the  degree  of protein 
expression  between  different  time  points  for  each  dose  of  radiation  and  when 
comparing expression levels between the two doses of RT.
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Figure 5.16 TS protein expression over time following single dose irradiation in the
HT29 cell line
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Area under curve:
2Gy  50.17 
lOGy  54.5
.4-
OGy 0.8 -
0.6
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Time (hours)
Figure 5.17 Comparison of the ratios of TS protein expression after 2 and lOGy 
normalised to OGy (HT29)
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5.6.3.2  SW48
In  a similar way to the results in the HT29  cell  line the data demonstrates that TS 
protein expression in SW48  cells in response to radiation is not consistent between 
the experiments. Again each flow experiment demonstrates different responses to the 
RT doses,  see Figure 5.18.  However there does appear to be more of a trend in the 
SW48  with  rises  in TS  in response to  RT  at  7-24  hours  normalising by 48  hours. 
There is also a slight dip at 2 hours which also occurred in the enzyme experiments.
When  the  experiments  are  analysed  together  in  Figure  5.19,  the  trend  becomes 
clearer.  This figure shows the ratio to OGy, of each of the time points for each dose 
combined for the three experiments. The error bars are smaller than those seen with 
the HT29 cell line and the trend is for a small drop in TS  levels at the 2 hour time 
point  with  a rise  to  24  hours.  In  the  case  of the  2Gy  dose  the  protein  expression 
continues to rise whereas following the lOGy dose the level starts to fall at 48 hours. 
However,  no  significant differences in protein  expression  were  observed  following 
each RT dose between the different time points.
There is  also  little variation in protein expression between the two doses of RT  as 
demonstrated  by the  similar  area  under the  curve  values  and  hence  no  significant 
differences  were  found  in  the  comparisons  of TS  protein  expression  at  each  time 
point between the two RT doses.
It is clear however that the results with flow cytometry are not as consistent as the 
enzyme activity assays.  The changes in enzyme activity levels are also not mirrored 
by the changes in protein expression.
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Figure 5.18 TS protein expression over time following single dose irradiation in the
SW48 cell line
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Area under curve:
2Gy  52.13 
lOGy  52.52
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Figure 5.19 Comparison of the ratios of TS protein expression after 2 and  lOGy 
normalised to OGy (SW48)
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5.6.4  Thymidine phosphorylase expression
5.6.4.1  HT29
Figure  5.20  shows  the  TP  protein  expressions  for  the  three  HT29  experiments  in 
response to  single  doses  of radiation.  This  demonstrates  that  there  is  a rise  in  TP 
protein  expression  from 24 to  48  hours  after  RT.  This  is not as obvious  as  in the 
enzyme  activity  experiments.  This  does  appear  to  be  more  prominent  following 
lOGy.
Figure 5.21  shows the TP activities at 2 and lOGy normalised to the OGy values. This 
figure  demonstrates  that there is  a rise  in protein  expression which  starts  from  24 
hours, the rise however is not as marked as seen in the enzyme experiments and the 
dose dependent effect is not so obvious. The level at 48 hours after 2Gy is on average 
1.18 times higher and after lOGy, 1.25 times higher than the equivalent control.
Table  5.7  shows  the  changes  in  TP  activities  between  the  time  points  for  each 
radiation dose. The differences between the 2 and 7 hour levels to the 48 hour levels 
after 2Gy were  significantly different.  After the  lOGy dose  the difference was  of 
borderline significance and this is not surprising because the error bars are larger than 
those at the 2Gy time points.
A comparison of TP protein expression was also made between the time points for 
the  different  doses  of RT.  There  were  no  significant  differences  between  the  two 
different radiation doses at each time point  This can be seen  from the overlapping 
error bars in Figure 5.21.
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Figure 5.20 TP protein expression over time following single dose irradiation in the
HT29 cell line
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Figure 5.21 Comparison of the ratios of TP protein expression after 2 and lOGy 
normalised to OGy (HT29)
TP expression at Time T test P value
2Gv
2° to 48° 3.44 0.026
7° to 48° 4.95 0.008
lOGy
7° to 48° 2.55 0.063
Table 5.7 Significant changes in TP between fractions (HT29)
229Chapter 5
5.6.4.2  SW48
Figure  5.22  shows  the  TP  protein  expressions  for the  three  SW48  experiments  in 
response to single doses of radiation. This figure demonstrates that there is a rise in 
TP protein expression from 24 to 48 hours after RT in the SW48 cell line. Again this 
is not as obvious as in the enzyme activity experiments. The rise in protein expression 
does appear to be more prominent following lOGy.
Figure 5.23 shows the TP activities at 2 and lOGy normalised to the OGy values. This 
figure  demonstrates  that there  is  a rise  in protein  expression  which  starts  from  24 
hours. In a similar way as with the HT29 protein levels the rise is not as marked as 
seen in the enzyme experiments and the dose dependent effect is not so obvious. The 
level at 48 hours after 2Gy is on average 1.2 times higher and after lOGy,  1.22 times 
higher than the equivalent control.
Table  5.8  shows  the  changes  in  TP  activities  between  the  time  points  for  each 
radiation dose. The differences between the 0 and 2 hour levels to the 48 hour levels 
after 2Gy were significantly different.  There were no significant differences between 
the time points following the lOGy dose. This can be seen from Figure 5.23 where the 
error bars are clearly overlapping.
A comparison of TP protein expression was also made between the time points for 
the  different  doses  of RT.  There  were  no  significant  differences  between  the  two 
different  radiation  doses  at  each  time  point.  Again  this  can  be  seen  from  the 
overlapping error bars in Figure 5.23.
230T
P
 
p
r
o
t
e
i
n
 
e
x
p
r
e
s
s
i
o
n
 
T
P
 
p
r
o
t
e
i
n
 
e
x
p
r
e
s
s
i
o
n
 
T
S
 
p
r
o
t
e
i
n
 
e
x
p
r
e
s
s
i
o
n
Chapter 5
■ — OGy 
•   2 G y
-  1  OG y
3.5
3.0 -
2.0  -
50 30 40 20 0 10
Time after irradiation (Hours)
4 .0
3.0
2.0  -
30 40 50 0 10 20
Time after irradiation (Hours)
3.5 -
3.0
2.0
o 10 20 30 40 50
Time after irradiation (Hours)
Figure 5.22 TP protein expression over time following single dose irradiation in the
SW48 cell line
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Area under curve:
2Gy  52.84 
lOGy  56.71
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Figure 5.23 Comparison of the ratios of TP protein expression after 2 and lOGy 
normalised to OGy (SW48)
TP expression at Time T test P value
2Gv
0° to 48° 2.70 0.054
2° to 48° 6.15 0.004
Table 5.8 Significant changes in TP between fractions (SW48)
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5.7  Fractionated experiments protein expression
5.7.1  Thymidylate synthase
5.7.1.1  HT29
Figure 5.24 shows the ratio of TS protein expression after 2, 4, 6 and 8Gy (equivalent 
to 24, 48,  72 and 96 hour time points) normalised to the control levels at each time 
point.
This demonstrates that TS protein expression rises over the fractionated course of RT 
to  a  maximum  at  72  hours,  after  which  there  is  a  fall.  The  changes  in  protein 
expression  between  fractions  were  then  analysed.  Table  5.9  shows  that  only  the 
change in expression between 2 and 6Gy was significant, the changes from 2 to 4Gy 
and 2 to 8Gy were of borderline significance.
These results are in direct contrast to those seen in the enzyme activity assays where 
the TS levels fall with fractionation.
5.7.1.2  SW48
The changes in TS protein expression in the SW48 cell line are similar to those seen 
in the HT29 cells over a fractionated course. The TS expression increases from 2Gy 
to a maximum at 24 hours after 6Gy before the levels start to fall. See Figure 5.25.
There  were  no  significant  differences  in  protein  expression  between  the  different 
doses of RT in the SW48 cell line unlike with the HT29 cells.
The similar areas under the curve for the two cell lines demonstrate that the changes 
between fractions are very similar.
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Area under curve:
TS fractionation 82.80
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Figure 5.24 Comparison of the ratios of TS activity after a fractionated course of 
radiation normalised to OGy controls (HT29)
TS expression at Fraction T test P value
2 to 4Gy -2.72 0.053
2 to 6Gy -5.63 0.005
2 to 8Gy -2.64 0.058
Table 5.9 Significant changes in TS between fractions (HT29)
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Area under curve:
TS fractionation 84.74
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Figure 5.25 Comparison of the ratios of TS activity after a fractionated course of 
radiation normalised to OGy controls (SW48)
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5.7.2  Thymidine phosphorylase
5.7.2.1  HT29
Figure 5.26 shows the ratio of TP protein expression after 2, 4, 6 and 8Gy (equivalent 
to 24, 48, 72 and 96 hour time points) normalised to the control levels at each time 
point.
This  figure  demonstrates  that  over  a  fractionated  8Gy  course  of RT,  TP  protein 
expression rises after 4Gy and is still rising 24 hours after 8Gy. These are identical 
findings to the enzyme activity assays in this cell line but are not as striking.  Table 
5.10  shows  the  significant  changes  in protein  expression,  which  occurred between 
fractions.  In  particular the  difference between  2Gy  with  6  and  8Gy,  showing  that 
there is a significant rise in TP over the course of RT.
5.7.2.2  SW48
Figure 5.27 shows the ratio of TP protein expression after 2, 4, 6 and 8Gy (equivalent 
to 24, 48,  72 and 96 hour time points) normalised to the control levels at each time 
point.
The changes in TP protein expression seen in the SW48 cell line are similar to those 
in the HT29 cells. The rise in TP occurs earlier after 4Gy rising to a maximum after 
6Gy.  The  TP  expression  then  starts  to  decrease.  These  are  similar  findings  to  the 
enzyme activity assays except that the increase in TP expression occurs for a further 
24  hours  before  starting  to  fall.  There  were  no  significant  changes  in  protein 
expression between the RT fractions. This is demonstrated by the overlapping error 
bars.
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Area under curve:
TP fractionation 78.68
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Figure 5.26 Comparison of the ratios of TP activity after a fractionated course of 
radiation normalised to OGy controls (HT29)
TS expression at Fraction T test P value
2 to 4Gy -2.72 0.053
2 to 6Gy -5.63 0.005
2 to 8Gy -2.64 0.058
Table 5.10 Significant changes in TP between fractions (HT29)
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Area under curve:
TP fractionation 86.13
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Figure 5.27 Comparison of the ratios of TP activity after a fractionated course of 
radiation normalised to OGy controls (SW48)
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5.8  Comparison of protein expression between single dose &
fractionated RT
A  comparison was made between the ratio of protein expression for TS  and TP  to 
OGy, after a single lOGy dose at 24 hours and an 8Gy fractionated dose at 24 hours, 
see Figure 5.28.
In the case of TS this revealed that in the SW48 cell line the rise in TS levels at 24 
hours after lOGy was less than after the fractionated 8Gy; however the opposite was 
true in the HT29 cells.
TP levels in both cell lines were higher after the fractionated 8Gy.
These differences may be partly explained by the finding that HT29 cells appear to 
have  a higher enzyme level  and protein  expression  of TP,  and  SW48  have  similar 
higher enzyme levels and protein expression of TS.
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Figure 5.28 Comparison of single 1  OGy and fractionated 8Gy for Thymidylate 
Synthase (upper) and Thymidine Phosphorylase (lower)
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5.9  Discussion
Combined  modality  treatment  regimens  of radiation  and  chemotherapy  are  being 
increasingly used in the treatment of anorectal  carcinomas.  In particular 5FU-based 
chemoradiation has now become the mainstay of treatment. Early studies showed that 
the doses  of radiation that were inhibitory but not curative in rodent tumours were 
made curative by combining the radiation with 5FU [339].
However, the mechanism by which 5FU influences the cellular response to radiation 
however,  remains  poorly  understood.  Conflicting  results,  as  discussed  in  the 
introduction,  exist over the timing of administration of the  5FU with the radiation. 
Commonly  used  regimens  administer  5FU  first,  approximately  1-2  hours  prior  to 
radiation.  There  is  evidence  to  suggest  that  providing  the  two  modalities  are 
administered within 2 hours of each other, it does not seem to matter in which order 
they are administered [81].
There  is  also  considerable  variation  in  the  mode  of  administration  of the  5FU. 
Currently  infusional  or  bolus  forms  are  used  and  these  two  regimens  have 
significantly  different  pharmacokinetics.  In  a  well  controlled  study,  Moertel  and 
colleagues showed that bolus 5FU given on the first three days of radiation improved 
tumour response and survival at a statistically significant level in patients with gastric 
adenocarcinomas [95]. In the same study, similar trends were also seen in pancreatic 
and bowel  carcinomas as well as in head and neck squamous cell  carcinomas.  This 
method of administration of 5FU is commonly used in chemoradiation regimens in 
rectal and upper gastrointestinal carcinomas. However, there is increasing evidence to 
suggest that relatively long, low levels of 5FU exposure will be required to maximise 
tumour cell  kill  in  combination with radiation  [81];  this has been  demonstrated  in 
other in vitro  studies  [340].  Byfield et al  [81]  suggested that,  since the sensitization 
phenomenon requires  at  least 24-48  hours to develop, bolus  5FU  and radiation are 
likely  to  produce  only  additive  effects  [81].  In  their  study  the  concentration  and 
duration of 5FU required to achieve radiosensitization was similar to the 96-120 hour 
infusions typically administered in the clinical setting.
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In patients who are sensitive to 5FU, the cytotoxic effect mainly depends on the local 
concentration  of the  drug  that  can  be  achieved  within  the  tumour.  However,  the 
systemic  administration  of 5FU  will  also  result  in  toxicity to  normal  tissues,  e.g. 
mucosal epithelial cells of the GI tract or bone marrow cells.  One of the strategies for 
diminishing the side effects of 5FU is some form of selective delivery.  Among them, 
5’-DFUR is a prodrug which is activated by TP to its cytotoxic form.  As has already 
been discussed TP is elevated in many types of carcinoma cells compared with levels 
in non-neoplastic regions of the same organ.  Potentially this preferential increase in 
TP in neoplastic cells could be exploited, so that 5’-DFUR is preferentially activated 
within the tumour cells thus reducing cytotoxic effects on the normal tissues.  As a 
result of this  finding the role of suicide  gene therapy has been explored  and  looks 
promising. Several in vitro studies have investigated transfecting neoplastic cell lines 
with  the  TP  gene,  resulting in  increased  sensitivity  to  5’-DFUR  [264,  341]  [342]. 
Another  strategy  to  exploit  preferential  expression  of  TP  in  tumour  cells  is  to 
combine radiation with capecitabine.
Sawada  and  colleagues  [92]  demonstrated,  using human  tumour xenograft models, 
that  TP  was up-regulated in response to radiation.  Several  human  cancer cell  lines 
were  used  including  cervical,  gastric,  colorectal  and  mammary.  Radiation  was 
administered as either a 2.5Gy or 5Gy single dose. Up-regulation of TP was observed 
in four of the cell lines and it was maximally increased at day nine and then gradually 
decreased up to day eighteen. The increase in TP was greatest following the 5Gy dose 
of radiation.  In addition increases in TP expression were found to correlate with up- 
regulation of TNF-a; TNF-a is a known regulator of TP [343].
Xeloda (capecitabine) is a rationally-designed, orally administered, tumour-activated 
fluoropyrimidine  carbamate.  The  active  drug  is  formed  by  a  three-step  enzymatic 
conversion  to  5FU.  In  the  liver,  capecitabine  undergoes  initial  conversion  to  5’- 
deoxy-5-fluorocytidine by carboxylesterase,  followed by conversion  to  5’-deoxy-5- 
fluorouridine by cytidine deaminase in the liver and tumour tissue.  The final step is 
conversion to  5FU by thymidine phosphorylase.  The interest in capecitabine is the 
preferential  conversion  to  5FU  at  the  tumour  site  exploiting  the  higher  levels  of 
thymidine phosphorylase found in tumour cells compared to normal cells [91].  There 
may also be a reduction in the radiosensitization and hence toxicity in normal tissues
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i.e. an enhanced therapeutic ratio. Sawada demonstrated [92] that when capecitabine 
or 5’-dFUrd were combined with a single 5Gy irradiation in the WiDr human colon 
cancer xenograft, the efficacy of the irradiation in combination was much higher than 
that  of either  treatment  alone.  As  a  result  it  was  concluded  that  X-ray  irradiation 
would be a rational partner with capecitabine.
There are other distinct advantages to oral Xeloda,  in that it is pharmacokinetically 
similar to infusional 5FU providing a constant level but without the need for a central 
venous line. It therefore presents a more convenient and patient friendly alternative to 
infusional 5FU.
The aim of this current study was to  confirm that TP  is upregulated in response to 
radiation  and  establish  a  dose-time  relationship.  As  well  as  single  doses,  a 
fractionated course was also investigated to mimic the clinical situation.  Two colon 
cancer cell  lines were used, HT29  and SW48.  The  experiments  were performed in 
triplicate  and  compared  to  unirradiated  controls.  The  degree  of  TP  activity  and 
protein expression was examined.
In both cell lines TP  activity increased significantly following both  single doses of 
radiation  and  over a fractionated course.  The increase in  TP  activity following the 
single dose started at 24 hours post irradiation and continued  at 48  hours.  The rise 
was  more  prominent  following  lOGy with  a level  3-3.75  times  higher than  in the 
controls, compared to  1.5 times higher at 2Gy (p=0.031  and 0.028), showing a dose 
dependent  effect.  Following  an  8Gy  fractionated  course  there  was  a  continuous 
increase in TP activity in the HT29 cell line (p=0.001). This rise was not as prominent 
in  the  SW48  cells  and  levels  started  to  drop  at  6Gy;  however  they  remained 
significantly higher than the control levels.
These results confirm that TP is upregulated in response to radiation in two different 
colon cancer cell lines. The upregulation appears to be dose dependent and that a high 
single dose appears to be equivalent to a similar dose given as a fractionated course. 
This has not previously been shown.
243Chapter 5
Protein  expression  of  TP  was  also  examined  in  this  present  study  using  flow 
cytometry. In a study by Saito [344], also using flow cytometry, TP was expressed by 
the majority of the colorectal carcinoma cell lines studied but at varying levels. This 
was mirrored in the present study where the expression of TP was higher in HT29 
cells compared to SW48 cells for the same level of confluence.
Comparison  of TP  protein  expression  with  the  enzyme  activity  revealed  similar 
results but the level  of upregulation after irradiation was not as prominent.  In both 
cell  lines  TP  protein  expression  increased  at  24-48  hours  following  single  dose 
irradiation,  and  it  was  more  prominent  following  the  higher  dose.  Following  a 
fractionated course the TP protein expression increased continuously in the HT29 cell 
line and started to fall after 6Gy in the SW48 cell line. This is similar to the changes 
observed in the enzyme activity levels.  The degree of TP protein upregulation was 
higher following the fractionated course compared to the  single  lOGy dose in both 
cell lines.
The  demonstration  that  TP  is  upregulated  significantly  following  a  fractionated 
course of radiation is important, as it is more clinically relevant to  current practice 
and  confirms  the  logical  step  to  investigate  the  incorporation  of capecitabine  into 
current radiation regimens in colorectal cancer.
The  other  finding  in  this  study  was  that  increasing  cell  confluence  resulted  in 
increased  expression of TP  in both cell lines.  This  is  consistent with evidence that 
cytokine release [343,  345-348]  or an increasing hypoxic environment or change in 
the environmental pH [216] can upregulate TP expression.  This was not examined as 
part  of  this  study.  In  contrast  TS  protein  expression  decreased  with  increasing 
confluence as the need for DNA synthesis decreased.
In addition to  examining the response of TP to radiation the effect on TS  was also 
studied. This was examined due to mounting evidence that the higher TS expression 
levels correlate with poorer response to 5FU-based chemotherapy both in vitro and in 
vivo.  In  an  in  vitro  study  of  19  different  cell  lines,  high  expression  of TS  was 
associated with 5FU resistance [349]. The cell lines most sensitive to 5FU exhibited 
the lowest TS levels. Similar results have been demonstrated in other in vitro studies
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[350, 351]. In vivo work has demonstrated that  high TS gene expression, in patients 
with colorectal cancer and gastric cancers, was also associated with resistance to 5FU 
[314].  However, high gene expression levels cannot directly be translated to high TS 
protein expression [70, 71]. In addition, patients with low intra-tumoral levels of TS 
on  IHC  show  a higher response rate  and  longer  survival  than those  with high  TS 
levels after treatment with 5FU for GI cancers [171, 352-354].
The purpose of this study was to examine the effect of radiation on the activity and 
protein  expression  of TS.  Patients  may  be  less  likely  to  respond  to  5FU-based 
chemoradiation regimens if the TS levels are high or induced by radiation. However, 
there are few studies investigating the effect of radiation on TS. TS is a key enzyme 
in  DNA  synthesis  that  is  activated  during  S  phase  and  is  degraded  after  the 
completion of DNA synthesis [355-358].
In this current study, irradiation caused a reduction in TS enzyme activity, in both cell 
lines,  during the first two hours followed by a significant rise at  7  hours, reaching 
approximately  1.5 times the control level.  These changes were not dose dependent. 
Thereafter,  levels  fell  significantly at 24  hours,  more prominently  following  lOGy 
compared to 2Gy,  decreasing at 48 hours to  50% of the control  activity.  However, 
there was no significant difference between the two doses. Some of this effect may be 
due  to  increasing  confluence  as  the  TS  levels  also  generally  fell  over time  in  the 
controls.  However,  the  reduction  following  radiation  was  significant  compared  to 
control  levels.  This  downregulation  of  TS  is  likely  to  be  due  to  decreased 
proliferation as a result of the radiation. However, this effect with single doses is only 
likely to  last  approximately 24 hours,  prior to  escape  from  cell  cycle delays.  This 
would explain TS activity starting to rise again compared to controls at 48 hours after 
radiation. In contrast to the present data, Wei and colleagues showed that TS activity 
increased in response to  single doses (0.5,  1.5,  3.75  and 7.5Gy) of radiation in two 
colon  cancer  cell  lines  [359].  This  group  also  found  that  TS  activity  decreased 
temporarily at 3 hours and then rose at 7 hours. However, unlike in this present study 
where TS activity decreased at 24 hours, they found a dose-dependent increase. The 
time points were slightly different as were the doses of radiation, however the same 
activity  assay  was  used.  Changes  were not more prominent  in the HT29  cell  line 
which  is  more  radioresistant  than  the  SW48  cell  line,  which  has  been  found
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previously [359].  A direct comparison of the two  cell  lines is complicated by their 
different  cell  division times which results  in  different  levels  of confluency  at  later 
times; this affects the unperturbed expression of TS. Also, Western blotting showed 
that SW48 cells show higher intrinsic levels of TS expression than HT29 cells.
The decrease in TS seen in this study agrees with results from Stammler et al  [360] 
who  showed  a  decrease  in TS  mRNA  in murine NIH  3T3  cells  after  exposure to 
single doses of radiation ranging from 5-20Gy. TS mRNA in this study increased in 
the first 6 hours post irradiation and then decreased to a minimum at 72 hours.
In the fractionated experiments activity levels of TS significantly fell over the course 
of the radiation to a maximum low at 72hours. At 96 hours TS levels started to rise, 
however they were still significantly lower than the corresponding controls. Whether 
this is an indication of TS levels starting to recover is unclear.  These changes were 
seen for both cell lines and there did not appear to be a dose dependent effect. This 
downregulation  of TS  in  response to  fractionated  radiation  has  been  demonstrated 
previously [361].
When a comparison of the fractionated course was made with the single  lOGy dose 
the  fall  in  TS  activity  levels  was  more  prominent  following  the  single  lOGy 
irradiation.  Suggesting  there  may  be  some  recovery  with  repeated  small  dose 
exposures.
When the protein expression of TS was analysed the changes demonstrated did not 
necessarily correlate with those changes seen in enzyme activity. The results were not 
as consistent even between the three experiments. Overall TS protein expression rose 
at 24 hours following single doses of radiation in both cell lines and then fell at 48 
hours.  However,  in the HT29 cell  line there was  considerable overlap between the 
error bars  at  the  different time points  and between the two  different  doses  and no 
significant differences were seen. In the SW48 cells the error bars were smaller and 
there was a trend for a fall in TS protein expression at 2 hours similar to the enzyme 
experiments but the subsequent rise continued to 24 hours.
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When  the  fractionated  experiments  were  analysed  for  TS  protein  expression  the 
discordance  with  the  enzyme  activity  changes  were  more  prominent.  In  direct 
contrast, the protein expression significantly increased over the radiation course, to a 
maximum  at  72  hours,  in  both  cell  lines.  There  were  no  significant  differences 
between  the  two  doses  demonstrating  that  the  increase  did  not  occur  in  a  dose 
dependent manner. In the HT29 cell line the increase at 24 hours was more prominent 
following the single lOGy dose whereas in the SW48 cell line the increase was more 
prominent following the fractionated 8Gy at 24 hours.
A  major  difference  between  the  data  for  TP  and  TS  was  the  correlation  between 
enzyme  activity  and  protein  expression  for  the  former  enzyme  and  the  lack  of 
correlation  for the latter.  There are  few reports  correlating protein  expression with 
enzyme activity for either TS or TP.  A recent study in colorectal and gastric tumours 
[273]  looked  at the relationship between TS  measured  by enzyme  activity,  mRNA 
levels  or protein  expression  assessed by  IHC.  No  linear relationships  were  found 
between the mRNA levels and the enzymatic activity and no relationship was found 
between the protein expression and enzyme levels.  This suggests that TS levels vary 
with  the methods  used  to  measure  them.  These  discrepancies  must  be  taken  into 
account  when  interpreting  correlation  between  TS  levels  and  clinical  outcome. 
However, some studies in cell lines have shown that TS protein content as determined 
by western blot analysis may correlate with enzyme activity [362]. Also, in a series of 
colorectal  and  gastric carcinomas the protein  expression of TS  on western blot did 
correlate  linearly  with  gene  expression  [363].  The  factors  responsible  for  these 
discrepancies  remain  unclear.  Some  reports  have  demonstrated  that  TS  has  a 
complicated transcription mechanism.  TS has been  shown to  interact with its own 
mRNA to regulate its transcription [364], and polymorphic tandem repeats in the TS 
gene have  been  shown  to  be  associated with  its protein  expression  and  enzymatic 
activity in gastrointestinal cancers [365].
These findings may help explain why there are differences in this study between the 
changes in the enzyme activity and the protein expression of TS. However, unlike in 
the  enzyme  activity  assays  which  were  consistent  and  reproducible,  the  flow 
cytometric protein analysis was not consistent and may reflect a less reliable method 
for assessment.
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This  study has  demonstrated  that  TP  is  upregulated  in  response to  radiation.  This 
effect is seen not only following single doses but, importantly, following a clinically 
fractionated  course.  It  is  likely  that  in  the  future  capecitabine  will  become 
increasingly used in 5FU-based chemoradiation schedules due the selective delivery 
and  activation  in  the tumour  cells by  TP;  the  activation  of TP  adds  an  additional 
rationale for the combination. Phase I studies have now been completed and phase II 
studies are underway to investigate the combination of capecitabine with radiation in 
the treatment of both locally advanced rectal and anal cancer. A recent phase I trial in 
rectal carcinomas [366] demonstrated that the capecitabine/radiation combination was 
well  tolerated,  convenient  for  patients  and  easy  to  administer,  simplifying  the 
chemoradiotherapy schedule.
In  this  study TS  activity was  shown to  decrease  in  response  to  radiation which  is 
likely to reflect its role in proliferation. If this is in fact the case its role in promoting 
resistance  to  5FU  may  not  be  as  important  in  the  context  of  5FU-based 
chemoradiation regimens. This may well explain the lack of prognostic significance 
for TS in either the anal or rectal series presented earlier in this current study.
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Chapter 6  General Discussion
Optimising  locoregional  control,  disease-free  and  overall  survival  remains  a 
challenging  goal  in  the  management  of adenocarcinoma  of the  rectum  and  anal 
carcinomas.  Although  significant  therapeutic  gains  from  radiotherapy  alone  and 
combined chemoradiation have been demonstrated in a number of trials, therapeutic 
outcome is far from satisfactory.
Advances in our knowledge of tumour biology have led to a rise in studies of new 
biological markers in many different tumour sites.  The aim is to  identify markers 
with  prognostic  value  or predictive  of treatment  response,  so  that  patients  can be 
selected, on the basis of the biology of their tumour, for more aggressive therapy or 
for  alternative  treatment  modalities.  To  date  none  of these  markers  have  been 
established in routine clinical practice either in colorectal cancer or anal cancer to aid 
the prescription of treatment.  One reason for the lack of success  in establishing a 
definitive role for these new biomarkers is the poor methodological quality of many 
studies  reported  in  the  literature.  For  most  markers,  published  studies  report 
diverging  or  inconclusive  results,  due  to  biological,  technical  and  tumour-related 
differences.
6.1  Methodology
There  are  several  available  methods  for  measuring  these  markers  including; 
biochemical assays, quantitative reverse-transcriptase polymerase chain reaction (RT- 
PCR),  and  IHC.  The  use  of biochemical  assays  is  limited  to  prospective  clinical 
studies  requiring  fresh  or  fresh-frozen  tissue,  and  they  require  a  relatively  large 
amount  of tissue  [367].  In  addition  quantitative  RT-PCR  cannot  distinguish  gene 
expression  in  tumour  tissues  from  that  in  adjacent  normal  tissues.  IHC  is  thus  a 
favourable method because of its convenience for routine clinical studies and because 
it  can  distinguish  relatively  easily  tumour  from  normal  tissues.  Ultimately  the 
usefulness of these biological markers in clinical  decision-making depends on easy 
determination at the lowest possible costs.  In colorectal cancer, some newly proposed 
markers  such  as  microsatellite  instability  [368,  369]  appear promising,  but  not  all 
laboratories are equipped for this analysis.
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The selection of the primary antibody and application of an antigen retrieval system 
to detect the antibody are of great importance in optimising IHC  [105]. An example 
of this is highlighted by the current issue of p53 staining using IHC. Several technical 
considerations may obscure a relationship between p53  expression and the endpoint 
of interest.  These include variable definitions of a positive p53 IHC result, different 
antibodies being used with some detecting both normal and mutant epitopes of p53 
[370],  and different techniques for tissue fixation  and antigen retrieval, which may 
all influence the sensitivity of the IHC  assay [371, 372].  Also mutations in the p53 
gene  may  take  the  form  of point  mutations,  deletions  or  insertions,  resulting  in 
abnormal or no p53 protein being produced.  Some p53 mutations result in negative 
immunostaining, or a wild-type p53 gene may be associated with p53 overexpression 
[370, 373].  These disparities can also be applied to most of the current markers being 
analysed  in  clinical  studies  and  these  discrepancies  may  give  rise  to  some  of the 
disparate prognostic results from IHC studies.
6.2  Quality and classification of staining
One of the main factors contributing towards disparity between studies is the lack of 
consistent  reporting  on  the  quality  and  classification  of staining.  There  is  often 
considerable variation in the degree of staining, which is considered sufficient for a 
positive  result.  Within  different  regions  of  a  particular  tumour,  the  number  and 
intensity of positive cells appear to vary, which makes it difficult to characterise the 
actual  status  of the tumour as a whole, this has been noted by Baas  [105]  for p53 
staining. This has resulted in the case of p53, for studies to use different arbitrary cut­
offs for negativity and positivity.  Some studies have [114] used 70% or more nuclei 
staining  as positive  for p53,  whereas others  [117]  used greater than  10% nuclei  as 
positive staining.
The character of positive staining also varies among the studies.  Some quote only 
one method  of scoring the positivity and others use both intensity and percentage. 
There is no consensus on which is the most important.  For this reason in this current 
series  of anorectal  carcinomas  both  the  intensity  and  percentage  of cells  staining 
positively  were  recorded  and  analysed  for  each  marker.  There  was  no  one 
predetermined percentage cut-off for positivity.  For the proliferation markers cyclin 
A and Ki-67 only the percentage of cells were recorded as this is generally considered
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the  most  important  for these markers.  For  all  the  other markers;  both  intensity of 
staining and percentage of cells staining were scored, and they correlated significantly 
with  each  other,  with  a  p-value  <0.001  in  all  cases.  It  may  therefore  not  be 
unreasonable to  focus  on one  staining scoring  system  for  each marker,  as they do 
correlate significantly.
However, studying these molecular markers using IHC also highlights other potential 
difficulties  in  interpretation.  Different  tumour  types  for  example  have  quite 
significantly  different  staining  patterns.  TP  staining  in  the  squamous  cell  anal 
carcinoma samples clearly demonstrated nuclear, cytoplasmic and stromal expression. 
In  contrast  in  the  rectal  adenocarcinoma  tumours  almost  all  the  positive  staining 
occurred within the stromal cells, this has been demonstrated by others  [203].  The 
importance  of these  different  TP  localisations  is  unclear  as  described  in  previous 
chapters  and  in  fact the  predominant role  of TP  in  these  two  carcinomas  may be 
different.  However,  it  does  lead  to  interpretation  difficulties  in  both  the  scoring 
methods and comparisons of the importance of TP between different tumour types. 
TS also stained differently between the two tumour types with almost all of the anal 
tumours  staining  positively  but  in  the  rectal  tumours  the  percentage  of  cells 
expressing  TS  varied  quite  significantly.  Scoring  systems  should  be  validated  for 
each molecular marker in individual tumour types and comparisons between different 
tumour sites should be guarded.
6.3  Effect of treatment
Treatment modalities will also affect the clinical importance of some of the molecular 
markers.  In particular some markers have a clear relevance to certain treatments; in 
particular in this series to preoperative 5FU-based chemoradiation. This is highlighted 
by  the  findings  of TP  in  the  anal  series.  In  the  whole  group  of patients  and  the 
radiation  alone  arm,  increasing  TP  expression  significantly predicted  for  a  poorer 
DFS. However, in the combined modality treatment arm this effect was not seen and 
those patients whose tumours strongly expressed TP had an equivalent DFS to those 
whose tumours  expressed  no  TP.  Differences between  the two  treatment  arms  can 
also be  seen  for the effect of CD34  in this series.  It is therefore very important to 
interpret the importance of certain molecular markers in the context of the treatments 
patients have received in each study. For example; TP may be a negative prognostic
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factor by virtue  of its  angiogenic properties  in  patients  receiving  surgery  alone  or 
radiation but in the context of 5FU treatment this may not be the case. Comparisons 
across  all rectal  carcinoma series, regardless  of the treatment modalities used,  may 
well explain some of the contradictory results seen with certain markers.
A similar point is the issue of using biopsy or surgical specimens to analyse markers 
with IHC.  From the rectal carcinoma series it can be seen that certain markers;  in 
particular the proliferation indices, bcl-2 and EGFR are altered in response to CRT. 
This may well lead to some markers assuming more importance and others less, by 
virtue  of the  possible  pre-surgical  treatment  the  patient  may have  received.  More 
correlations were seen with bcl-2 in the surgical  specimens compared to the biopsy 
specimens.  It  is  important  therefore  to  also  take  this  issue  into  account  when 
determining the clinical relevance of these markers.
Discrepancies between previous studies may also be due to whether a tumour biopsy 
or  a  surgical  specimen  has  been  analysed.  Analysing  biopsies  may  not  be 
representative  of  the  tumour  as  a  whole.  Tumours  are  very  heterogenous  and 
molecular marker expression may differ considerably across the tumour specimen. In 
particular the expression of CD34  and CA9 may be difficult to  assess on a biopsy 
alone and this may account for the lack of prognostic and response significance in the 
anal  cancer  series.  CA9  staining  for  example  occurs  especially  around  areas  of 
necrosis and at the periphery of the tumour and this may not be adequately assessed 
on  small  tumour punch biopsy specimens.  For the  anal  cancer  series  however,  the 
surgical  specimens would have only been available on those patients who required 
salvage surgery.
The  importance  of molecular  markers  may  also  change  over  time because  of the 
introduction of new radiation and chemotherapy schedules.  As part of the UKCCR 
trial, from which the anal carcinoma patients for this study were selected, a six week 
gap between the two radiotherapy phases was implemented.  A gap of six weeks was 
typically recommended between large-field pelvic and small-volume boost treatment, 
to allow resolution of acute cutaneous and mucosal toxicity, and to allow assessment 
of tumour response.  This  now  would be  a  criticism  of the  study  as  groups  have 
identified  that  this  gap  may worsen  local  control  [231,  374,  375].  This  may  well
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affect the relevance of some of the findings in this series and it will be interesting to 
see the future results in ACT II where this treatment gap has been eliminated.
6.4  Statistical analysis
One of the other major criticisms of studies to date investigating the role of molecular 
markers  is  that  the  statistical  analyses  are  often  not  robust  and  most  studies  are 
retrospective and small with varying lengths of follow-up. A recent report by Riley et 
al  [96]  who  performed  a  meta-analysis  of  prognostic  factors  in  neuroblastoma 
highlighted the poor statistical analyses for many of these prognostic marker trials. 
They  identified  several  problems;  no  appropriate  statistical  analysis performed,  no 
hazard ratios reported, inexact p-values reported and marker studies too small.  In the 
current  series presented here robust statistical analyses have been used with hazard 
ratios.  In particular in the anal series the numbers are not small and they have been 
recruited from a randomised trial.
The  identification  of factors  that  reflect  biological  behaviour  of individual  cancer 
tissues correlating with tumour aggressiveness is a key determinant of prognosis and 
a fundamental issue for the improvement of cancer therapy. Despite recent progress 
in  defining  the  molecular  mechanisms  of  cancer  development  and  tumour 
progression,  only  a  few  individual  molecular  biomarkers  providing  prognostic 
information have been identified.
Tumour  response  to  combined  modality  treatment  is  heterogenous  and  can  be 
influenced  by  differences  in  pretreatment  size,  differentiation,  and  the  biological 
properties of the individual lesions.  If it was possible to identify patients with radio- 
responsive tumours at the time of diagnosis, a selective and individualised policy of 
preoperative  chemoradiation  could  be  pursued.  This  would  be  highly  clinically 
relevant.  In  rectal  carcinomas  it  might  be  possible  then  to  consider  less  radical 
surgery with  possible  sphincter preservation  in  low  lying tumours  or  even  a  local 
resection without lymphadenectomy in very early stage lesions.
Despite all the current potential problems molecular markers are likely to play a role 
in  the  future  in  the  treatment  decision-making  process  in  patients  with  anorectal 
carcinomas.  The  most  promising  from  this  current  series  are  p53,  CD34,  TP  and
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EGFR.  Already trials are underway looking at the role of capecitabine in both anal 
and rectal chemoradiation regimens and this is as a direct result of its activation by 
TP.  A  recent  phase  II  study  of  cetuximab,  an  EGFR  monoclonal  antibody,  in 
metastatic  colorectal  cancer  has  shown  good  response  rates  and  improved 
progression-free times.
However  issues  of  inconsistent  assay  methods  and  patient  and  treatment 
heterogeneity, which detract from the ability to draw definitive conclusions, must be 
addressed.  Ideally future studies using larger cohorts of uniformly staged and treated 
patients  to  define  the  clinical  usefulness  of  these  promising  markers  should  be 
undertaken.  Wherever possible the analysis  of these markers  from patients  entered 
into  phase  III  randomised  clinical  trials  should  be  performed.  Finally  for  these 
potential prognostic factors to be clinically useful there must be practical and reliable 
assays that can be broadly available to all centres with agreed validated IHC protocols 
for each marker.
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